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Thromboprophylaxis Use among Pregnant Women in Gaza Governorates 
 
Abstract 
 
Risky pregnancy and bad pregnancy outcomes are increasing in the last years due to 
accumulated risk factors so the demand of thromboprophylaxis use is increasing to 
improve pregnancy comes. 
 
Aim: This study is aimed to determine the main determinants of thromboprophylaxis use 
identify the possible effects of it on pregnancy outcomes and discuss the different 
management practices that contribute to the need of thromboprophylaxis among refugee 
risky pregnant women attended UNRWA health care services in Gaza governorates in 
order to explore possibilities for improving pregnancy outcomes. 
 
Method :An analytical comparative triangulated study has been performed between April 
2017 and completed  by July 2017, 440 mothers who attending united nations relief and 
work agency for Palestinian refugees in the near east health centers which divided in two 
groups (with and without thromboprophylaxis use in last pregnancy), consisted of 220 
mothers for each , stratified sampling was used collected through face interviewed 
questionnaire  along with medical records revision and genetic study review . Moreover, 
in-depth interview with concerned health care providers was done. Statistical analysis was 
performed using chi-square, odds ratio, ( P-value≤0.05). Helsinki and managerial 
approval were granted and consent form was obtained from participants. 
 
Findings: Mothers with thromboprophylaxis use had statically differences (P≤0.05) in 
maternal age > 30 years (36.6% vs 15.9%) , history of non communicable 
disease(P=0.000) ,history of surgical operations (p=0.000) , Gravida two and more (P-
value=0.000), para two and more (P- value 0.000) ,History  of dead children(P-
value=0.000), history of SB(P-value=0.000), history of infertility (P-value=0.000), history 
of early pregnancy loss (P-value=0.000) and history of pregnancy complications (P-
value=0.000) , thromboprophylaxis use has a role of improving pregnancy 
outcomes(78.2% vs 41.9%), majority of cases had high frequency of  genetic abnormdities 
which is abse of thromboprophylaxis use.despite of that majority of cases had access to 
heparin therby from private sectors with high cost(82.2%). 
 
Conclusion: thromboprophylaxis use in pregnancy is a new model in gynecology and 
obstetrics, there is a significant risk among these women and thromboprophylaxis is 
improving their pregnancy outcomes compared to women without thromboprophylaxis use. 
Standardization of diagnosis and harmonization of national guidelines are recommended 
to improve the use of thromboprophylaxis among pregnant women. 
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Chapter 1: Introduction 
 
1.1 Background  
Pregnancy and childbirth is an existing event in the women's and family life as to be 
pregnant is to be vitally alive. At the same time is a big stress of life. Pregnancy process 
large demands and challenges the women's physiology. Pregnancy is a physiology, not a 
pathology or diseases, many physiological changes had occurred to an adapt new changes 
in the pregnant women, This Period of life is a joyful anticipation time but it is carrying 
many health hazards association that may affect maternal and fetal life. 
 
 At the same time is a big stress of life, Pregnancy process large demands and challenges 
the women's physiology. Different physiological changes occur during the process of 
pregnancy, which affects all of the woman systems; these include metabolic adaptations 
and hormonal changes. However, we are interested in those changes that affect the 
coagulation factors. It is due to a secondary increase in the concentrations of pre-coagulant 
factor, a reduction of the naturally occurring anticoagulant proteins and increase in 
fibrinogen that characterized pregnancy with hypercoagulability (Christopher et al, 1998). 
Pregnant Women are at an increased risk of both venous and arterial thromboembolism 
during pregnancy, compared to women who are not pregnant, the risk of arterial 
thromboembolism (strokes and heart attacks) is increasing  3to 4 folds and the risk of 
Venous Thromboembolism (VTE) is increasing 4to 5fold,3 folds will increase in the 
Postpartum, the risk is even higher (James et al, 2005),but the venous thromboembolism 
and pregnancy complications are rare in healthy pregnant women as natural anticoagulant 
slow up excessive fibrin formation and finally the fibrin- lytic system gets rid of the 
formed fibrin Thrombophilia, either acquired or hereditary, may shift the hemostatic 
balance towards enhanced coagulation thrombophilia can be found in as many as 50% of 
patients with VTE during pregnancy (Greer, 2003).  Thrombophilia can be found up to 
40% worldwide in women who had bad pregnancy outcomes (BogdovaMarkovo, 2019)  
Thrombophilia risk factors are also frequent in women with other vascular placental 
pathologies, such as preeclampsia, intrauterine growth retardation, placental abruption, and 
late fetal loss (Brenner, 2003). A successful pregnancy is highly dependent on the 
establishment and maintenance of an adequate placental circulation.It has been postulated 
that the abnormalities of placental vasculature leading to inadequate feto-maternal 
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circulation are responsible for some poor pregnancy outcomes, which that  is triggered by 
thrombophilia events, like abortion (either during the first or second trimester), intrauterine 
fetal death (IUFD), intra uterine growth restriction (IUGR), stillbirth(SB), preeclampsia 
(PET), abruption placenta (Said, Joanne M. MBBS, 2013) . 
 
The prevalence of thrombophilia among pregnant women worldwide is not known Bates 
and colleagues (2008) reported that thrombophilia accounts for 8%-15% of whites. Many 
studies showed that the prevalence of different genetic thrombophilia occurred more 
frequently with a history of obstetric complications, factor V Leiden, prothrombin and 
MHFR mutations occur up to (24%,10%,24%) respectively(Australian assessment Report, 
2002 ).  
 
1.2 Research problem 
Pregnancy is a unique period in every woman's life, it is a natural goal for every family to 
get their child, it is characterized by different complicated physiological changes as the 
woman undergoes many physiological changes, so, pregnancy poses large demands and 
challenges the woman's physiology, in some women, the adaptation to these changes is 
insufficient so the pregnancy complication can occur. According to that, one of the most 
important and the hottest topic among pregnant women is the risk of thrombosis and the 
use of thromboprophylaxis. Risky pregnancy in Gaza is with many complicated health 
issues, in the last years the prevalence of risk pregnancy, bad pregnancy outcomes and 
complications are increasing dramatically, due to socioeconomic 
deterioration.Thrombophilia and thromboprophylaxis use is a new fashion and a recent 
Phenomenon among risk pregnancy and the demand for thromboprophylaxis increases in 
the last years, this study is the first study in Palestine will conduct about 
thromboprophylaxis use in pregnancy  as it will measure the magnitude of the problem 
among risky pregnant women,  It will discuss the differently associated determinants with 
this phenomena, different pregnancy outcomes and different management  practices of 
thromboprophylaxis use and so will help us to answer the main question, 
thromboprophylaxis use  is a new fashion or a real risk .  
 
1.3 Justification of Study  
According to the Center for Disease Control’s National Pregnancy Registry Surveillance 
System, between 1991 and 1999, pulmonary embolism (PE) was the first cause of maternal 
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mortality. Pregnancy is a state that conveys 4-5 times the risk of venous thromboembolism 
(VTE). The prevalence of VTE in pregnancy is 0.8-2.0 per 1,000 pregnancies and accounts 
for 1.1 deaths per 100,000 pregnancies. Approximately 80% of embolic events in 
pregnancy are venous (James et al, 2006). 
 
Pregnancy failure is extremely distressing for couples who desire to have children. Pre-
eclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, low platelet counts) 
are leading causes of maternal and perinatal mortality as well as extensive morbidity, 
which that has an association with thrombophilia in pregnancy. According to American 
and Society collage, Thrombophilia is associated with 30 % of pregnancy complications. 
Palestine is with significant rate of maternal mortality rate which increases from 23,4 per 
100000 to 31 per 100000 in the last 5 years , PE is one of the main causes of maternal 
mortality in Palestine which accounts for  29,4 % of all maternal deaths, 17,6 % of 
maternal deaths is related hemorrhage, 11,8 % heart diseases,11,8 % PET ,others are 
unknown (PHIC, MOH, 2015 ). 
 
In the last years,  bad pregnancy outcomes are increasing due to different health hazard and 
risk changes, Low birth weight accounts of 34% from total infant mortality per 
1000livebirths, Neonatal mortality accounts 11.8 per 1000 live births (PHIC, MOH,2014). 
Spontaneous abortion increases to reach annually 2662 registered cases among refugee 
pregnant women (UNRWA,2014 ).On the other hand, risky pregnancy increases in the last 
5 years in Gaza Governorates 24.1% risky pregnancy from newly registered pregnant in 
MOH clinics (PHIC-MOH, 2014), and 15 % high-risk pregnancy and 24.8 %  are alert 
pregnancy from new registered pregnant women in UNRWA Health clinics (UNRWA, 
2014). 
 
Many past studies were done on PIH, GDM and its associated relations with bad 
pregnancy complications and outcomes, thrombophilia is a new Phenomenon among risky 
pregnancy which plays a significant role in pregnancy complications (Maternal and Fetal 
complications). 
 
The problem of thromboprophylaixs use  in pregnancy is a recent emerging problem and 
the demand for the uses of different anticoagulants in pregnancy increases dramatically 
under the role of controlling bad pregnancy outcomes and pregnancy complications, This 
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study is the first study in Palestine to determine a real picture of the problem, differently 
associated determinants, different pregnancy outcomes and different management 
practices.  
 
1.4 Study Objectives 
1.4.1 Aim of the study 
The main aim of this study is to determine the main determinants either maternal or fetal 
factors, consequences, management practices that contribute to the need of 
thromboprophylaixs among refugee risky pregnant women in Gaza Strip, in order to 
explore possibilities for reducing maternal and fetal complications and controlling 
phenomena.  
 
1.4.2 Specific objectives 
i. To assess the current status of thromboprophylaixs use among risky pregnant 
women at UNRWA Health Centers in Gaza Governorate 
ii. To assess the differences associated determinants of thromboprophylaxis use 
among risky pregnant women at UNRWA Health Centers in Gaza Governorate. 
iii. To identify the maternal and fetal related problems that contribute to 
thromboprophylaixs use among risky pregnant women. 
iv. To assess the management practices of using  thromboprophylaixs among pregnant 
women 
v. To propose and suggest recommendations that might help in enhancing proper 
health care services regarding risky pregnant women and the used 
thromboprophylaixs in pungency  
 
1.5 Research Questions 
i. What is the current status of thromboprophylaixs use among risky pregnant women 
at UNRWA Health Centers in Gaza Governorate? 
ii. What are the epidemiological and statistical features of existing risk factors that 
enhancing the risk of thromboprophylaixs uses among pregnant women in the study 
population? 
iii. What is the association between maternal age and the use of thromboprophylaxis 
among risky pregnant women in the study population? 
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iv. What is the role of family history that contributes to thromboprophylaixs uses 
among risky pregnant women in the study population? 
v. What is the association between maternal history (Past, Current obstetric history, 
and preexisting medical history) with thromboprophylaixs use among risky 
pregnant women? 
vi.  How much inherited and acquired thrombophilia is affecting the use of 
thromboprophylaixs among risky pregnant women? 
vii. How much of thromboprophylaxis use among risky pregnant women is preventing 
birth outcomes problems? 
viii. How much of thromboprophylaixs use among risky pregnant women is preventing 
maternal complication? 
ix. What are the different management practices of thromboprophylaixs use in risky 
pregnant women among health providers? 
x. Is thromboprophylaixs use a fashion or a real risk among risky pregnant women? 
 
1.6 Operational definitions 
i. Thrombophilia: Is an abnormality of blood coagulation that increases the risk of 
thrombosis (blood clots in blood vessels) (Heit, 2007). 
ii. Maternal Thrombophilia: Is a miss balance between the procoagulant 
physiological changes and thrombosis risk among pregnant ladies (Rosendaal, 
2005). 
iii. Inherited Thrombophilia: It refers to inborn conditions, it can be inherited from 
one present (Heterozygous), or the same gene for two parents (homozygous), that 
increase the tendency to develop thrombosis (Rosendaal, 2005). 
iv. Acquired Thrombophilia: It refers to a group of disorders that an individual is not 
born with, but may develop throughout his or her life due to another illness or 
situation. An example of acquired thrombophilia is the development of a lupus 
anticoagulant or antiphospholipid antibody syndrome (Ruiz-Irastorza et al, 2010) 
v. Fetal Demise: The National Center for Health Statistics defines fetal death as death 
prior to the complete expulsion or extraction from its mother of a product of human 
conception (MacDorman et al, 2012). 
vi. Pregnancy-induced Hypertension: PIH is defined as hypertension (blood pressure 
≥ 140/90mmHg) with or without proteinuria ( ≥ 300 mg/24 hours  )emerging after 
20 weeks gestation, but resolving up to 2-6 weeks postpartum (Mageee et al,2008) 
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vii. Thrombosis: Is the formation of a blood clot, inside a blood vessel, impaired the 
flow of blood through the circulatory system. When a blood vessel is injured, the 
body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood 
loss (Furie, 2008). 
viii. Thromboembolism: Is the combination of thrombosis and its main complication, 
embolism (Furie, 2008). 
ix. Thromboprophylaixs: Any preventive measure or medication that reduces the 
likelihood of the formation of blood clots (ACOG, 2010). 
 
1.7 Context of the study   
1.7.1 Gaza Governorate demographic characteristics 
Gaza is a small piece of land located in the southern west area of Palestine. It is divided 
into five governorates: North Gaza, Gaza City, Mid Zone, Khanyonis and Rafah (PCBS, 
2013). Palestinian population was estimated about 4.8 million mid-year 2016, distributed 
as (62.2%) in the West Bank and (37.8%) in Gaza Strip, Population Density (Capita/km2) 
in Gaza Governorate is 5.239 annual growth rate, Mid-Year 2016 is (3.3), an average of 
household Size, 2015, is -5.7-(PCBS, 2016).That means Gaza is a very crowded area with 
crowded population, that faces many bad socio-economic due to Israel siege, The 
percentage of Population Less than 15 Years (42,7%).   Unemployment Rate at 15 Years 
and over, is (41.6 %) which is nearly high in comparison with West bank 18.2%) (PCBS, 
2016) .The poverty rate among Palestinian individuals was 25.8 (17.8% in the West Bank, 
and 38.8% in Gaza Strip). Data revealed that 12.9% of the individuals in the Palestinian 
Territory was suffering from deep poverty in 2010 according to consumption patterns. 
(7.8% in the West Bank and 21.1% in Gaza Strip) (PCBS, 2012). 
 
1.7.2 Health Care System and health status 
The health services in Palestine, and in Gaza Strip provided by the Palestinian healthcare 
system which consists of: (1) governmental health care system, (2) NGOs healthcare 
system (3) UNRWA health care system, (4) private health care system. 
Health care is provided through a three-tier system, consisting of primary health care 
(PHC) clinics, secondary and tertiary healthcare facilities.MOH is the only health authority 
responsible for supervision, regulation, licensure, and control for all health services is the 
main healthcare provider in the governorates; it provides PHC, secondary and tertiary 
services for the whole population. It purchases advanced medical services through 
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referring patients to the neighboring countries and other private and NGO health care 
facilities. 
 
UNRWA provides PHC services to the refugee population and purchases secondary and 
tertiary care services when needed. The NGO sector ranges from missionary hospitals to 
facilities supported by international organizations, to community health centers. The 
private for-profit health sector also provides the three levels of care through a wide range 
of practices.Hospitals are mainly provided by MOH, according to annual reports of MOH 
(2013). Palestine has 80 hospitals,30 in Gaza governorate, most of them are general and 
related to MOH with high bed occupancy rate (85%), MOH is with overcrowded hospital 
beds 1,4 per 1,000 population (MOH, 2013). PHC centers provide accessible and 
affordable health services for all Palestinians, especially for children and other vulnerable 
groups MOH is working with other health sectors in providing the primary health services, 
mainly NGOs organizations 
 
1.7.3 Primary Health Care 
PHC is the fundamental care of heath care system and the vertebral column of it, PHC puts 
all people at the center of health care, Primary Healthcare centers in Palestine 767centers, 
604centers in West Bank, 163 centers in Gaza Strip, 61,5% is related to MOH,62 clinics 
are related to UNRWA Health Centers, 23 clinics are related to NGOs (MOH,2014),  PHC 
ratio per 10000 population is 0,87population per PHC is 114011, PHC-Centers at Palestine 
are with highly overcrowded and highly demand from Palestinian population (MOH, 2014 
) 
 
1.7.4 UNRWA 
UNRWA is a United Nations agency established by the General Assembly in 1949 
following the first Arab-Israeli War in 1948, which became operational in 1950. It is 
mandated to provide assistance and protection to a population of over 5 million registered 
Palestine refugees. Its mission is to help Palestine refugees in Jordan, Lebanon, Syria, 
West Bank and the Gaza Strip to achieve their full potential in human development, 
pending a just solution to their plight (UNRWA, 2014). UNRWA has long been providing 
primary health services in three main programs, is divided into separate clinics within each 
health center: maternal and child health care (MCH), non-communicable disease (NCD) 
care, and general outpatient services. 
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A health reform package was introduced as a part of the Agency-wide organizational 
development plan, Family Health Team (FHT) is a primary care package focused on 
providing comprehensive and holistic primary health care for the entire family, 
emphasizing long-term provider-patient family relationships in late 2011. UNRWA 
provided a good example of how primary health care reform including the integration of a 
family practice approach could improve quality of care and patient satisfaction under 
difficult situations (UNRWA, 2014). 
 
1.7.5 Antenatal Care Coverage at UNRWA 
UNRWA encourages pregnant women to receive their first antenatal assessment as early as 
possible and to have at least four antenatal care visits throughout their pregnancy to 
promote early detection of risk factors and management of complications. Pregnant women 
receive a comprehensive initial physical examination and regular follow-up care, including 
screening for pregnancy-related hypertension, diabetes mellitus, anemia, oral health 
problems and other risk factors. UNRWA primary health care facilities cared for 88,615 
pregnant women which represented a coverage rate of 79.0% of all expected pregnancies 
among the served refugee population. 
Gaza Governorates is with ANC 87.3%, West Bank is with ANC %.( UNRWA, 2014), our 
focus study will be done at UNRWA clinics among risky pregnant women. 
 
1.7.6 Health issues of Maternal Health in Gaza  
Gaza is a small geographical area with many complicated health issues due to, 
socioeconomic status deterioration.  Maternal mortality in Gaza ranges between 20-40 per 
100,000 live births, with a most common leading cause is pulmonary embolism 20% 
(MOH, 2010). The prevalence of pregnancy complicated diseases is increasing among 
refugee pregnant women in Gaza (UNRWA, 2012), the prevalence of high-risk pregnancy 
(HRP) increases to 13,9%, the scope of bad pregnancy outcomes among pregnant women 
increases,  there are nearly 3038  reported abortions yearly among registered pregnant 
women at UNRWA health centers (UNRWA, 2012( ,also Prevalence of late miscarriages 
and stillbirths are 23.3/1,000 and 7.4/1,000 respectively, and that of premature births 
19.6/1,000 (Environ, 2012). 
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Chapter2 :LiteratureReview 
 
2.1 Conceptual framework  
The researcher conceptualizes the main framework of the research as it is conceptualized 
from different literature. This framework joins the different associated variables dependent 
and independent variables which help to understand the problem of research and its 
associated dimensions.  
 
2.1.1 Demographic factors 
Many Studies showing that demographic factors are as important as physical health 
variables in affecting of health status outcomes, mainly maternal age as many kinds of the 
literature confirmed the risk of maternal age for developing thrombotic changes. 
 
2.1.1.1 Maternal age 
Many epidemiologic studies have reported advanced maternal age to be associated with 
increased risk of stillbirth, not explained by age-related risk for pregnancy-related 
complications such as pre-eclampsia, gestational diabetes, multiple pregnancy or placental 
abruption, The reported ORs for the risk of IUFD associated with advanced maternal age 
are in the range 1.3-1.9 for age 35-39 years and 1.7-3.3 for age over 40 years (Froen et al, 
2009).Also, Frozen and dear colleagues reported an OR of 5.1 (95% CI 1.3-19.6) for the 
risk of unexplained intrauterine death among women 35 years and older. 
 
2.1.2 Family history  
It is the second factor will be studied as it discusses the risk of a family history of 
thrombosis and the use for the thromboprophylaixs uses in pregnancy as the researcher will 
ask about family history of earlier onset of thrombosis (venous, arterial) or any family 
member with thrombophilia and thromboprophylaixs uses.Sundquis et al (2015) reported 
that family history of thrombophilia is a risk factor for VTE recurrence in patients who had 
unprovoked first VTE. Furthermore, the presence of a Family history of venous 
thromboembolism may be an additional risk factor for VTE recurrence in thrombophilia-
positive patients. 
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2.1.3 Maternal History  
This part consist from the following factor 
2.1.3.1 Obstetric history  
 
This is the third factor to be studied as the researcher will look for the associated of 
maternal and fetal problems in past pregnancy histories (PIH, early onset of pre-eclampsia, 
HEElP syndrome, abruptio-placenta, miscarriages, early and late pregnancy loss, still 
births,  prematurity,  perinatal mortality, and IVF.  
 
2.1.3.2 Past Medical History  
This is the third factor, to study different associated chronic medical diseases, preexisting 
medical conditions  like HTN, DM, auto-immune diseases, acquired thrombophilia 
(thrombocytosis, nephrotic syndrome, polycythemia, malignancy, history of venous, 
arterial thrombosis and DVT). 
 
2.1.4 Inherited thrombophilia  
The fourth factor is talking about the association of molecular genetic study and the risk of 
thrombosis and thrombophilia as the genetic study is diagnostic for hereditary 
thrombophilia, this genetic study describes factor V, Prothrombin, Protein C, S, 
antithrombin deficiency, prothrombin, MTHFR, and others. 
 
2.1.5 Acquired Thrombophilia 
This fifth factor discusses a number of acquired conditions augment the risk of thrombosis. 
A prominent example is anti- phospholipid syndrome which is caused by antibodies 
against constituents of the cell membrane, particularly lupus anticoagulant and 
anticardiolipin antibodies. 
 
2.1.6 Management Practices 
There are different types of anticoagulant medications are used as thromboprophylaxis 
among risky pregnant women (unfractionated heparin, low molecular weight heparin, low 
dose aspirin and combinations between two factors), the researcher will look for the type, 
dose, frequency, continuity, and availability of used medication. 
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2.1.6.1 Types of different management practices  
This item will discuss different medical management practices among health provider, as 
the researcher will ask about the diagnostic criteria for thromboprophylaxis use, screening 
about thrombophilia and its adherence to international guidelines . 
 
2.1.7 Pregnancy outcomes  
The researcher will discuss the different pregnancy outcomes among the studied 
population, as it includes fetal outcomes (live birth, fetal demise, full term, preterm 
delivery, normal weight, low birth weight, SCBU admission, perinatal mortality, 
associated congenital anomalies) and maternal outcomes (Pregnancy complicated diseases) 
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2.2 Thrombophilia  
Thrombophilia means a predisposition to thrombosis, an increased tendency to have blood 
clots in veins or arteries. Thrombophilia may be inherited or acquired.Thrombophilia 
results from perturbations of the normal physiological coagulation cascade. The cascade is 
a complex, multi-step feedback mechanism with the ultimate of producing thrombin, 
which in turn cleaves fibrinogen to form a stable fibrin clot. Thrombophilia promotes the 
formation of thrombosis in individuals by one of two actions (a) facilitating the production 
of clotting factors in the coagulation cascade or (b) inhibiting anticoagulant function in the 
coagulation cascade (McLintock et al, 2001; Walker, 2000). 
A successful outcome of pregnancy depends on proper placental formation. In the early 
stage of this process, trophoblastic invasion and fibrin deposition into the wall of the spiral 
veins play an important part. Pregnancy is an acquired hypercoagulable state and women 
with a prior tendency to thrombosis may develop clinical symptoms of placental vascular 
complications such as preeclampsia, intrauterine growth restriction, fetal death for 
unknown causes, that impact the maternal-fetal morbidity and mortality. 
 
Thrombophilia is associated with an increased risk of pregnancy-related venous 
thromboembolism (VTE) and may also be linked to placental-mediated pregnancy 
outcomes, such as fetal loss , Thrombophilia have been recently explored as a cause of 
placental thrombosis, severe preeclampsia/eclampsia, HELLP syndrome, placental 
abruption, intrauterine growth restriction, unexplained stillbirth and recurrent 
miscarriage(Tranquilli, Giannubilo et al, 2004). Thrombophilia can be defined as a 
predisposition to  thrombosis Abnormalities in hemostasis that is associated with clinical 
thrombophilia include heritable defects, such as mutations in the genes encoding the 
natural  anticoagulants antithrombin, protein C and protein S, or clotting factors 
prothrombin , factor V, and acquired factors defects, such as antiphospholipid  syndrome 
(Walker, 2003). 
 
A number of studies have examined the association between thrombophilia and 
complications of pregnancy. The thrombotic disease is a major cause of maternal 
morbidity and mortality worldwide. Development of thrombosis in pregnancy is 
multifactorial due to the physiologic changes of pregnancy which induce a relative 
hypercoagulable state as well as physical changes leading to increased stasis and also the 
effects of both the inherited and the acquired thrombophilia.  
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2.2.1 Types of thrombophilia  
 
Inherited thrombophilia includes deficiencies of antithrombin, protein C or protein S, 
homozygous or heterozygous mutations of factor V (Leiden, G1691A) or prothrombin) 
G20210A), and homozygosis for the variant of methylenetetrahydrofolatereductase -
MTHFR C677T-(Greer, 2000, McLintock et al, 2001; Thomas, 2001; Walker 2000). 
 
2.3 Coagulation Changes of pregnancy  
During the course of normal pregnancy, dramatic changes occur in the hemostatic system .
Coagulation factors increase physiologically in pregnancy and this is thought to be an 
evolutionary mechanism to prevent excessive blood loss during childbirth (Lindqvist, 
Merlo, 2006). Owing to hormonal changes, increased concentrations of procoagulants, 
decreased numbers of anticoagulant factors and diminished fibrinolysis activity. These 
changes may be important for reducing intrapartum blood loss, but they determine an 
increased risk of thromboembolism during pregnancy and puerperium. The changes in the 
coagulation system in normal pregnancy are consistent with a continuing low-grade 
process of intravascular coagulation. During pregnancy, the concentrations of coagulation 
factors VII, VIII, IX, X, XII and von Willebrand factors rise significantly accompanied by 
a relevant increase in the concentration of plasma fibrinogen. 
 
Thrombin generation markers such as prothrombin F1 and 2 and thrombin-antithrombin 
(TAT) complexes are also increased (Szecsi, Jorgensen, Klajnbard, 2010). There is also a 
marked decrease in anticoagulant activity including reduced protein S levels and acquired 
activated protein C resistance (Sarig, Drori et al, 2011). Fibrin- lytic activity is also 
reduced with plasminogen activator inhibitor type 1 (PAI).levels increased by ﬁve-fold and 
increases in placental-derived plasminogen activator inhibitor type 2 (PAI-2), particularly 
during the third trimester (McLean, Bernstein, Brummel, 2012).These changes in the 
hemostatic system act as a physiological “safety net” for the peripartum period, but can 
predispose both the mother and fetus to complications during the pregnancy. For the 
mother, this risk begins from the point of conception well into the postnatal period, with 
recent data suggesting that the risk extends to at least 12 weeks (Kamel, Navi et al, 2014). 
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2.4 Thrombophilia affecting natural anticoagulation 
This part consist from the following  
2.4.1 Factor V Leiden  (FV Leiden) mutation 
FV is the most common hereditary thrombophilia, which is found in approximately 5% (2–
15%) of Western populations. Normally activated protein C inhibits coagulation cascade 
by splitting activated factor V (Va),(Rees et al, 1995). 
This mutation slows down the proteolytic degradation of factor Va by activated protein C 
(APC), leading to increased generation of thrombin. Resistance to APC has been found in 
24–60% of women with pregnancy-associative VTE (Hellgren,2003) 
 
2.4.2 Deficiencies of Antithrombin, protein C, and protein S 
Antithrombin deficiency is the most severe thrombophilic condition associated with a 70- 
90 % lifetime risk of VTE. Antithrombin has its thrombin inhibitory properties, and it can 
also inactivate coagulation factors Xa, IXa, VIIa, and plasmin so, the lifetime risk of VTE 
associated with both protein C or S deficiency and both are associated with adverse 
pregnancy outcome (Girling, Swiet,1998) 
 
2.5 Thrombophilia affecting procoagulants 
2.5.1 Prothrombin gene 20210A mutation 
Prothrombin is the inactive precursor of thrombin, which is required in order to convert 
fibrinogen into fibrin, the primary goal of the coagulation cascade is present in 1–2% of the 
healthy population and it increases the risk of VTE three folds than others (Rosendaal et al, 
1998). 
 
2.5.2 High level of factor VIII 
The significance of a high level of FVIII is unclear, but it is evident that high levels 
increase the risk of deep venous thrombosis (Kraaijenhagen et al, 2001). 
 
2.5.3 Hyperhomocysteinemia 
Hyperhomocysteinemia is known to cause direct endothelial injury through increased 
oxidative stress, to induce impairment in the endothelial synthesis of vasodilator 
substances to increase the expression of procoagulants and increase platelet aggregation 
Most mild or moderate forms of hyperhomocysteinemia are the result of homozygosis of 
the methylene tetrahydrofolatereductase (MTHFR) mutations, the prevalence of which 
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among Europeans is about 11%.Although hyperhomocysteinemia is a risk factor of 
arteriosclerosis, its role solely in pregnancy complications is not defined (Jaaskelainen et 
al, 2006) 
2.6 Acquired thrombophilia  
This item is associated with external events that occur in pregnancy and increase the risk of 
thrombosis. Acquired thrombophilia is hypercoagulable states secondary to various 
etiologies. In particular, during pregnancy, the risks are exaggerated due to the underlying 
physiological changes (Manjiri, Catherine, 2003). 
 
2.6.1 Antiphospholipid syndrome 
Antiphospholipid syndrome (aPS) is an autoimmune disorder in which patients have 
antibodies against phospholipids structures in their blood and at least one clinical 
manifestation such as adverse pregnancy outcome or thromboembolism (primary aPS). 
Literature says that anti phospholipid bodies are found about 1% to 5% of population 
(Petri, 2000), also Antiphospholipid antibodies can be present in association with some 
autoimmune conditions (secondary aPS), especially systemic lupus erythematous (SLE) 
Among such patients aPLs have been found in 30% (Love,2000). The clinical 
manifestations related to these antibodies include both arterial and venous thrombosis, 
spontaneous pregnancy losses and others are the same. 
 
Robertson et al (2006) showed significant associations between aPLs and both early and 
late fetal loss and an increased risk of preeclampsia and lupus anticoagulant Anti 
phospholipid antibody syndrome is described by its presence of lupus anticoagulant (LAC) 
and/or anti-cardiolipin antibodies (ACL) with recurrent miscarriage (RM), thrombosis, 
preeclampsia, IUGR and placental abruption. The most specific clinical features are 
thrombosis (both venous and arterial thrombosis), RM and fetal loss in the second and 
third trimester and autoimmune thrombocytopenia (Kupferminc, 2003). 
 
There are many pathological changes occur with placenta vasculature wit APL syndrome, 
that resulted in placental infarction leading to miscarriage, IUGR, Stillbirth and early sever 
preeclampsia ( Kupferminc, 2003). 
 
Literature says that 10 % to 15% of recurrent miscarriages below 20 weeks with 
antiphospholipid antibodies (Kupferminc, 2003), also many studies showed the association 
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between preeclampsia and antiphospholipid antibody syndrome, as there is 16 % estimate 
of incidence of pre-eclampsia with positive APL, many studies show strong association 
between early onset of pre-eclampsia and APL ( Kupferminc, 2003) .Women with APS are 
also at a substantial risk for IUGR, which is around 30%. In one study, 24% of mothers 
delivered of IUGR infants had medium or high positive tests for Anti- cardiolipin 
antibodies (Kupferminc, 2003). 
 
2.7 Thrombophilia and pregnancy complications 
2.7.1 Recurrent fetal loss  
The recurrent fetal loss is a common problem of the women in reproductive age group, 1% 
to 2% with 3 or more losses, and 5% with 2 or more losses (Gottl et al, 2004). 
Inherited and/or acquired thrombophilia has been diagnosed in 50% to 65% of women with 
a history of unexplained RPL and in nearly 20% of women with RPL with age of more 
than 35 years (Marquard, 2009). 
 
The recurrent Fetal loss has a strong association of inherited and acquired thrombophilia , 
as there were  at least 16 case-control studies have found a high prevalence of VFL in 
women with the unexplained fetal loss (up to 30%) compared to 1%-10%of control 
subjects (Kujovich, 2002). 
 
Ohel and colleagues (2000) said that women with thrombophilia have an increased 
percentage of losses at a later stage of gestations; However, APC resistance with factor V 
can be associated with pregnancy loss at an earlier stage. 
 
 A number of recent meta-analyses have demonstrated an association of factor II with 
second and third-trimester loss and also first-trimester loss (Hoffman et al, 2002).Some 
documented studies have reported a statically significant increased frequency of RFL  with 
Prothrombin gene mutation, one of these studies reported a frequency of 9 %in women 
with recurrent miscarriage, while  a frequency of 2% occurred in the control group (Foka et 
al, 2000 ).A second study reported a frequency of 6.7 %compared to 8 % in the control 
group (Pihusch et al, 2001).  
 
In a meta-analysis, protein S deficiency conferred an overall 15 folds increased the risk of 
recurrent pregnancy and a 7 fold higher risk of late fetal loss (Rey et al, 2003). A meta-
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analysis study reported a 3 to 4 folds increased risk of recurrent early pregnancy loss in 
women with MTHFR mutation (Nelen et al, 2000). There are several studies that have 
shown the association between hereditary APCR and pregnancy loss. Gradone and 
colleagues (2007) reported a 31.2% prevalence of factor V Leiden in women with second-
trimester fetal losses compared to 4.2 % in matched controls.  
 
 A composite study of the association between the known thrombophilia and fetal loss 
demonstrated that fetal loss occurred among 10 of 48 women with thrombophilia (21%), 
and among 10 of 60 control women (17%). There was a similar risk of fetal loss in women 
with the factor V Leiden mutation compared to those without (Vossen et al, 2003). 
 
The NOHA (Nimes Obstetricians and Hematologists) first study, a large case-control study 
nested in a cohort of nearly32,700women, of whom 18% had pregnancy loss with their 
first gestation found on multivariate analysis a clear association between unexplained first 
pregnancy loss between 10 and 39 weeks gestation and heterozygosis for factor V Leiden 
(OR 3.46; 95%CI, 2.53–4.72) (Lissalde-Lavigne et al, 2005).In addition to that Sarigand 
colleague(2002) point out that non-factor V Leiden APCR is one of the most common 
thrombophilic defects associated with recurrent pregnancy loss. 
 
The reported prevalence of acquired activated protein C resistance from studies so far 
ranges from 9% to 26.8% in women with first, second and third trimester losses. Fifty- one 
women with recurrent pregnancy loss and acquired APCR was recruited and their factor V 
gene was intensely analyzed (Dawood et al, 2007) .as Brenner and colleagues (1999) tested 
women with 3or more first trimester losses, 2 or more second trimester losses or one or 
more third trimester loss the FV Leiden mutation was more frequent in the fetal loss group 
compared to controls. Overall, 49% of women with pregnancy loss had a thrombophilia 
compared to 22% of controls. Other authors studied 1384 women enrolled in the European 
Prospective Cohort on Thrombophilia (EPCOT), They analyzed the frequencies of 
miscarriage fetal loss at or before 28 weeks of gestation and stillbirth (fetal loss after 28 
weeks of gestation) jointly and separately with cases group. 
 
Kupferminc and colleagues (1999) found a 50% prevalence of Thrombophilia in women 
with IUFD more than 23 weeks. Another study investigated women with IUFD at 27 
weeks' gestation or more In 40 women with unexplained IUFD, the prevalence of inherited 
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thrombophilia was 42.5% in the study group compared with 15% in controls (Kupferminc, 
2002).In addition to that Monari et al (2012), conducted a case-control study showed the 
presence of thrombophilia defect was significantly more prevalent in mothers with SBs 
compared to controls. In particular, SB mothers showed an increased risk of carrying 
Factor II mutation (OR=3.2, 95% CI: 1.3-8.3, p=0.01). 
 
2.7.2 Thrombophilia and Pregnancy-induced hypertension 
Pre-eclampsia is an important cause of maternal and fetal morbidity complicating 2-7 % of 
pregnancies.Pre-eclampsia  is one of the leading causes of maternal mortality Preeclampsia 
and eclampsia cause about  12%of maternal deaths(Tikkanen et al,2009).Numerous studies 
with different designs have assessed between pre-eclampsia and thrombophilia , many 
meta-analyses  has tried to determine the true association (Helsinki,2011).The first report 
of an association between early onset and sever pre-eclampsia and APL was described by 
Branch et al (1989).Later, Dekker et al (1995) reported an association between an inherited 
thrombophilia mutation and preeclampsia as he reported that 16 % of women had activated 
protein C resistance . 
 
Recent meta-analysis as Robertson et al  (2006) have indicated that pre-eclampsia is 
significantly associated with factor V Leiden and prothrombin mutations, 
anticardiolipin,antibodies, MTFHR, homozygosity and hyperhomocysteinemia , where's 
protein S protein C  and anti- thrombin deficiency. Mello et al (2005) showed not only an 
association between thrombophilia and sever pre eclampsia but also a tendency towards 
increased risks of maternal complications such early onset of disease less than 28 weeks of 
gestations. 
 
Van Pamus et al (2000) reported an increase prevalence of activated protein C resistance in 
284 women with a history of severing preeclampsia, compared with controls (11.3% vs. 
1.5%). 
 
2.7.3 Thrombophilia and IUGR  
Intrauterine growth retardation (IUGR) contributes significantly to fetal morbidity and 
mortality, but its etiology is unknown in most cases. IUGR is a frequent cause of stillbirth, 
perinatal morbidity, and long-term sequels, but its etiology is unknown in most cases. It 
has been suggested to be associated with abnormal placental vascular and disturbance of 
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homeostasis leading to inadequate maternal-fetal circulation. There is a growing view that 
inherited thrombophilia may predispose to adverse pregnancy outcome.The probable 
mechanism may be associated with pathological placental vascular leading to inadequate 
feto-maternal circulation. Some studies showed an association between inherited 
thrombophilia and complications, such as intrauterine fetal death, preeclampsia and 
placental abruption but the association between IUGR and thrombophilia is controversial 
(Hoffman et al, 2012). Mirzaei and Mahajeri (2012) reported in their study case-control 
study which is conducted at a tertiary center in Iran that 68% of a pregnant lady with IUGR 
had thrombophilia, 32 %of other ladies don't have thrombophilia. 
 
The association between thrombophilia and IUGR is weaker than in preeclampsia and 
pregnancy loss. Robertson et al (2006) reported that the only association between 
thrombophilia and IUGR is anticardiolipin   antibodies. On the other hand, Larciprete 
(2007) described the strong association between genetic thrombophilia and IUGR and 
percentage of IUGR among cases group reached 12.8 % in contrast to control group no 
association.Kupfemnic et al (1999) investigated 110 women with sever preeclampsia, 
IUGR, abruption placenta and IUFD more than 23 weeks, he found that prevalence of 
thrombophilia with IUGR was 61.4%. Zeev et al (2004) found significantly higher 
prevalence of thrombophilia (%37) was found in women who delivered small for 
gestational age stillborn compared with women who delivered normal birth weight 
stillborn (73% vs.18.4%, P < 0.0001).  
 
 2.7.4 Thrombophilia and Abruption placenta  
Abruption placentae, also called placental abruption, a significant cause of third-trimester 
bleeding associated with fetal and maternal morbidity and mortality, placental abruption 
must be considered whenever bleeding is encountered in the second half of pregnancy. 
 
It occurs on average in 0.5%, or 1 in 200 of deliveries(Cunningham et al, 2014).Literature 
reported a strong associate on between maternal thrombophilia and abruption placenta 
Giovanni et al (2007) had reported the more prevalent of abruption placenta among cases 
than control, Kinzler ( 2009) reported in his case-control study  that 63.0% of cases with 
abruption placenta  had at least one diagnosed maternal thrombophilia in comparison with 
44% among control .One of the recent studies factor V mutation was found in 20 %of the 
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women with preeclampsia, placenta abruption, fetal growth retardation, or still birth 
compared to only 6 %of control women without complication.(Kupfermnic et al, 1999)  . 
Hyperhomocysteinemia was documented in 26 %of women with placenta abruption, in 
11%of IUFD, and in 38 %of women delivering babies whose birth weight was below fifths 
percentile compared with an estimated 2% to 3 % in control population (De Vries et al, 
1997) 
2.7.5 Thrombophilia and preterm birth  
Preterm birth is the most common cause of death among infants worldwide. About 15 
million babies are preterm each year (5% to 18% of all deliveries). The chance of survival 
at less than 23 weeks is close to zero, while at 23 weeks is 15%, 24 weeks 55% and 25 
weeks about 80% ( Cloherty, 2012) chances of survival without long-term difficulties are 
lower (Jarjour, 2015). 
 
Kramer and colleagues (2009) had shown in his case-control study association between 
preterm labor and thrombophilia with adjusted odds ratio (ORs) =1.9.Not all previous 
studies showed able to replicate the association between thrombophilia and pre-term labor, 
but Erhardt and collogues (2000) reported an increased risk of mothers with preterm labor 
and thrombophilia, also, Gopel et al (1999) reported similar risk between thrombophilia 
and preterm labor. 
 
2.8 Thrombophilia and infertility  
A finding of a higher incidence of thrombophilia in women submitted to repeat cycles of in 
vitro fertilization (IVF) and implantation failure has become increasingly common 
compared to fertile women. Azem et al (2004) evaluated women were submitted to 
investigate the following thrombophilic factors: prothrombin gene mutation, MTHFR gene 
mutation, the presence of factor V Leiden, and antithrombin, protein C and protein S 
deficiency. A high frequency of thrombophilia was found in the subgroup of women with 
implantation failure (17.8%) compared to the group of fertile women and the group of 
women who became pregnant at the first IVF attempt (a frequency of 8.9% in both 
groups).Grandone et al (2001) also reported similar results in a case-control study 
involving a smaller sample of women the results of the two above mentioned studies, 
although indicative of a possible association between thrombophilia and failed 
implantation, do not positively confirm this association. On the other hand, Martinelli et al 
(2003) conducted a case-control study with the largest sample size evaluated up to the 
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present time and found no evidence of a higher frequency of thrombophilia in infertile 
women. 
 In 2009, a Turkish group published the findings of a study between thrombophilia and 
implantation failure was evaluated. This was a case-control study comparing a group of 51 
women with implantation failure and a group of 50 fertile women. a finding of at least one 
thrombophilic factor (62.7%) was more common in the group of women with implantation 
failure compared to the control group (53.9%). In 2010, Casadei et al, published a case-
control study that included a total of 300 women, 100with infertility of no apparent cause 
and 200 fertile women. The following hereditary factors were investigated: factor V 
Leiden (G1691A), prothrombin gene mutation (G20210A) and MTHFR enzyme mutation 
(C677T). This study found no difference in the frequencies of thrombophilic factors 
between the two populations evaluated (Casadei, 2010). A study was recently published on 
the prevalence of thrombophilia in a fertile and infertile female population in Brazil. This 
study found a high frequency of thrombophilia among infertile women (Soligo, 2007). The 
association between thrombophilia and infertility remains controversial; however  ,studies 
have tended to associate this coagulation disorder with implantation failure. 
 
2.9 Venous thromboembolism and pregnancy 
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are major health problems 
with potentially serious outcomes. Venous thrombo-embolism represents one of the main 
causes of maternal mortality in the world (2 per 100,000 live births). The overall 
prevalence of thromboembolic events during pregnancy is approximately 2 per 1000 
deliveries, approximately 20% of these events are arterial, and the other 80% are venous. 
Approximately 80% of venous thromboembolic events during pregnancy are deep vein 
thrombosis (DVT) and 20% are pulmonary emboli (Jameset al, 2005, James et al, 2006, 
Heit et al, 2005 ). 
 
The literature showed the risk of thrombosis and DVT increased by the presence of genetic 
thrombophilia and acquired thrombophilia. Anderson and Spencer (2003) reported that 
thrombophilia is one of the major risk factors for thrombosis; the overall prevalence of 
anticardiolipin antibodies and lupus anticoagulants has been established with cases with 
DVT. 
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James (2009) reported that inherited thrombophilia has a big role in thrombo -embolism 
disorder in pregnancy, as he showed in his case-control study, Factor V homozygous with 
odds ratio 34.4, Factor V heterozygous with odds ratio 8.32, Prothrombin gene 
homozygous with odds ratio 26.36, Prothrombin gene heterozygous with odds ratio 6.8 
,protein C deficiency with odds ratio 4.76, protein S deficiency with odds ratio 2.19. 
 
2.10Thrombo-prophylaxis in pregnancy  
The management of thrombosis during pregnancy includes treatment of acute deep vein 
thrombosis episodes, primary prophylaxis in a symptomatic women, and secondary 
prophylaxis of recurrences in women with a history of thrombosis.The diagnosis has 
serious implications not only for the immediate management of the pregnancy but also for 
the management of future pregnancies. 
 
2.10.1 Thrombo-prophylaxis and pregnancy complications 
A recent collaborative study demonstrated the safety of using low-molecular-weight 
heparin during 486 gestations a success-full outcome was reported in 83 (89%) of 93 
gestations in women with a history of recurrent pregnancy loss and in all 28 gestations in 
women who experienced preeclampsia during a previous pregnancy (Lepercq et al, 2001) 
In Carpe et al , (2003) study reported a cohort study undertaken to assess the effect of 
enoxaparin on subsequent live birth rate in women with 3 or more consecutive pregnancy 
losses and hereditary thrombophilia, live birth rate was higher in women treated with 
enoxaparin, 26 (70.2%) of 37 compared with 21 (43.8%) of 48 in untreated patients. 
 
Brenner (2004) demonstrated in his study that Data on antithrombotic prophylaxis for 
IUGR at index pregnancy and on subsequent gestations are limited. However, in view of 
the risk for recurrences of other gestational complications including IUGR, prophylaxis 
can be considered. This case can be managed with LMWH at a prophylactic dose once 
daily throughout gestation, and for 6 weeks in the postpartum period. This regimen may 
also be useful for prevention of other vascular complications.  
 
Many Literatures is confirming the management among pregnant ladies with previous 
VTE, but the problem of managing women with thrombophilia and fetal loss, IUGR, and 
preeclampsia, Women with a history of VTE with or without thrombophilia are believed to 
have a higher risk of recurrence in subsequent pregnancies.  
23 
 
 
Estimates of the rate of recurrent venous thrombosis during pregnancy in women with a 
history of VTE have varied between zero and 13%, the higher of these estimates has 
prompted authorities including (the American College of Chest Physicians) to recommend 
anticoagulant prophylaxis during pregnancy and the postpartum period in women with a 
history of VTE (Ginsberg, 2001). Also, he confirmed women with recurrent pregnancy 
loss, including at least one-second trimester miscarriage or a history of intrauterine death 
or severe or recurrent preeclampsia or growth restriction, should be screened for 
underlying congenital thrombophilia. In contrast to patients with APLA syndrome with 
recurrent miscarriage, where a combination of heparin and low-dose aspirin have been 
shown to be effective in reducing miscarriage rates, we have no data to indicate whether 
such antithrombotic therapy is beneficial (Ginsberg, 2001),Women with APLAs and 
neither previous venous thrombosis nor pregnancy losses should probably still be 
considered to have an increased risk of VTE and should be treated either with careful 
clinical surveillance for VTE or prophylactic UFH or LMWH. (Ginsberg, 2001). 
 
The treatment of recurrent miscarriage has traditionally been based on evidence, personal 
bias and the result of uncontrolled trials. The American College of Obstetricians and 
Gynecologists recommends low-dose aspirin (81mg) orally per day, along with 
unfractionated heparin (5000 units) subcutaneously, twice daily. This therapy begun when 
pregnancy is diagnosed is continued until delivery. Although this treatment may improve 
overall pregnancy success, these women remain at high risk for preterm labor ,prematurely 
ruptured membranes, fetal-growth restriction, preeclampsia, and placental abruption 
(ACOG, 2005). 
 
 Gris (2004) reported a prospective study for evaluation the effect of low dose low dose 
aspirin, or LMWH was done in women with one unexplained pregnancy loss, a total of 160 
patients with heterozygous factor V Leiden mutation, prothrombin G20210A mutation, or 
protein S deﬁciency were given 5 mg folic acid daily before conception, to be continued 
during pregnancy, and low-dose aspirin 100 mg daily or low-molecular-weight heparin 
enoxaparin 40 mg was taken from the 8
th
 week. Twenty-three of the 80 patients, treated 
with low-dose aspirin and 69 of the 80 patients treated with enoxaparin had a healthy live 
birth odds ratio (OR,15.5, 95 %conﬁdence interval [CI], P < .0001). 
 
24 
 
2.10.2 Thrombo-prophylaxis and venous thromboembolism 
Women at risk of venous thromboembolism should ideally have preconception assessment 
to outline the management plan for their pregnancy. The highest risk for VTE is in the 
postpartum period but it must be remembered that VTE related deaths occurred in all three 
trimesters of pregnancy. 
Thromboprophylaxis should be instituted from the earliest possible stages of risky 
pregnancy.Therefore women known to be at risk should be seen and counseled 
preconceptually (Ireland, Institute of Obstetricians and Gynecologists, 2013). 
 
2.10.3 Primary prophylaxis of thrombosis in asymptomatic women 
In asymptomatic women with known protein C deficiency, protein S deficiency, FV 
Leiden or prothrombin mutation, who have never experienced VTE, recommend either 
clinical surveillance or prophylactic therapy during the last weeks of pregnancy and 2–6 
weeks in the puerperium. (Kupferminc, 2003 ). 
Recently Literature confirmed the need of thromboprophylaxis among pregnant ladies with 
factor V homozygous and the prothrombin gene mutation to prevent thrombosis (Martinelli 
et al, 2001 ).Clinical surveillance is usually reserved for women who are allergic to 
heparin, refuse to use heparin or LMWH, or who have experienced a previous VTE in 
association with a transient risk factor (Kupferminc, 2003 ). 
 
2.10.4 Secondary prophylaxis in women with previous thrombosis: 
All patients with a personal or family history of VTE should be considered for antenatal 
prophylaxis and be screened for a thrombophilia.The two general approaches 
recommended for pregnant women with previous VTE are active prophylactic therapy with 
heparin or LMWH and clinical surveillance.Women with thrombophilia and a history of 
previous VTE should receive thromboprophylaxis during pregnancy and puerperium 
(Kupferminc, 2003). 
Literature show thromboprophylaxis in pregnancy is a controversial and critical issue as 
the decision of heparin thereby is not easy, it is a very expensive, inconvenient and painful 
to administer and associated with complications like bleeding and osteoporosis. The 
researcher will identify the different determinants associated with thromboprophylaxis uses 
in Gaza among risky pregnant women and the availability of agreement of risk assessment 
between different health providers, and answer a real question heparin is a new fashion or a 
real risk. 
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Chapter 3: Materials and Methodology 
 
3.1 Study Design  
 
The type of this study is an observational, analytic, retrospective, clinic-based comparative 
design with the triangulated mixed methodology. The present study will enroll a group of 
risky pregnant women with thromboprophylaxis use and a group of normal pregnant 
women without use in pregnancy and compared their patterns of previous exposures. The 
two groups are matched with at least three variables, the site of living (Governorate), the 
clinic of registration and follow up of antenatal care, the month of delivery. 
 
We select this type of this study because it is inexpensive, short time, it can give complete 
picture of comparison of determinants, outcomes, and different management practices, also 
in this study the researcher will use triangulation and mixed methodology because that 
Triangulation is a powerful technique that facilitates validation of data through cross 
verification from two or more sources. In particular, it refers to the application and 
combination of several research methods in the study of the same phenomenon, so the 
researcher will use qualitative and quantitative methods to validate data and confirm 
results. 
 
3.2 Study Population  
This study consists of two groups: 
 First, Delivered pregnant women at the last six months of the year (2016), and who 
were registered and followed up her ANC at UNRWA Health Centers -Gaza 
governorates-. 
 Second, Health Providers who are concerned with thromboprophylaxis use among 
risky pregnant women.    
3.3 Sample Population 
First, these populations selected randomly from study population as two groups cases 
group are risky pregnant women and are characterized as alert or high-risk pregnancy 
according to UNRWA risk scoring program. Each risky case compared with normal 
pregnant women who were registered, followed up at UNRWA Health Centers and 
delivered at the same period. 
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Second. a non-probability purposive sample of three key health providers (health providers 
who concern with uses among pregnancy). 
 
3.3.1 Study settings 
The study carried at UNRWA Primary Health Centers (Gaza Governorates) Nearly, it 
carried at five Health Centers of UNRWA mainly large clinics  (North Gaza, Gaza, Middle 
Zoon, Khan-Younis, and Rafah ). 
 
3.4 Study Period  
The study started from April 2016, by conducting the administrative procedures and the 
ethical approval. The study consumed 12 months It started in April 2016 and completed by 
July 2017. 
 Annex (1) describes the activities of the research and expected duration for each 
activity. 
 
3.5 Sampling 
3.5.1 Sample size  
The sample size for this study determined by using the statistical calculator of the 
EPI_INFO program sample size: The proposed sample size was 430 participants 
(Annex,2). The researcher increased the actual sample size to 440 participants to 
compensate any missing or non-respondents. The larger the sample size, the greater 
representatives and the greater the statistical power. 
The researcher studied 220 cases with thromboprophylaxis use and compared it with 220 
pregnant women without thromboprophylaxis use, a ratio of one to one. 
 
3.5.2 Sampling Process 
Multistage sampling technique used to select 5 UNRWA  PHC clinics from the 21 clinics.  
First, GG areas will be divided into five areas (clusters). In each area, the clinics will be 
divided into3 groups; Large, Medium, Small, according to refugee population served 
(Annexes3,4). 
 
The sample of the 440  clients divided among GG areas according to the total number. 
Also, the sample in each area divided into  two groups cases with thromboprophylaxis and 
comparative normal group without thromboprophylaxis .both groups will be chosen 
27 
 
according to an eligible criteria as all cases of studied phenomena will be taken from the  
delivered women at the same period of study , comparative normal group will be selected 
by systemic random selection by selecting the next one (Annex3,4 ). 
 
A non-probability purposive sample of three key health providers (health providers who 
concern with thromboprophylaxis uses among pregnancy), they selected. The qualitative 
component carried out after the quantitative one in order to explore issues that emerge 
from the quantitative study. 
 
3.6 Eligibility Criteria 
Quntatitive Part  consisit from the following part :  
3.6.1 Inclusion criteria  
The participants studied, meet the criteria of the study. 
3.6.1.1 Cases with thromboprophylaxis 
 Newly delivered women who were categorized as high-risk pregnancy 
 Had received thromboprophylaxis during pregnancy.  
 Attended antenatal care at UNRWA centers 
 
3.6.1.2 Comparative group without thromboprophylaixs  
 Newly delivered women who were classified as normal pregnancy 
 Did not received thromboprophylaxis during pregnancy 
 Attended antenatal care at UNRWA centers 
 
 3.6.2 Exclusion Criteria  
QualitativePart consists from the following part: 
 
3.6.2.1 Cases with thromboprophylaxis 
 Delivered risky pregnant women who are not registered at UNRWA Health 
Centers. 
 Delivered risky pregnant women who have not attended UNRWA Health centers in 
the defined period of study. 
 Delivered Risky Pregnant women without Thrombophilia and thromboprophylaxis 
during her pregnancy. 
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3.6.2.2 Comparative group without thromboprophylaxis 
 Delivered normal Pregnant Women who are not attendant at UNRWA Health 
centers. 
 Delivered normal pregnant women who are not attendant in the defined Health 
Centers. 
 
3.7 Study instruments   
This study utilized three types of instruments; the first is an Interviewed structured 
questionnaire for target Clients. The main items for the questionnaire will be: 
 Personal and demographic data: Age, address, Years of education, and current 
occupation. 
 Socioeconomic information: such as the type of family, type of house, number of 
rooms, and monthly income. 
 Family History: Thrombophilia, thromboembolic disorders 
 Past Medical history: Arterial, venous thrombosis, DVT, chronic diseases, and SLE 
(systemic Lupus Erythrocytosis ). 
 Past obstetric history: Gravida, Parity, Age of marriage, infertility, IVF, Abortion, 
Habitual Abortions, IUFD, Early Fetal Death, still births, perinatal mortality, 
congenital anomalies, IUGR, LBW, PIH, pre-eclampsia, APH, PPH and Abruption 
Placenta. 
 Current Obstetric History: LMP, GA at registration, BMI at registration, number of 
ANC visits in her pregnancy, history of medical disorders during pregnancy, 
indication for pregnancy termination, common disorders associated with or caused 
by pregnancy. 
 Pregnancy outcome 
 GA of delivery, Mode of delivery, place of delivery, Live or dead child, Birth 
Weight at delivery, associated congenital anomalies and H/o of SCBU admission.  
 Source of Diagnosis: Hospitals, PHC centers, Private Doctors  
 Criteria and investigations of diagnosis: Inherited, A acquired thrombophilia, or 
others 
 The site of Follow up: Primary Health centers, Hospitals or Private. 
 Type, availability, and cost of thromboprophylaxis treatment. 
The second instrument is an open-ended (semi-structured) questions. these questions will 
be asked by the researcher within in-depth interviews with 3 key health providers (health 
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providers concerns of thromboprophylaxis ), this sample will be a non-probability 
purposive sample of five key informants (heath providers concerns of thromboprophylaxis 
) selected.  
 
The idea of including this sample is to dig deeply and understand in-depth the definite 
meaning of thromboprophylaxis, risk factors associated, the magnitude of the problem, 
indications of treatment, consequences of thromboprophylaxis use, harmonization between 
health providers and recommendations for that. The qualitative component suggests 
containing these questions: 
 What are the magnitude and current status of thromboprophylaxis use among risky 
pregnant women,? 
 What are the different associated risk factors and indicators for thromboprophylaxis 
uses among risky pregnant women? 
 What do you think about the benefits of thromboprophylaxis in pregnancy? 
 What do you think about an international guideline for thromboprophylaxis uses in 
risky pregnancy? 
 How can you describe the harmonization between different health providers in 
understanding this need of thromboprophylaxis among risky pregnancy? 
The third instrument is Medical records Review  
The researcher selected randomly clients medical records for these who received 
thromboprophylaxis during their pregnancy as researcher selected the secondmedical card 
from 220 cases, as it will be nearly 100 cards.This Review will compare the of 
adherencethromboprophylaxis management practices with international guidelines, the 
researcher will construct self-developed abstract sheet that is based on literature review, 
the domains which will be included with it will be. 
 Past Obstetric history  
 Past Medical history  
 Gestational age of starting thromboprophylaixs treatment  
 Continuity of treatment overall pregnancy and 6weeks after delivery 
 Diagnostic investigations (Hereditary –Acquired  thrombophilia ) 
 Follow up investigations  
 type and dose of treatment  
 combinations of thromboprophylaxis  
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3.8 Data Collection   
The researcher and one data collector conducted structured –interviewed questionnaire 
with target clients and medical records review which is a complementary for the 
questionnaire.This took place within 6 months with delivered pregnant women at that 
period, The  two data collector are one is  a nurse, she is trained  to collect  data  as the 
researcher. 
 
The second component of the data collection was three in-depth interviews with three key 
health providers.Semi-structured questions will be designed and questioned for them by the 
researcher.Notes taken through the interviews and recorded to allow further capturing of 
information. 
 
3.9 Data entry and analysis 
3.9.1 Quantitative Method 
The researcher used Statistical Package of Social Science (SPSS) program for data entry 
and analysis. Data analysis carried out as the following: 
 Reviewing the questionnaire. 
 Developing an appropriate entry model. 
 Coding of the questionnaire. 
 Cleaning the data. 
 Formulation of frequency table for the study variables. 
 Defining and recoding of variables. 
 Cross-tabulation of the results .  
 Statistical relationship between the risk factors and thrombophilia 
These assessed using Chi-Square and Odds ratio with confidence interval 95%. Statistical 
level of significance used was 0.05. 
 
3.9.2 Qualitative part 
Open coding thematic analysis method used to analyze the transcripts of the in-depth 
interviews. The researcher obtained the main findings from the transcripts of the 
interviews. Then, categorization of related ideas and comparison and integration between 
the quantitative and the qualitative findings was done to create rich items for discussion 
and representation. 
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3.10 Scientific rigor  
3.10.1 Quantitative part (questionnaire)  
3.10.1.1 Validity    
 The questionnaire tested by experts to assess its relevance, evaluated all the 
components and the context of the instrument, in order to ensure that it is highly 
valid and relevance and their comments were taken into consideration. The 
researcher presented the questionnaire to 8 experts specialized in the field of public 
health (Appendix 1) in order to take their views and benefits from their long 
experience on the questions of belonging to the subject of the study, and the 
accuracy of the wording, the researcher completed the amendments recommended 
by the arbitrators to delete, add, and amend the questionnaire in its final form 
consisting of (8) parts as shown in Annex (2).  
 . The questionnaire was nicely formatted in order to ensure face validity, this 
including appealing layout, and logical sequences of questions and clarity of 
instructions 
 A pilot study conducted before the actual data collection to examine clients’ 
responses to the questionnaire and how they understand it. 
 
3.10.1.2 Reliability   
The following steps are done to assure instruments reliability 
 Training of data collectors on the clients interviewing steps and the way of asking 
questions.  This will assure standardization of questionnaire filling . 
 Then, the data entry on the same day of data collection would allow possible 
interventions. 
  Check the data quality or to re-fill the questionnaire when required  . 
 Re-entry of 5% of the data after finishing data entry will assure correct entry 
procedure and decrease entry errors. 
 
3 .11 Reliability of questionnaire  
Before applying the study tool, the researcher verified the validity and consistency of the 
questionnaire through the following steps: 
3.11.1 Compact Factor 
The researcher verified the persistence of the questionnaire by finding the coefficient of 
agreement between the mobilization of mothers and the data on the medical health records  
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in the clinic of each mother  with the aim of the absence of any ambiguity in the 
understanding of the questions by the mothers, and it actually measured what was set for 
measurement, The researcher chose 12 questions, which have an important and direct 
answers to the study. 
 
The researcher then selected a sample of 100 MHR of chosen clinics in the sample and 
asked them to fill out the questionnaire. The researcher then obtained answers to the 
questionnaire of mothers from maternal health records. After monitoring the quantitative 
estimates of the cases, and the difference between the researcher and the other cases using 
the Cooper equation, which states: 
 
 
 
×100 
 
 
 
 
Number of times of agreement 
 
 
Agreement ratio =  
Number of times of agreement + number of 
times of disagreement 
It is noted from the previous table that the ratio of the coefficient of agreement ranges 
between (91.66 - 97.7%) and the total agreement coefficient (95). These ratios are a 
function of the accuracy of the questionnaire, which reassures the researcher before 
applying them. 
 
Table (3.1) Ratio of the agreement between the observers 
 
Region 
Number 
of cases 
Points of 
agreement 
Points of 
difference 
Total points of 
agreement and 
difference 
the 
coefficient of 
agreement 
North of 
Gaza 
20 230 10 240 95.83 
Gaza 20 225 15 240 93.75 
Central 20 220 20 240 91.66 
Khan 
Younis 
20 232 8 240 96.66 
Rafah 20 233 7 240 97.70 
total 
summation 
100 1140 60 1200 95 
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3.11.2 Qualitative part (in-depth interviews) 
The following methods are used assure the trustworthiness of the qualitative part in this 
study.  
 A peer check w did through health experts to revise the in-depth interview. 
 Questions to assure that they cover all the required dimensions. 
 A member check done to assure accuracy and transparency of the transcripts during 
the interviews. 
 Recording the interviews would enhance the accuracy of the transcripts. 
 All the transcripts and recordings will be kept for tracking the information by 
others at any time (Audit trail). 
 
3.12 Pilot study 
A piloting process was conducted before starting the data collection.  The piloting process 
aimed to help in identifying problems in the research design; test the data collection tool 
for validity and reliability. Also, Piloting allows data collectors training for collecting data 
and where is the week piont in data collection.  
The pilot study was 5% of sample size, as it nearly consists of 20 clients,10 cases, 10 
controls with the same eligibility criteria for cases and controls, It was held at Jabalia 
Health Center as it is a large health center and it contains a large number of risky 
pregnancies. As a result of piloting some modifications to data collection tools were done.  
Subjects who have been selected for piloting had been excluded from the study. 
 
3.13 Ethical matters  
 An ethical approval will be asked for from Helsinki Committee. 
 An Academic approval will be asked for from School of Public Health at Al-
Quds University. 
 An Admin approval will be asked for from the Director of UNRWA Health 
Programs in Gaza Governorate.  
 Every participant in this study received a complete explanation of the 
research, purpose, and confidentiality. 
 We should guarantee and take approval for every participant health provider 
is an in-depth interview.  
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 Every woman of the study population knew that participation in the research 
is optional and she has the right to refuse. 
 
3.14 Anticipated Limitation of Study  
 The study will include a sample from UNRWA clinics and there are other 
PHC clinics for MOH, NGOs will not be included and private clinics.  
 The study will include only clients who are attending UNRWA PHC setting 
within the study period and it is not including all population which is 
important for complete reality. 
 Case-Control study doesn't give a picture of the prevalence of phenomena, 
with a risk of recall bias.  
 Poor availability of basic systemic studied about studied phenomena. 
 Lack of resources and materials needed for the study concern.  
 Frequent power shortage.  
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Chapter 4: Results and Discussion 
 
In this chapter, we draw a framework about how we work in research, how we collect data 
and describe different statistical,methods used in research. as well as the result and analysis 
of the work. 
 
4.1 Study Population 
The studypopulation consists of delivered pregnant women in the last six months of the 
year (2016),andwho were registered and followed up her ANC  at UNRWA Health Centers 
–Gaza governorates- Cases will be risky pregnant women with thromboprophylaxis,and 
are characterized as alert or high-risk pregnancy according to UNRWA risk scoring 
program. Each case (risky with thromboprophylaxis) will be matched with normal 
pregnancy who is registered, followed up at UNRWA Health Centers and delivered at the 
same period.Matching criteria includeplace of living, the month of delivery and the clinic 
for follow up.  
The study  carried at UNRWA Primary Health Centers (Gaza Governorates), It carried at 
five Health Centers of UNRW mainly large clinics  (North Gaza, Gaza, Middle Zoon, 
Khan-Younis, and Rafah ).as we found North Gaza had the majority (58 cases ) followed 
by Rafah (52cases ), then Gaza (40 cases), then Khanyounis(38 cases). Finally,the least 
clinic is Midzoon (32 cases), which is nearly total numbers 220 cases,these cases matched 
with the same number of another comparative group (control) who do not use 
thromboprophylaxis during pregnancy. 
 
4.2 Data collection tools 
Data collection tools divided into two main parts, as the following  
 
i. Quantitative part 
a. Interviewed Questionnaire  
b. Medical Records Review 
c. Generic Study Review 
 
ii.  Qualitative part (In-depth interviews with concerned health providers) 
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The following Figure describes the explanation of this part  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1:  Data collection tools 
 
4.3 Interviewed questionnaire 
The study questionnaire designed and prepared to compile information relating to the 
objectives of the study. An Arabic version of the questionnaire had been used during 
interviews with participants;the questionnaire had been reviewed by 7 experts who are 
qualified in many fields related to this study. 
The interviewed questionnaire consists of 9 parts,as these main parts compared between 
both groups and describe the experience of thromboprophylaxis use among cases and 
different managerial practices. 
Interviewed  
Questionnaire 
Data collection tools 
Quantitative part Qualitative part 
Medical Records 
Review 
Genetic Study 
Review 
Interview concerned  
Health providers 
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Figure 4.2 : Interviewed questionnaire 
 
4.4 Medical records review  
In this section we reviewed 100 fileswhich were randomly selected from cases group, who 
usedthromboprophylaxis during pregnancy, this review is done according to 3 main parts, 
which include, as described in chapter 4 
i. Review of distribution of bad obstetric history  
ii. Review of distribution of risk factors  
iii. Review of Review of management practices 
Past medical history 
Past obstetric history 
Interviewed 
questionnaire 
Socio -demographic 
charterstics. 
History of hormonal 
contraceptive  
History of pregnancy 
complications: Recurrent Ab, 
IUD, Medical & obstetrical 
complications 
History of thrombosis and 
thromboprophylaxis use in 
previous pregnancy 
History of last pregnancy and 
thromboprophylaxis use 
Evaluation of (BP, BMI) 
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Figure 4.3: Medical records review. 
 
 
4.5 Genetic molecular study review  
According to the questionnaire results, 153 cases did investigation profile, 112 cases did 
molecular genetic study, we found 96 genetic molecular studies available with studied 
cases, was  reviewed for 6 main genetic studies, 3 main different genetic alleles description 
1. Prothrombin G2010A(homozygous, heterozygous, normal ) 
2.  ACE 1/0(homozygous, heterozygous, normal) 
3. PAI - 4G/5G(homozygous, heterozygous, normal) 
4. Factor v(homozygous, heterozygous, normal) 
5. MTHFR(homozygous, heterozygous, normal) 
6. Factor XIII (homozygous, heterozygous, normal) 
4.6 Statistical design  
The researcher used the Statistical Package for Social Sciences version 23 (SPSS, 2016) 
for data coding, entry, and analysis. Simple distribution and frequencies of the study 
variables, the cross tabulation, and normal chi-square had been applied P value had been 
calculated for the ordinal level measures (P< 0.05), variables that are statistically 
significant by chi-square test had been analyzed using odds ratio and 95% confidence 
interval. 
Review of management practices 
Medical records review 
Review of distribution of risk 
factors 
Review of distribution of bad 
obstetric history 
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Figure 4.4:Genetic molecular study reviews 
 
 
4.7 Statistical analysis 
Chi-square ( ) test was used to establish the p-value using SPSS program. 
 4.7.1 Significance of results 
 When P> 0.05 it is statistically not asignificant difference. 
 When P< 0.05 it is thestatistically significant difference. 
 When P< 0.01or P< 0.001 it is thehighly statistically significant difference. 
4.7.1 Significant of odds ratio   
Odds ratios are used to compare the relative odds of the occurrence of the outcome of 
interest (e.g. disease or disorder), given exposure to the variable of interest (e.g. health 
characteristic, anaspect of medical history). The odds ratio can also be used to determine 
whether a particular exposure is a risk factor for a particular outcome and to compare the 
magnitude of various risk factors for that outcome. 
 OR=1 Exposure does not affect odds of outcome 
 OR>1 Exposure associated with higher odds of outcome 
 OR<1 Exposure associated with lower odds of outcome 
PAI-4G/5G 
MTHF
R 
V Leiden 
Factor  
Genetic molecular study 
review 
Prothrombin 
G2010A factor 
ACE 1/0 
Factor XIII 
40 
 
However, the odds ratio (OR), its standard error and 95% confidence interval are 
calculated according to (Altman, 1991). 
 
4.8Interviewed questionnaires 
In this chapter, the researcher presents the main results of the study variables that were 
attained the study objectives, as it includes, this  part first quantitative method  which is 
interviewed questionnaire, as explained in previous chapter, the nature of the 
questionnaire,  it consists of main 9 parts, which  are related to the main study objectives  
we use a comparative study design, between both groups, cases in treatment group (220 
cases ), who use thromboprophylaxis during pregnancy, and control group who did not use 
thromboprophylaxis, this questionnaire compared the different determinants associated 
with both groups,  it also described the experience of thromboprophylaxis use among 
treatment group,  the results collected from UNRWA health centers as described in chapter 
2 and chapter 4, analyzed according to the last version of SPSS by using, chi-square, P-
value and odds ratio. The researcher highlights the findings of this study compared with 
other global and regional studies and tried to interpret the results and its implication. 
 
4.9 Characteristics of the study population 
This part explains the Distribution of cases by sociodemographic variables 
 
4.9.1 Distribution of sociodemographic factors of wife 
Table 4.1 summarizes the distribution of both treated group and non-treated group 
regarding sociodemographicfactors, it compares the 220 treated women with 220 non 
treated women.matched by place of residence, clinic of registration and follow up and the 
month of delivery.In both groups, North Gaza governorate had the largest number of 
treated women  (n=58, 26.4 %) as well as non-treated women, while middle governorate 
had the smallest number (n=32,14.5% ),  Rafah, Gaza and Khanyounis Governorates 
constitute 52, (23.6%), 40, (18.2%) &38, (17.3%), from the total percent of treated women 
and non-treated women.According to the place of living, the researcher also matches 
treated women and non-treated women,  So women live in cities 42.75 % of treatedwomen 
and 47.3 5% of non-treated women. Women who live in refugee camps were 54.5%of 
treated women and 44.1% of non-treated women, while 2.7% of treated women and 8.6% 
of non-treated women live in villages, as shown most of the women were living in camps 
and cities as Palestinian refugee demographic distribution (UNRWA, 2016).Regarding to 
41 
 
age groups distribution  were divided into four groups, in which 38.6 % of treated clients 
and 40.9 % non-treated clients were located in the age group 26-30 years which constitute 
the majority group in the study, the other three groups, less than 20 years old, 20-25 years,  
Table 4.1 Demographic characteristics of Wife (N=440) 
 
Variables 
Cases Controls Total 
Freq. % Freq. % Freq. % 
Residency 
North Gaza 58 26.4 58 26.4 116 26.4 
Gaza 40 18.2 40 18.2 80 18.2 
Midzoon 32 14.5 32 14.5 64 14.5 
Khanyounis 38 17.3 38 17.3 76 17.3 
Rafah 52 23.6 52 23.6 104 23.6 
Place of 
living 
city 94 42.7 104 47.3 198 45.0 
camp 120 54.5 97 44.1 217 49.3 
Village 6 2.7 19 8.6 25 5.7 
Age 
 
< 20 21 9.5 12 5.5 33 7.5 
20 – 25 62 28.2 83 37.7 145 33.0 
26 – 30 85 38.6 90 40.9 175 39.8 
> 30 52 23.6 35 15.9 87 19.8 
Age at 
marriage 
< 20 130 59.1 107 48.6 237 53.9 
20 – 25 80 36.4 100 45.5 180 40.9 
26 – 30 7 3.2 10 4.5 17 3.9 
> 30 3 1.4 3 1.4 6 1.4 
Total Years 
of  education 
Primary school 17 7.7 107 48.6 31 7.0 
Preparatory school 53 24.1 100 45.5 56 12.7 
Secondary school 97 44.1 10 4.5 186 42.3 
University / collage 53 24.1 3 1.4 167 38.0 
employment 
Employed 30 13.6 32 14.5 62 14.1 
Unemployed 190 86.4 188 85.5 378 85.9 
It yes, specify  
employer 
Governmental 11 5.0 18 8.2 29 6.6 
Non-Governmental 6 2.7 12 5.5 18 4.1 
Self-employed 13 5.9 2 0,.9 15 3.4 
 
 
more than 30 years,9.5 % of treated clients  and 5.5 % of non –treated clients, 28.2 % of 
treated clients  and 37.7 % of no-treated clients, and 23.6 % of treated clients  and 15.9 % 
of non-treated clients  respectively.According to the women age at marriage, were divided 
into four groups, it is clear from the table that 59.1% of treated women and 48.6% of non-
treated women were married at age less than 20 years old. The other three groups 20-25, 
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26-30, &>30 years, 36.4 %of treated women and 45.5 % of non-treated women, 3.2 % of 
treated women and 4.5 %of non-treated women respectively, which that constitutes with 
UNRWA(2015), as percentage of women married by age <18 years at Gaza field 33%, and 
mean marital age at Gaza 19.2 (UNRWA, 2015).Regarding to the distribution, of  women 
according to educational level, 7.7 % of total treated women, 48.6% of total non-treated 
women finished primary school, 24.1% of total treated women, 45.5% of non-treated 
women  finished preparatory school, 44.1 % of total treated women, 4.5 %of total non-
treated women finished secondary school, while 24.1 % of treated women, 1.4% of non-
treated women finished diploma and university level as shown the education level is higher 
among treated women than non-treated women.Regarding the distribution of women 
according to their employment status,13.6% of treated women and 14.5% of non-treated 
women were employed, most of them are governmental employees, 5.9% of treated 
women, and 8.2 % of non-treated women respectively   
 
4.9.2 Distribution of sociodemographic factors of husband 
 
Table 4.2 summarizes demographic characteristics of husbands, as shown age groups like 
wife were divided into 4 major groups .it is clear from the table, the majority of the 
husband were older than 30 years in 53.2% of treated women and 44.1% of non-treated 
women, respectively.Other age groups, <20 years, 20-25 years, 26-30 years were 0.5% of 
controls, 13.2% of treated women and 18.2 of non-treated women husbands, 33.2 % of 
treated women and 37.3 % of non-treated women husbands, respectively.According to 
husband’s age at marriage, as shown in the table, the majority of husband’s ages at 
marriage were between 20-25 age group, 57.7% of treated women and 62.3% of non-
treated respectively, other age groups <20 years, 26-30 years,&>30  years  11.4% of 
treated women  and 10 % of untreated women, 26.4% of treated women  and 24.5% of 
non-treated women and 4.5 % of treated cases and 3.2 % of non-treated, respectively. 
Regarding the distribution of women husbands to the years of education as shown in table, 
19.1% of treated women and 7.3 5% of non-treated women husbands had finished primary 
school level 14.5% of treated women and 5.9% of non-treated women husbands had 
finished preparatory school, while 36.4% of treated women and 33.2% of non-treated 
women husbands had finished secondary school level while 30% of treated women  and 
53.6% of non-treated women husbands had attained  diploma and or  a university degree. 
According to the employment status of husband, it is clear from that table that 68.2% of 
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treated women husbands and 59.5% of non-treated womenhusbands were not employed, 
31.8% of treated women husbands and 40.5% of non-treated women husbands were 
employed, the majority of them were governmental employee (32.3% of treated women 
and 29.5% of non-treated women). 
 
Table 4.2:Demographic characteristics of husbands (N=440) 
 
Variables 
Cases Controls Total 
Freq. % Freq. % Freq. % 
Age 
 
< 20 1 0.5 1 0.5 2 0.5 
20 – 25 29 13.2 40 18.2 69 15.7 
26 – 30 73 33.2 82 37.3 155 35.2 
> 30 117 53.2 97 44.1 214 48.6 
Age at marriage 
< 20 25 11.4 22 10.0 47 10.7 
20 – 25 127 57.7 137 62.3 264 60.0 
26 – 30 58 26.4 54 24.5 112 25.5 
> 30 10 4.5 7 3.2 17 3.9 
Total Years of 
education 
Primary school 42 19.1 16 7.3 58 13.2 
Preparatory 
school 
32  13 5.9 45 10.2 
Secondary 
school 
80 36.4 73 33.2 153 34.8 
University or 
collage 
66 30.0 118 53.6 184 41.8 
Employment  
employed  70 31.8 89 40.5 158 35.9 
unemployed  150 68.2 131 59.5 282 64.1 
If yes, specify 
type of employer  
Governmental 67 30.5 65 29.5 133 30.2 
Non-
Governmental 
12 5.5 14 6.4 26 5.9 
Self-employed 71 32.3 52 23.6 123 28.0 
Consanguineous  
Marriage 
Yes 115 52.3 147 66.8 262 59.5 
No 105 47.7 73 33.2 91 40.5 
Specify 
Consanguinity 
First degree 55 25.0 36 16.4 91 20.7 
Second degree 34 15.5 30 13.6 64 14.5 
Far relative 16 7.3 7 3.2 23 5.2 
 
On the other hand, 30.5% of treated women husbands and 23.6% of non-treated women 
husbands were self-employed, 5.5% of treated women and 6.4% of non-treated women 
were non-governmental employees. According to the consanguine marriage, as shown by 
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table (5.2.2), the majority of study population with positive consanguinity, 52.3% of 
treated women and 66.8% of non-treated women respectively, while 47.7% of treated 
women and 33.2 % of non-treated women were not, most of the consanguinity degrees, 
were first degree consanguinity, as shown by table (5.2.2), 25% of treated women and 
16.4%of non-treated women with first degree consanguinity. 
 
4.9.3 Economic level  
Table 4.3: Characteristics of economic level of the study population 
 
Variables 
Cases Controls Total 
Freq
. 
% Freq. % Freq. % 
Average 
family 
income 
less than 1000 NIS. 140 63.6 136 61.8 276 62.7 
1500-2000 NIS. 36 16.4 52 23.6 88 20.0 
 more than 2000 NIS.  44 20.0 32 14.5 76 17.3 
House Owned 184 83.6 179 81.4 363 82.5 
Rented 36 16.4 41 18.6 77 17.5 
Type of 
house 
Concrete house 154 70.0 169 76.8 323 73.4 
Asbestoses house 58 26.4 45 20.5 103 23.4 
Mud house 8 3.6 6 2.7 14 3.2 
Number of 
rooms 
One room 50 22.7 67 30.5 117 26.6 
Two rooms   83 37.7 78 35.5 161 36.6 
Three or more rooms 87 39.5 75 34.1 162 36.8 
 
 
Table 4.3 summarizes economic level described among study population, by the following 
variables, average family income, type of house, and number of rooms, Regarding to the 
average of income, it is clear the majority of them, are less than 1000 NIS, 63.6% of 
treated women, 61.8% of non-treated women, others 1500 NIS-2000 NIS, &more than 
2000 NIS.16.4% of treated women and 23.6% of non-treated women, 20% of treated 
women and 14.5 %of non-treated women, respectively.Regarding to the type of house, 
most of them are with owned house ,83.65% of treated women  and 81.4%of non-treated 
women, respectively, most of them had concrete houses, 70 % of treated women and 
76.8% of non-treated women but on the other hand, the majority of treated women are 
39.5% had three or more, but the majority of non-treated women nearly,37.7% had 2 
rooms, 22.7%of treated women and 30.5%of  non-treated women have one room, 
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respectively. All these tables reflected the bad socioeconomic status and the poverty rate 
among the studied population which is constant with statically of Palestinian refugees.   
 
4.10Past medical history of the study population  
 
The table 4.4shows that the  majority of non-treated women which is nearly 97.9% did not 
have chronic non-communicable diseases on the other hand,87.3% of treated women did 
not have non-communicable diseases, while 12.7 % of them had  non communicable 
diseases, the calculated chi-square is significant at p-value 0.000, which means that 
mothers in treated and non-treated conditions are not equal in distribution of chronic non- 
communicable diseases as odds ratio is (calculated  6.27), that means women who treated 
with thromboprophylaxis  had a risk 6 times than non-treated women of exposure to non-
communicable diseases. 
Table 4.4: Relationship between past medical history non -communicable diseases 
and thromboprophylaxis use. 
 
Variables 
Cases ((220) Controls 
s(220) 
 
Freq. % Freq. % Chi Sig 
1 
Is there a past history 
of Non-communicable 
diseases 
Yes 28 12.7 5 2.3 
17.33 .000 
No 192 87.3 215 97.7 
Odd ratio = 6.270895 % CI   =2.3741 to 16.5634 
 
Table 4.5: Relationship between past medical history- hematological diseases- and 
thromboprophylaxis use  
Variable 
Cases (220) 
Freq. % 
1 
Is there a past history of 
Hematological Diseases? 
Yes 76 34.5 
No 144 65.5 
1.1 If you choose, yes  specify 
Congenital 
thrombophilia 
37 48.7 
Acquired 
thrombophilia 
11 14.5 
Thromboembolism  
disorder 
28 36.8 
1.2 If you choose i, ii  specify 
Lab.test done 44 91.7 
Lab. test not done 4 8.3 
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The  table 4.5 part 1summarizes that 76 cases with 34.5% of total treated women  had 
chronic hematological diseases, while 144 cases with 65.5% of the total treated women did 
not have hematological diseases, on the other hand, none of the non-treated women  had 
chronic hematological diseases, where calculated value of chi-square is significant at (P-
value, 0.000), which is highly statistically significant, that means treated women is with 
high risk to be exposed to chronic hematological diseases, concerned health providers 
confirmed “the use of thromboprophylaxis during pregnancy is a hematological decision, 
not an obestetriation decision”. 
 
The table 4.5 part 1.1summarizes 37 cases with 48.7% of the total treated women had 
congenital thrombophilia, 11 cases with 14.5% of total treated women  had acquired 
thrombophilia  and 28 cases (36.8% of cases) had thromboembolism disorders, which is 
that constant with Hellgren(2003), who confirmed in his study thrombophilia conditions is 
associated with 70-90%of risk of thrombosis, also that is constant with Robesteron et al 
(2006), showed significance association between acquired thrombophilia and the risk of 
thrombosis, also, Kupfeminc (2003), showed strong association between congenital 
thrombophilia and acquired thrombophilia, and the risk of thrombosis 2-15%&10-15% 
respectively.  
 
The table 5.4 part 1.2 summarizes lab.test significance among cases with thrombophylxais 
use, regarding to the cases with thromboprophylaxis use had hematological diseases 44 
with 91.7%of the treated women are laboratory-based diagnosis- and 4 with 8.3%of the 
total cases are not laboratory-based diagnosis, which that is constant with concerned health 
providers opinions that “ all women  with a risk of thrombosis either bad medical history 
or bad obstetric history should be investigated well to the presence of thrombophilia”, 
while other said “Investigation should not be done in every case, medical history and 
obstetric history is enough to start thromboprophylaxis during pregnancy”. 
 
Table (4.6 part 1) showed that 26 cases with 11.8% of  total treated women cases had 
positive history of vascular diseases, while 194 cases with 88.2% of total treated women 
did not have history of vascular diseases, on the other hand only one case with 0.5% of 
non-treated women had a history of vascular disease, The calculated value of chi-square is 
highly significant at (P-value- 0.000, odds ratio 29.3), that means cases with 
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thromboprophylaxis use had a risk of 29.3 times than non-treated women of exposure to 
vascular diseases.       
 
Regarding to the distribution of vascular diseases types among cases as shown in Table 
(4.6 part 1.1) , 14 cases with 54% of the total treated women  had  varicose  veins, 3 cases 
with 12% of the total treated women had thrombophlebitis, 9 cases with 35% of the total 
treated women had  deep venous thrombosis and no any reported cases of vasculitis,these 
results are constant with literature as James et al (2005), James et al (2006), Heir et al 
(2005), 80% of venous thromboembolism during pregnancy are deep venous thrombosis, 
also concerned health providers confirmed this strong association between vascular 
diseases and thromboprophylaxis one of them said that  “History of one DVT is one of the 
main indication of starting heparin therapy in pregnancy”, other  said “50% of VTE 
(venous thromboembolism) link between thromboprophylaxis and pregnancy loss “. 
 
Table 4.6: Relationship between past medical history -vascular diseases-and 
thromboprophylaxis use  
 
Variables 
Cases (220) 
Freq. % 
1 
Is there a past history 
of vascular diseases? 
Yes 26 11.8 
No 194 88.2 
1.1 
If you choose, yes  
specify 
Varicose veins 14 54 
Thrombophlebitis 3 12 
Deep Venous 
thrombosis 
9 35 
Vascuilitis 0 0 
 
 
Table (4.7 part 1) described that 152 cases with 69.1% of total treated women, 62 women  
with 28.2% of total non-treated women had past history of surgical operations, On the 
other hand 68 cases with 30.9% of the total treated women, 158 women with 71.8% of the 
total non-treated women did not have history of surgical operations, calculated chi-square 
with statistically significant at (P-value 0.001,odds ratio 5.6), that means cases with 
thromboprophylaxis use had  high proportion of positive history of  surgical operations 
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than non-treated  groups with a risk 5.6 times more than non-treated group,these results are 
constant  with Gold, M. et al (2012),the risk of thrombosis and thromboprophylaxis need is 
increasing with positive history of surgical operations as patient with history of surgical 
operations is with a risk than non-surgical operations. (Odds ratio 21.72, CI 9.44-49.93). 
 
Table 4.7:Relationship between past medical history - surgical operations-and 
thromboprophylaxis use  
 
Variables 
Cases (220) 
Controls 
(220) 
 
Freq. % 
Fre
q. 
% Chi Sig 
1 
Is there a past 
history of surgical 
operations? 
Yes 152 69.1 62 28.2 
73.69 .000 
No 68 30.9 158 71.8 
1.1 
If yes, specify 
Number of 
surgical operations 
One 50 33 35 56 
86.48 .000 Two to five 81 53 27 44 
More than 
five 
21 14 0 0 
1.2 
Type of surgical 
operations 
Cesarean 
section 
117 77 43 69 
86.78 00 
Uterine
surgery 
24 16 4 6 
.Pelvic surgery 1 1 3 5 
Abdominal 
surgery 
152 69.1 12 19 
orthopedic 
surgery 
68 30.9 0 0 
 
 
According to the Table (4.7 part 1.1) showed that 50 cases with 33% of treated women and 
35 women with 56% of  non-treated women had a history of one surgical operation, 81 
cases with 53% of total treated women  and 27 women with 44% of non-treated women  
had a history of two to five surgical but on  the other hand 21 cases (14%) of the cases had  
a history of more than five surgical operations, while there was no one had  more than 5 
operations among non-treated group. the calculated chi-square is highly significant at (P-
value 0.000), which showed that cases with thromoprolylaxis use had a proportion with a 
high number of past surgical operations than the non-treated group which is a strong risk 
factor. 
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Table (4.7 part 1.2) describes different surgical operations types distribution among both 
groups, 117 with 77% of  total treated women and 43 with 69% of total non-treated 
women, had history of caesarean sections, 24 with 16%  of treated women  had a history 
of uterine surgery, while 4 with 6% of non-treated women had past history of uterine 
surgery, one with 1%  of treated women, 3 with 5% of non-treated had a history of pelvic 
surgical operations 9 with 6% of treated  and 12 with 19% of non-treated women had a 
history of abdominal surgery, while  there one reported case with 1% of the total treated 
women with orthopedic surgery which that is not constant withGold, M. et al (2012) the 
risk of thrombosis of orthopedic surgery, (with odds ratio 44, CI 42-47), also, and there is 
no any reported one of the non-treated women for orthopedic surgery, calculated chi-
square is calculated and statistically significant at (P-value-0.000), as the proportion of 
different types of surgical operations is more with treated group rather than non-treated 
group, mainly with CS section and uterine surgery operations, which that is constant with 
Gold, M. et al (2012), most of CS surgery with (odds ratio 24, CI 23-26), Gynecology 
surgery with (odds 16, CI 13-19), Orthopedic surgery with (odds ratio 44, CI 42-47), most 
of the concerned health providers agreed with these results and one of them said “When 
you check MHR, who use thromboprophylaxis use during pregnancy, you will find the 
most recurrent risk factor for that is CS “. 
 
Table 4.8: relationship between past medical history–family history-and 
thromboprophylaxis use  
Variables 
Cases (220) Controls(220)  
Freq. % Freq. % Chi Sig 
1 
Are there 
associated 
family 
diseases? 
Yes 31 14.09 7 3.2 
2.880 0.090 
No 189 85.91 213 96.8 
1.1 
If yes, 
specify 
Congenital 
thrombophilia 
8 25.8 0 0 
- - 
Acquired 
thrombophilia 
4 12.9 0 0 
SLE 2 6.5 0 0 
Inflammatory 
bowel diseases 
15 48.4 2 28.6 
Rhematologica
l diseases 
2 6.5 5 71.4 
Odd ratio = 4.99               95 % CI=2.1476 to 11.5986 
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Table (4.8 part  1 ) describe that 31 cases with 14.09% of the total treated women and 7 
women with 3.2 % of the total non-treated woman had family history diseases, while 189 
cases with 85.9% of the total treated women and 213 women with 96.85% of the total non-
treated women did not  have family history diseases. Chi value is calculated and significant 
at (P-value-0.030, theodds ratio is 4.99), which is statically significant as treated women 
with Thromboprophylaxis use had more proportion with positive family history diseases 
than non-treated women,), that means cases with a risk 4.99 times than non-treated women 
in exposure to the family history diseases. 
Table (4.8 part 1.1) describes the distribution of different types of family history diseases 
among studied groups, 25.8% of total treated women had positive family history of 
congenital thrombophilia, 12.9 %of total treated women had positive family history of 
acquired thrombophilia, 6.5%of total treated women had positive family history of SLE 
diseases,48.4 % total treated women had positive family history of chronic inflammatory 
bowel  diseasesand 6.5 % of total cases with positive family history of rhematological 
diseases,on the other hand, 71.4% of total non-treated women had positive history of 
rhematological diseases and 28.6% of total non-treated women had positive family history 
of inflammatory bowel diseases, and there is no any reported women of positive family 
history of congenital or acquired thrombophilia and no any related numbers of SLE  family 
history),that means positive family history is with significant value in thromboprophylaxis 
use , especially positive family history of thrombophilia, which that is constant with  
kupfemnic (2003), that all patients with a personal or family history of VTE should be 
considered for antenatal prophylaxis and be screened for thrombophilia, also, that agreed 
with concerned health providers opinions one of them said that “family history of 
thrombophilia and thrombosis is a guide for clinician to look for thrombosis evidence in 
current pregnancy” Other said that “ family history of VTE alone, in the absence of a 
personal history or other risk factors for VTE, does not increase the personal risk of VTE, 
but is  sufficient to warrant antepartumthromboprophylaxis”. 
 
4.11 Past Obstetric history of the study population  
Table (4.9 part 1) show the relationship between past obstetric history and 
thromboprophylaxis use among treated group, where 23cases with 10.5 % of the total 
treated women and 53 women with 24.1% of the total non-treated women are 
primigravida, 21cases 55% of the total treated women and 142 women with 64.5% of the 
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total non-treated women are with Gravida two to Gravida five, 34.5% of treated women 
and 11.4 % of the non-treated women are gravid 6 or more, chi-square is calculated and is 
statically significant at ( P-value- 0.000), that means the risk of thromboprophylaxis use is 
high with gravida 2 and more. Also the table shows that 56 cases with 25.5% of the treated 
women and 73women with 33.2% of the total non-treated women are Para one, 61.8% of 
treated women and 61.4%total non-treated  women  are Para two to Para five, while 12.7% 
of treated women and 5.5% of non-treated women are Para 6 or more respectively . chi-
square is calculated and significant at (P-value-.013 as it is clear statically difference 
between both groups, so the risk of thromboprophylaxis use is high with Para 2 and more, 
which that is constant with Chan et al (2006), the risk for thrombosis, and the use for 
thromboprophylaxis is increasing in multipara, as it is more in cases of more than Para 2, 
also, concerned health providers agreed that one of them said  “Multigravida and 
Multipara will give a mirror about her obstetric history to be a guide for starting 
thromboprophylaxis use “ 
 
Table 4.9:Past obstetric history relationship and thromboprophylaxis use   
 
 
 
cases (220) controls (220)  
Freq. % Freq. % Chi Sig 
1 
Gravida 
(Number of 
previous 
pregnancy) 
Primigravida 23 10.5 53 24.1 
39.27 .000 Gravida  two to 
gravida five 
121 55.0 142 64.5 
Gravida 6 or more 76 34.5 25 11.4 
2 
Parity 
(number of 
previous alive 
complete 
deliveries) 
Para one 56 25.5 73 33.2 
8.644 .013 Para two to para 
five 
136 61.8 135 61.4 
Para 6 or more 28 12.7 12 5.5 
3 
Number of 
alive children 
Zero 16 7.3 6 2.7 
5.572 .062 One to two 96 43.6 110 50.0 
Three or more 108 49.1 104 47.3 
 
On the other hand, 49.1% of the total treated women  and 47.3% of the total non-treated 
women had three and more alive children, 43.6% of total treated women, 50% of the total 
controls have one to two alivechildren,7.3% of the total cases did not have a live 
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children,in the same way,2.7% of the total controls did not have alive children . chi-square 
is calculated at P-value 0.062 which is statically not significant as there is no difference 
between both groups.  
 
Regarding to the history of deal children as shown in table (4.10 part 4), 156 cases with 
70.9% of the total treated women and 205 women with 93.2% of the total non-treated 
women did not have a history of dead children while 52 cases with 23.6% of total treated 
women and 13women with 5.9% of non-treated women had one to two dead children, 12 
cases with 5.5% of total treated women and 2 women with 0.9% of total non-treated 
women had three and more dead children, Chi secure is calculated and is highly 
statistically significant at (P-value- 0.000), which that means there is a statistical difference 
between both groups, women with thromboprophylaxis had a significant history of dead  
Table 4.10: Relationship between the history of dead children and thromboprop-
hylaxis use    
 
Variables 
Cases (220) Controls(220)  
Freq. % Freq. % Chi Sig 
1 
Number 
of dead 
children 
Zero 156 70.9 205 93.2 
37.19 .000 One to two 52 23.6 13 5.9 
Three or more 12 5.5 2 0.9 
1.1 
Child age 
at Death 
28 GA. weeks - less 
than one week 
35 15.9 4 1.8 
42.60 .000 
One week-less than 
28 days 
13 5.9 2 0.9 
29 days to one year 15 6.8 7 3.2 
More than one year 1 0.5 2 0.9 
1.2 
Causes of 
death 
Unknown 37 16.8 7 3.2 
41.20 
 
 
.000 
 
 
Birth trauma 0 0.0 205 93.2 
Congenital 
anomalies 
17 7.7 13 5.9 
Accidents or injury 1 0.5 2 0.9 
others 9 4.1 4 1.8 
 
children,regarding to the age of dead children, 15.9% of treated women and 1.8% of non-
treated women had dead children at age  less than one week, 5.9% of treated women  and 
53 
 
0.9% of non-treated women  had dead children at age 29 days  to one year,0.5% of treated 
women and 0.9%of non-treated women had dead children at age more than one year. 
chi-square is calculated and is highly significant at (P-value- 0.000), which is highly 
statically significant, women who treated women with thromboprophylaxis had  history of 
high proportion of dead children in perinatal and neonatal period ( 28 weeks gestational 
age to less than one week, one week to 28 days of infancy period ) than non-treated 
women,that is constant with (Marquard, 2002), who describes there is a strong association, 
between thromboprophylaxis and thrombophilia to be diagnosed in 50%-65 %of women 
with history of unexplained recurrent fetal loss, also, Ohel and his colleagues (2000) said 
that women with thrombophilia have an increased Percentage of losses at later stage of 
gestations, also, concerned health providers agreed with that, as they said 
“Thromboprophylaxis use in pregnancy is improving stillbirth,IUFD, and perinatal 
mortality” . 
 
Regarding to the causes of death among dead children, the majority of causes of dead 
children is unknown cause, 16.8% of total treated women and 3.2% of non-treated women 
had dead children with unknown causes, 7.7% of treated women, 0.9% of non-treated 
women had history of dead children due to congenital anomalies, 0.5% of treated women  
and 0.9% of non-treated women had history of dead children due to accidents or injury 
causes while 4.1% of treated women and 1.8% of non-treated women had  other causes 
(some of them linked it to the presence of thrombophilia) and there is no any proportion 
related to birth trauma,chi-square is calculated and significant at( P-value- 0.000), which is 
highly statically significant as there is a clear statically difference between both groups, as 
most causes areunknown, it can be related to the presence of thrombophilia, these results 
are constant with Kupferminc (2002), who confirmed that women with unexplained IUFD 
nearly 42.5 % of cases in the study group compared with 15 % in controls are at risk of 
thrombosis, also concerned health providers agreed with that “Unknown causes  of  SB, 
IUFD, and perinatal mortality is related to the presence of unknown thrombophilia and the 
need of thromboprophylaxis use “. 
 
Table (4.11 part 1) presents relationship between the Thromboprophylaxis use and past 
history of infertility, 30.5% of treated women and 3.2% of non-treated women  had a 
history of infertility, chi-square is calculated and is significant at (P-value-0.001,odds 
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ratio13.3), as there is a significant difference between both groups,  treated women  had a 
risk 13.3 times than non-treated women to infertility.  
 
Table 4.11: Relationship between the history of infertility and thromboprophylaxis 
use   
 
Variables 
Case( 220) Control (220)  
Freq
. 
% Freq. % Chi Sig 
1 
history of 
infertility 
Yes 67 30.5 7 3.2 
58.48 .000 
No 153 69.5 213 96.8 
1.1 
 
 
Years of   
infertility 
 
if yes specify 
 
59.35 .000 
One to two years 19 28.4 4 57.1 
Three to five 
years 
27 40.3 2 28.6 
More than five 
years 
21 31.3 1 14.3 
1.2 
History of 
associated 
production 
technique 
Yes 58 86.6 4 57.1 
59.86 .000 
No 9 13.4 3 42.9 
1.2.1 
if yes 
specify 
 
IVF ( In vitro 
fertilization ) 
28 48.3 3 75 
55.04 .000 
IUI (Intra uterine 
insemination 
16 27.6 1 25 
Ovulation 
induction 
14 24.1 0 0 
If your answer 1 and 2 44  4   
1.2.2 
Number  
of IVF 
failure 
Non 19 43.1 4 100 
38.86 .000 1-2 21 47.7 0 0 
More than two 4 9.1 0 0 
 Odd ratio = 13.3249     95 % CI=5.9528 to 29.8271    
 
Regarding to the years of infertility, the majority of treated women, 40.3% of them had a 
history of infertility three to five years, 31.3% of them had a history of  infertility more 
than 5 years, and 28.4% of total treated women had a history of infertility one to two years, 
on the  other hand, the majority of non-treated women, 57.1% of them  had a history of 
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infertility years (one to two years),28.6% of them had a history of infertility years (three to 
five years ) and 14.3% of them had a history of infertility years more than five years, chi-
square is  calculated and is significant at (P- value-0.000) as there is clear difference 
between both groups in infertility years distribution, as treated women had a high 
proportion of years of infertility, as most of them, had infertility years more than 3 years. 
 
The results are consistent with Azem (2004), high frequency of thrombophilia was found 
in the subgroups of women with implementation failure (17.8 %), compared to the group 
of fertile women, also, that confirmed by Turkish study, in 2009, as  case-control study 
comparing 51 women with implementation failure , and group of 50 fertile women, a 
finding of at least one thrombophilia factor (62.7%)was more common in the group of 
women with implementation of failure compared to the control group (53.9 %), but these 
results are not consistent with Marinelli et al (2003) who conducted a case-control  study 
with the largest sample size evaluated up to the present time and found no evidence of a 
high frequency of thrombophilia in infertile women . 
 
As shown by table (4.11 part 1.2) 86.6% of treated women who had history of infertility 
had history of associated production technique and 57.1% of non-treated women who had 
history of infertility had history of associated production technique , odds ratio is 
calculated (4.8),that means a risk is 4.8 times among treated women than non-treated 
women to risk of pregnancy induction. 
 
Regarding the types of associated reproduction technique among who suffered from 
infertility 48.3% of treated women had IVF, 75 % of non-treated women had IVF, while 
27.6% of treated women had IUI and 25 % of non-treated women had IUI, on the other 
hand, 24.1% of treated women had a spontaneous induction. Regarding to the times of 
success and failure among who suffered from infertility and tried to do pregnancy 
induction with (IVF- IUI) as shown by table (4.11 part 1.3) 47.7% of treated women had 
on to two success times, 43.1% of treated women had no history of success, 9.1%of treated 
women had more than two times of success, While non-treated women had no history of 
success time of (IVF, IUI), chi-square is calculated at (P-value-0.000), which indicated a 
high statistically significant difference between both groups as treated women had varying 
history ofsuccess and failure times, the majority of treated women  had failure one to two 
times of (IVF-IUI) as that indicates the use of  thromboprophylaxis, on the other 
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hand,thromboprophylaxis use is improving the infertility induction outcome which that is 
constant with concerned health providers opinions, as one of them said that” 
thromboprophylaxis is indicted at a long time of infertility and in cases with IVF i failure 
more than twice “, on the other hand, one of them said “Thromboprophylaxis use is 
overestimated in cases with infertility, as many cases had infertility andIVF, and they 
succeed their pregnancies “   
 
Table 4.12:Relationship between the history of low birth weight and preterm labor 
with thromboprophylaxis use  
Variables 
Case 220) Control(220)  
Fre
q. 
% Freq. % Chi Sig 
1 
Is there a history 
of low birth 
weight?(fetal 
weight <2500gm) 
Yes 53 24.1 27 12.3 
10.32 .001 
No 167 75.9 193 87.8 
1.1 
 
the weight of the 
baby 
 
if yes specify 
 
 
 
14.50 .001 
less than or 
equal to 1.5 kg 
15 28.3 2 7.4 
2- > 1.5 -2.5 kg 38 71.7 25 92.6 
1.2 
How many times 
do you have it? 
 
1-once 39 73.6 18 66.7 
13.18 
 
.004 
 
2-twice 8 15.1 8 29.6 
More than twice 6 11.3 1 3.71 
1.3 
Is there a history 
of preterm 
labor? 
Yes 41 77.4 16 59.3 
12.88 .002 
No 
 
 
12 
 
22.6 
 
11 40.7 
 
If yes, answer the following 41 16   
1.3.1 
Gestational age 
at delivery 
< 28 weeks 3 7.41 3 18.8 
14.47 .002 28-32 weeks 20 48.8 5 31.3 
34-36weeks 18 43.9 8 50 
Odd ratio = 2.2686        95 % CI=1.3655 to 3.7688   For equation 1 
Odd ratio = 2.3490        95 % CI=0.8628 to 6.3952   For equation 1.3 
 
Table (4.12 part 1) presents  relationship between history of low birth  weight and preterm  
labor with  thromboprophylaxis use during pregnancy, as shown by table 24.1% of treated 
women and 12.3% of non-treated women had a history of low birth weight babies while 
75.9% of treated women  and 87.8% of non-treated women did not have a history of low 
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birth weight babies,chi square is calculated and  is significant at (P-value-0.001, odds ratio 
2.26) which indicated there is a significant difference between both groups, so treated 
women with thromboprophylaxis had high 2.26 times of risk of history of low birth weight 
than non-treated women,regarding to the weight of low birth weight babies among who 
suffered from a history of low birth weight babies 28.3% of treated women and 7.4% of 
non-treated women had baby weight less than or equal to 1.5 kg while 71.7% of treated 
women and 92.6% of non-treated women had baby weight more than 1.5 kg to less than 
2.5kg, chi-square is  calculated and significant at (P-value-0.001), which is showing a 
statistical difference between both groups as treated women are with high  proportion to 
have low birth weight, especially below 1.5 kg, which that is consistent with concerned 
health providers view, both  of them said that “Fetal U/S is a guide of detection, abnormal 
fetal growth ,and to start thromboprophylaxis in pregnancy”, also, that is consistent 
withDeVries JIP.,(1999),that thrombophilia was documented in 38% of women delivering 
babies whose birthweight was below the fifth percentile, compared with an estimated 2% 
to 3% in the general control population, also, while on the other hand Kupferminc et al 
(1999) confirmed that association with thrombophilia and the need for thromboprophylaxis 
use  remains controversial, withconflicting results from different studies,In one recent 
study,thrombophilia and thromboprophylaxis  need was found in 20% of the women with 
preeclampsia,placental abruption, fetal growth retardation, or stillbirth compared to only 
6% of control women without these complications (oddsratio 3.7), regarding to the times 
of recurrence of history of low birth weight as shown by table (4.12), 73.6% of treated 
women and 66.7% of non-treated women had once of low birth weight babies, 15.1% of 
treated women and 29.6% of non-treated women had twice of low birth weight babies, 
while 11.3%of treated women and 37.1% of non-treated women had more than twice 
history of low birth weight, chi-square is calculated and significant  at (P-value 0.004) 
which indicated statically difference between both groups, also, the table shows the 
relationship between low birth weight babies and history of preterm labor, 74.4% of the 
total treated women who had a history of low birth weight babies with a history of preterm 
labor, while 22.6% of non-treated women of low birth weight with history of preterm 
labor, in the other hand 59.3% of non-treated women had a history of low birth weight 
babies with a history of preterm labor and 40.7% of non-treated women who had a history 
of low birth weight babies without history of preterm labor, chi-square is calculated and 
significant at (P-value-0.002, odds ratio2.3), which indicated a statically difference 
between both groups as cases with thromboproplyxis use had high proportion of history of 
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low birth weight labor, and preterm with a risk 2.3 times than non-treated women, also as 
shown by table 48.8% of total treated women with history of preterm labor that occurred at 
gestational age (28-32 weeks), 43.9% of total treated women with history of preterm labor 
occurred at gestational age (34-36 weeks) and 7.4% of total treated women with preterm 
labor occurred at gestational age less than 28 weeks, regarding to non-treated women, the 
majority of them 50% with history of preterm labor occurred at gestational age 34-36 
weeks, 31.3% of non-treated women with history of preterm labor occurred at 28-32 
weeks, while 18.8% occurred at less than 28 weeks, Chi square is calculated and 
significant at (P-value-0.002) which that indicated statically differences as between both 
groups, that means cases with thromboprophylaxis use had a risk of premature delivery 
from 28 weeks to 36 weeks.  
 
Table 4.13:Relationship between a history of abortion (Miscarriages) 
andthromboprophylaxisuse 
Variables 
Case (220) Control(220)  
Freq
. 
% Freq
. 
% Chi Sig 
7 
Is there a 
history of 
miscarriages? 
Yes 171 77.7 35 15.9 
168.82 .000 
No 49 22.3 185 84.1 
If yes, answer the following 171 35  
7.1 
a number of 
miscarriages? 
One 35 20.5 24 68.6 
188.21 .000 Two 40 23.4 6 17.1 
More than Two 96 56.1 5 14.3 
7.1.1 
If two or// more, 
were they 
consecutive? 
 
 
Consecutive 109 63.7 15 42.9 
171.81 
 
.000 
 
Non 
consecutive 
62 36.3 20 57.1 
7.2 
Pregnancy age 
at abortion 
"Gestational age 
of abortion"   
 
One Week to 12 
weekPregnancy 
104 60.8 26 74.2 
189.61 .000 
From 13 weeks 
to 20 
weeksPregnanc
y 
21 12.2 3 8.57 
More than 20 
weeksPregnanc
y 
9 5.26 1 2.86 
Diverse 37 21.6 5 14.2 
Odd ratio = 18.4461       95 % CI=11.4024 to 29.8410 
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Table (4.13) summarizes the relationship between thromboprophylaxis use and history of 
miscarriage,  77.7% of treated women  had  a history of miscarriages, while 22.3% of 
treated women did not have a history of miscarriages,regarding to non-treated women 
15.9% of non-treated women had a history of miscarriages, while 84.1% of non-treated 
women  did not have a history of miscarriages, chi-square is calculated and  is highly 
significant at (P-value-0.000,odds ratio18.44), which indicated a significant difference 
between both groups, as treated women had a risk 18.44) times than non-treated women, 
that is consistent with Marquard (2009), thrombophilia and the need of 
thromboprophylaxis has been diagnosed in 50%-60% of patients with history of 
unexplained recurrent fetal loss, also concerned health providers confirmed that “if you did 
not find a cause to unknown fetal loss, you should start thromboprophylaxis to improve 
outcome “. 
 
Regarding to the distribution of history of miscarriages numbers which is divided into 3 
groups 56.1% of treated women had more than two, 23.4% of the non-treated women had 
two times and 20.5% of treated women had once abortion, while68.6% of non-treated 
women had once, 17.1% of treated women had two and 14.3% of non-treated women had 
more than two times frequency, chi-square is calculated  and significant at (P-value 0.000) 
which indicated statistically difference between bothgroups, women with 
thromboprophylaxis use had a history of risk to habitual  miscarriages than non-treated 
women, which “That is a clue for many Obstetricians to start thromboprophylaxis in 
pregnancy to avoid habitual abortions “as concerned health providers said. 
 
Regarding to the consecutive and nonconsecutive, the table describes that the majority of 
women with thromboprophylaxis use, 63.7% of treated women had a history of 
consecutive abortions and 36.3% of treated women had  non-consecutive abortion, 
regarding to non-treated women the majority of them,57.1% had non- consecutive 
abortions,while 42.9% of non-treated women had consecutive abortions,chi-square is 
calculated and highly significant at (P-value-0.000), which indicated statisticallydifference 
between both groups, as treated women had high  more proportion of consecutive abortions 
than non-treated women, which that is consistent with concerned health providers opinions 
“the need to improve habitual abortions is starting thromboprophylaxis”, also, that is 
consistent with foka et al (2000)thrombophilia and the need of thromboprophylaxis use, 
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reported a frequency of 9 % of in women with recurrent miscarriages, frequency of 2 % 
occurred in control group .  
 
4.12 History of hormonal contraceptive use   
 
Table 4.14:Relationship between contraceptive pills use and thromboproph-ylaixs use  
 
 
Variable 
Case (220) Control (220)  
Freq. % Freq. % Chi Sig 
1 
Is there a 
history of  
contraceptive 
pills use 
Yes 47 21.4 41 18.6 
.511 .475 
No 173 78.6 179 81.4 
1.1 
If yes, specify 
Type of 
contraceptive 
pills 
Minipills 18 38.3 21 51.2 
4.116 .249 
Combined oral 
contraceptive pills 
26 55.3 20 48.8 
Injectable 
hormone(DHPA 
injection 
3 6.4 0 0.0 
1.2 
Duration of 
use 
Less than 2 years 41 87.2 29 70.7 
6.445 .092 2 years -5 years 6 12.8 8 19.5 
More than 5 years 0 0.0 4 9.8 
Odd ratio = 1.1861           95 % CI=0.7427 to 1.8941 
 
Regarding to the gestational age of miscarriages, 60.8% of treated women and 74.2%of 
non-treated women had history of pregnancy loss at gestational age from four  weeks to 12 
weeks (1
st
trimester), 12.2% of treated women had a history of pregnancy loss from 
13weeks to 20weeks gestational age of pregnancy, 8.57% of total non-treated women had a 
history of pregnancy loss at gestational age from 13 weeks to 20 weeks, 5.26% of treated 
women had a history of miscarriages at gestational age more than 20 weeks, 2.86% of non-
treated women had a history of pregnancy loss  at gestational age more than 20 weeks, 
calculated chi-square is significant at (P-value-0.000), as cases with high proportion of 
miscarriages had occurred at first trimester gestational age (9 weeks  to 12 weeks 
pregnancy), that is consistent with Brenner and colleagues(1999), thrombophilia and the 
need to thromboprophylaxis is increasing with 3 or more first trimester loss, 2 or more 
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second trimester loss or one or more with third trimester loss. 49% of women with 
pregnancy loss had a thrombophilia compared to 22 %of controls. 
 
Table (4.14) summarizes relationship between history of hormonal contraceptive use and 
thromboprophylaxis use as shown, 21.4% of treated women and 18.6% of non-treated 
women  had positive history of Thromboprophylaxis use while 78.6% of treated women  
and 81.4% of non-treated women didn’t have history of hormonal contraceptive use, chi-
square is calculated and significant at (P-value-0.475,odds ratio1.1) which is not 
statistically significant that indicated there are no differences between both groups as both 
of them with the same history of hormonal contraceptive use, that is not consistent with 
Yen et al (2013)  a  strong relation was found between the use of oral contra-captives and 
the risk of thrombosis and the use of thromboprophylaxis, that also is confirmed in J.AM 
Study (1979), a perspective study by the Royal College of General Practitioners reported 
that the risk of developing deep venous thrombosis of the legs in women taking oral 
contraceptives was 5.66 times higher than women not on medication. 
 
Regarding to the distribution of hormonal Contraceptive use between both groups 38.3% 
of total treated women used combined oral contraceptive pills and 6.4% of total treated 
women used injectable hormone (DMPA)  injection, while 51.2% of total non-treated 
women used min-pills, 48.8% of total non-treated women usedcombined oral contraceptive 
pills and there are no women of non-treated women used injectable hormone injection, chi-
square is calculated to be significant at (P-value 0.2496) that indicated there is no statically 
difference between both groups, regarding to type of hormonal contraceptive use, 87.2% of 
total treated women and 70.2% of total non-treated women  use hormonal contraceptive 
less than 2 years, 12.8% of total treated women and 19.5% used hormonal contraceptive 
method from 2 years to five years, while non-treated women used hormonal contraceptive 
more than five years and no reported case of treated women used hormonal contraceptive 
more than  5 years, chi-square is calculated and is significant at (P-value 0.092) which is 
not statically significant, as there is no difference between in the duration of hormonal 
contraceptive methods use . 
 
 
 
4.13 History of pregnancy complications  
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In this part we asked about the presence of the previous history of pregnancy complications 
and compare both groups, also we asked about main pregnancy complications (PIH, GDM, 
PET, APH, PPH). 
 
Table 4.15: Relationship between the history of pregnancy complications and 
thromboprophylaxis use  
 
Variables 
Cases (220) Controls 220)  
Fre
q. 
% Freq. % Chi Sig 
1 
Is there a history of 
pregnancy 
complicated diseases? 
Yes 93 42.3 23 10.5 
57.36 .0001 
No 127 57.8 197 88.2 
 
Table(4.15) present a comparison between groups in their history of pregnancy 
complications, as shown by table 42.3 %of total treated women had positive  history of 
pregnancy complicated diseases, while only 10.5 % of total non-treated women  had a 
history of pregnancy complicated diseases, while 57.8 %of total treated women and 88.2 
%of total non-treated women did not have a history of pregnancy complicated diseases, 
chi-square is calculated and significant at ( P-value- 0.000,odds ratio 6.2 )which indicated 
highly statically differences between both groups, as treated women had high risk 6 times 
risk than non-treated women of history of pregnancy complicated diseases, concerned 
health providers agreed with that “thromboprophylaxis will improve the circulation of 
placenta, so will improve pregnancy complications especially preeclampsia and abruption 
placenta”  . 
4.14 History of Thrombosis and thromboprophylaxis use in previous 
pregnancies. 
 
Table 4.16: Relationship between the history of thrombosis and thromboprophylaxis 
use  
 
Variables 
Cases (220) 
Freq. % 
1 
Is there a history of Thrombosis in 
pregnancy? 
Yes 5 2.3 
No 215 97.7 
Table(4.16) compares between both groups, in their history of thrombosis during previous 
pregnancies, as shown cases with thromboprophylaxis use 2.3%total treated women had a 
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history of thrombosis evidence in their pregnancy while 100% of non-treated women did 
not have a history of thrombosis, chi-square is calculated and significant at (P-value- .000), 
which is highly statistically significant, treated women with thromboprophylaxis use had a 
high proportion of thrombosis, which that confirmed by concerned health provider, one of 
them said that “Thromboprophylaxis use is really needed when there is a clear thrombosis 
in previous pregnancies,  which is indicated for medically sound basic diagnosis “, 
 
Rregarding to the distribution of different types of thrombosis, 60%of total treated women 
who had history of thrombosis are DVT, (1.3% of treated women), 20% of total treated 
women who had history of thrombosis are pulmonary embolism ,(0.04%of treated 
women), 20% of total treated women who had history of thrombosis are  arterial 
thrombosis, (0.04%of treated women),, literature confirms  thromboembolism represents 
one of the main causes of maternal mortality with overall prevalence during pregnancy is 
approximately 2 per 1000 deliveries, approximately 20%, 2005), many literatures is 
confirming the thromboprophylaxis management among pregnant ladies with previous 
VTE, estimates of the rate of recurrent venous thrombosis during pregnancy with women 
positive history of VTE  have varied between zero and 13%(American Colleague of Chest 
Physicians),Ginsberg (2001) agreed with that and recommend thromboprophylaxis during 
pregnancy and postpartum period is playing an important role in a history VTE.  
 
Table (4.17) describes history of thromboprophylaxis use in previous pregnancies of 
studied cases (who used thromboprophylaxis in their last pregnancy ) .82.8 %of total cases 
(majority of cases) used thromboprophylaxis in their last previous pregnancies, while 17.3 
% of total cases did not use thromboprophylaxis in their previous pregnancies ,That is 
consistent with concerned health providers view who confirmed “Thromboprophylaxis use 
is changing from one pregnancy to another one is due to present pregnancy risk and US 
findings”. 
 
Regarding the frequency and the continuity of heparin use in their previous pregnancies, 
24.1 %of total cases used heparin therapy in all pregnancies and 58.6 % of total cases did 
not use heparin therapy in their pregnancies (calculated chi-square 310,3, p-value .0001 ),  
 
Table 4.17: History of thromboprophylaxis use in previous pregnancies 
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Variables 
Cases (220) 
Freq. % 
1 
Did you take 
anythromboprophyla
xis in previous 
pregnancies? 
Yes 182 82.8 
No 38 17.3 
If your answer yes, specify 
1.1 
Was it used in all 
pregnancies? 
Yes 53 24.1 
No 129 58.6 
 If No specify 
1.1.1 
What was the 
outcome of that 
pregnancy? 
An abortion 49 38.0 
Alive birth 54 41.9 
Early fetal death 16 12.4 
Congenitally malformed 
baby 
3 2.3 
Intra uterine fetal death. 2 1.6 
IUGR 0 0.0 
Early neonatal mortality 1 0.8 
Low birth weight baby 4 3.1 
1.1.2 
Is there associated 
complications of that 
pregnancy 
Yes 22 17.1 
No 107 82.9 
If yes, specify 
1.1.2.1 
What was the 
associated pregnancy 
complications in the 
index pregnancy 
PIH 15 68.2 
APH 2 9.1 
GDM 3 13.6 
PPH 2 9.1 
both (1,3) 0 0.0 
DVT 0 0.0 
1.1.2.2 
Was that pregnancy 
associated with 
preterm labor 
Yes 7 31.8 
No 15 68.2 
 
Regarding to the outcome of pregnancy which heparin therapy was not used, 41.9 %of 
total cases had alive birth ,38 %of total cases had abortion ,12.4 % of total cases had early 
fetal death, 2.3% of total cases had congenital malformed baby ,1.6 % of total cases had 
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intrauterine fetal death , 0.8 %o is of total cases had early neonatal mortalities and 3.1 % of 
total cases had low birth weight babies while there is no any reported cases of IUGR .  
According to pregnancy complications, which heparin therapy was not used, 82.9%of  
their pregnancies were without complications and 17.1 % of their pregnancies were with 
complications .Regarding to the types of pregnancy complications in that pregnancies, 
which heparin was not uses, 68.2 %of total cases complicated by PIH, 13.6 % of total cases 
complicated by GDM, 9.1%of total cases complicated by PPH ,while there are no reported 
cases complicated with PIH and GDM or reported cases of DVT. Also as shown by the 
table, 31,5 % of that index pregnancy associated with preterm labor and 68.2 %of total 
cases not associated with preterm labor in that pregnancy  
 
4.15 History of last pregnancy and thromboprophylaxis use   
History of last pregnancy in this part includes many variables we asked about it, some of 
these variables were compared between both groups (cases and controls), others variables 
were only related to cases, variables which asked about experiences of thromboprophylaxis 
use.  
4.15.1 Last pregnancy outcomes and thromboprophylaxis use 
Table 4.18:last pregnancy outcomes and thromboprophylaxis use. 
Variables 
Cases (220) Controls(220)  
Freq. % Freq. % Chi Sig 
1 
What was the 
outcome of 
last 
pregnancy? 
Abortion 24 10.9 4 1.8 
29.43 .000 
Alive baby 172 78.2 208 94.5 
Premature 
delivery 
8 3.6 6 2.7 
Congenital 
anomalies 
3 1.4 0 0.0 
Early fetal 
death 
9 4.1 2 0.9 
Perinatal 
mortality 
4 1.8 0 0.0 
1.1 
If your answer 
“ ii ” the 
weight of last 
a live baby 
<2500gm 27 15.7 20 9.6 
29.44 .000 
2500-3500 gm 106 51.0 131 63.0 
3500- 4500 gm 36 17.3 55 26.4 
>4500 gm 3 1.4 2 1.0 
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As shown by table (4.18) describe the outcome of last pregnancy, which type of heparin 
was used, 78.2 %of total cases delivered alive birth,10.9 % of total cases had abortion, 3.6 
% of total cases had premature delivery, 1,4 % of total cases had baby with congenital 
anomalies, 4.1 of total cases had early fetal deaths and1.8 % of total cases had perinatal 
mortality while 94 .5 % of untreated women had alive baby, 2.7 %of untreated women  had 
premature delivery, 0.9 % of untreated women had early fetal deaths but there are no 
reported numbers of congenital anomalies and perinatal mortalities chi-square is calculated 
to significant at (P-value 0.000 ) which indicates statically differences between both groups 
as they differ in their last pregnancy outcome, concerned health providers confirmed that 
by their words “In the past many clients did not know the cause of their fetal loss, recently 
thromboprophylaxis use improve really the outcome of many pregnant women “,Also, in 
Carpe et al (2003) study confirmed thatthe live birth rate was higher in women treated with 
heparin therapy, 26(70.2%) of 37 compared with 21(43.8%) of 48 in untreated patients. 
Regarding to the weight of delivered alive baby in both groups, the majority of treated 
women (who use thromboprophylaxis ), and untreated women (who did not use 
thromboprophylaxis) had normal birth weight (2500gm-3500gm), 51 % and 63 % 
respectively,15.7 % and 9.6 %of treated and untreated women had low birth weight (less 
than 2500 gm.) respectively while 17.3% and 26.4%of treated and untreated women had a 
live baby weight (3500gm-4500gm) respectively, 1.4 % and 1% of treated and untreated 
women had macrocosmic babies (more than 4500) respectively, chi-square is calculated to 
be significant at (P-value- 0.000), which indicated significant statistical difference between 
both groups, as untreated women had high proportion of normal live birth weight than 
treated women, and cases who used thromboprophylaxis had higher proportion of low birth 
weight than untreated women as shown by table(5.9.1) thromboprophylaxis use is 
improving pregnancy outcome especially live birth weight ,  but some of them still  had 
abnormal birth weight of alive baby mostly low birth weight, “which that indicated for 
further investigation, or adjusting the dose of thromboprophylaxis use “ as concerned 
health providers said. 
4.15.2Thromboprophylaxis used in last pregnancy 
In this part the only group who used thromboprophylaxis answered questions as there is no 
single untreated woman  used thromboprophylaxis according to the sampling methodwhich 
described in chapter(3),The following table shows the experience of thromboprophylaxis 
use among cases (thromboprophylaxis use ) 
Table 4.19-A: Thromboprophylaxis used in the last pregnancy (part 1) 
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Variables 
Cases (220) 
Fre
q. 
% 
1 
Have you used 
thromboprophylaxi
s used in the last 
pregnancy? 
yes 220 100 
No 0 0 
 If yes, specify 
1.1 
What is the type of 
thromboprophylaxi
s used in the last 
pregnancy? 
Low dose aspirin alone 53 24.1 
Un-Fractioned heparin 50 22.7 
low molecular weight heparin (clexan, 
fraxiheparin 
48 21.8 
Combination of low dose aspirin and 
heparin  therapy 
69 31.4 
Total number how to answer (ii, iii, iv) 167 
1.1.1 
The dose of heparin 
therapy 
5000I.U/U.N heparin/OD/SC 29 17.4 
5000I.U/U.N hepain/BID/SC 83 49.7 
0.3 mg fraxihepain/OD/SC 11 6.6 
Clexan (20,40,60,80) mg/ OD/SC one 
time 
 
 
37 22.2 
Clexan (20,40,60,80) mg/ OD/SC two 
time 
 
7 4.2 
1.1.2 
The frequency of 
heparin therapy 
Daily 156 93.4 
Alternative days 11 6.6 
Weekly 0 0.0 
others 0 0.0 
1.1.3 
Gestational age at 
starting heparin 
First trimester(0-13 weeks) 144 86.2 
Second trimester(14- 26 weeks) 12 7.2 
Third trimester (27- 40 weeks) 11 6.6 
1.1.4 
Gestational age at 
stopping heparin 
First trimester(0-13 weeks) 11 6.6 
Second trimester(14- 26 weeks) 10 6.0 
Third trimester (27- 40 weeks) 56 33.5 
Directly after delivery 63 37.7 
1 week after delivery 27 
 
 
16.2 
Table 4.19-B: Thromboprophylaxis used in the last pregnancy (part 2)  
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2.1.4 
Variables Freq. % 
1.1.5 
Who prescribed that 
medication for you 
Hospital physicians 38 22.8 
UNRWA physicians 20 12.0 
Private physicians 103 61.7 
others 6 3.6 
 
 
1.1.6 
How did you access to 
medication 
(thromobroph-ylaxis ) 
UNRWA clinics 
 
 
0 0 
Public Hospitals 18 10.8 
Governmental clinics 11 6.6 
Private Pharmacies 134 80.2 
 Non-Governmental clinics 4 2.4 
1.1.7 
Did you completely 
comply with  regular 
use of the prescribed 
medications 
Yes 156 93.4 
No 
 
11 6.6 
 
 
Table (4.19-A) describe that 31,4% of total cases used combination of both low dose 
aspirin and heparin thereby, 24.1% of total cases used low dose aspirin only ,22.7% of total 
cases used un-fractioned heparin and 21.8 %of total cases used low molecular weight 
heparin (clexan, fraxiheparin), chi-square is calculated to be significant at (P-value 0.000), 
which is indicated significant statistically differences between different types of used 
thromboprophylaxis, as majority of cases used combination thereby, and the least 
proportion is low molecular weight heparin (clexan, fraxiheparin), regarding to concerned 
health providers, most of them agreed that “Un-fractioned heparin is the cheapest and the 
most accessible medication for pregnant women, which that is influenced by 
socioeconomic status “, one of them said that “the trend toward the use of LMWH, because 
is easy of administration, more effective and did not need to follow up “  
Regarding to heparin prescription, as shown by table(4.19-B), the majority of heparin 
therapy 61.7 % of total cases prescribed by private physicians, 22.8% prescribed by 
hospital physicians, 12% prescribed by UNRWA physicians and 3.6% prescribed by 
others, chi-square is calculated to be significant at (P-value- 0.000 ), that is  consistent with 
concerned health providers view “Thromboprophylaxis is a secondary hospital 
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management, it is not a primary health management, as these cases should be investigated 
well at hospitals and assessed to heparin therapy “ 
 
Regarding compliance 93.4 % of total cases completely complied with regular use of 
heparin therapy, while 6.6 % of total cases did not completely comply with regular use of 
heparin therapy. Chi-square is calculated to be significant at(P-value- 0.000). 
 
Table (4.20) describe the  investigation profile to support heparin therapy, 91.6% of total 
cases performed complete investigation profile, while 8.4% of total cases did not perform 
complete investigation profile to support heparin therapy, chi-square is calculated to 
significant at  (P-value 0.000). 
 
Regarding to the types of  thrombophilia use investigation profile, 84.4 % of total cases 
performed molecular genetic thrombophilia study, 40.5%of total cases performed 
coagulation profile, 11.1% of total cases performed anti-phospholipid antibodies and 
there’s no any reported cases performed anti DNA  antibodies, “investigation profile is 
supporting the need of thromboprophylaxis during pregnancy”(concerned health 
providers), on the other hand, both of them said that “genetic molecular study of 
thrombophilia is not enough to support thromboprophylaxis, as real genetic study should 
include 13 genes, while 6 genes were done”, the other said “Most of the investigationsdone 
at un-accredited  laboratories, so these investigations should be done at accredit able 
labs”.  
 
Regarding to the total cases of heparin therapy during pregnancy, the majority of cases 
66.7% had cost more than 1500NIS, 21.6 % of total cases had cost 5000-1000 NIS,and  
20.9 % of total cases had cost 1000 -1500 NIS, calculated chi-square is significantat (P-
value-0.000), the cost of heparin therapy is expensive which that is overcome the economic 
status of treated cases, most of them have access to medication from private pharmacies, 
from their out pockets. 
 
 
 
 
Table 4.20:Thromboprophylaxis used in the last pregnancy 
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2.1.4 
Variables Freq. % 
1.1 
Did you perform a complete 
investigation profile to 
support the use of heparin 
therapy during pregnancy? 
Yes 153 91.6 
No 14 8.4 
If your answer yes specify the following  
1.1.1 
Types of used  
thrombophilia investigation 
profile 
Molecular Genetic 
thrombophilia study 
112 73.2 
Coagulation profile 27 17.6 
Antiphospholipid 
Antibodies 
13 8.5 
Anti DNA antibodies 1 0.7 
1.1.2 
What was the total cost of 
heparin therapy? 
5000-1000 NIS 33 21.6 
1000-1500 NIS 32 20.9 
More than 1500NIS 102 66.7 
1.1.3 
Did you suffer any heparin 
therapy side effects in last 
pregnancy? 
Painful injecting site 52 34.0 
bone ache 86 56.2 
Itching / allergy 20 13.1 
Associated 
thrombocytopenia 
7 4.6 
Ecchymosis patches 1 0.7 
Bleeding 1 0.7 
Others, specify 0 0 
1.1.4 
Did you have any health 
complic-ations during last 
pregnancy? 
Yes 54 35.3 
No 113 73.9 
1.1.4.1 
What areTypes of 
pregnancy complications 
PIH 26 17.0 
DVT 9 5.9 
GDM 10 6.5 
APH 2 1.3 
PPH 4 2.6 
Anemia 3 2.0 
 
Table (4.20)shown that, “UNRWA cannot save this medication at their pharmacies, to be 
an item in non –inventory drugs list, because a trial was done in 2009, they found there 
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was an overestimation and over diagnosis of heparin thereby prescription “  concerned 
health provider (FFHO) . 
 
Heparin therapy is very expensive, inconvenient and painful to administer, as shown in 
table (5.9.2 ), 56.2% of total cases complained of bone ache, 34% of total cases 
complained of painful injection site, 13.1 %of total cases complained of itching and 
allergy, 4.6 % of total cases complained of associated thrombocytopenia, 0.7 % of total 
cases complained of ecchymosis patches, and 0.7 % of total cases complained of  bleeding 
,calculated  chi-square is significant at (P-value-0.000 ), which that makes“heparin 
prescription is controversial issue, you should weight benefits and risk” a concerned health 
providers, (FFHO) 
 
Regarding to the health complications registered in pregnancy who used 
thromboprophylaxis, 73.9 % of total cases did not have health complications and 35.3 % of 
total cases had complication, chi-square is calculated to be significant at  (P-value- 0.000), 
regarding to the types of pregnancy-related complications, the majority of cases 17.0 %of 
total cases complained of PIH, 6.5 % of total cases complained of GDM, 5.9 %of total 
cases complained of DVT, 2.6 %of total cases complained of PPH, 2 %of total cases 
complained of anemia and 1.3 % of total cases complained of APH, chi-square to be 
significant at (P-value 0.000 ), these results in compare to pregnancy which not treated 
with thromboprophylaxis, different types of health complications is less(PIH 17% vs. 
68.%, GDM 5.9%vs13.6%, APH 1.3%vs 9.1%, PPH 2.6% vs. 9.1%). 
 
Regarding the management practices, as shown in the table (4.21), 96.7 %of total cases had 
been followed up by a specialist, 12.4 %of total cases were not followed up by a specialist 
As showed by the table (4.21), 38.6 % of total cases visited specialist room more than 4 
times, 32.0% visited specialist room once only, the remaining of cases 26.1 % visited 
specialist room from 2 to 4 times during their pregnancy period.  
Regarding to times of fetal us during pregnancy period, 35,3 % of total cases did more than 
4 times fetal us during pregnancy period, 30.7 % of total cases did 2 -4 times fetal us 
during pregnancy period, and 30.7% of total cases did once fetal us during pregnancy 
period . 
Table 4.21: Management practices and follow up with cases with thromboprophylaxis 
use 
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Variables 
Cases (220) 
Freq. % 
 
1 
 
 
 
 
 
 
 
 
 
Did you follow by a 
specialist? 
Yes 148 96.7 
No 
 
 
 
 
 
 
 
 
 
 
19 12.4 
1.1 
How many times 
during pregnancy did 
you visit a specialist 
clinic 
1 times 49 32.0 
2-4 times 40 26.1 
More than 4 59 38.6 
1.2 
How many times has a 
fetal us done for you 
at the clinic? 
one 47 30.7 
2-4 times 47 30.7 
more than 4 54 35.3 
1.3 
Did you have a follow 
up at the high-risk 
department at the 
hospital? 
yes 73 47.7 
No 
 
 
79 51.6 
1.4 
 
Where did you 
deliver? 
 
Private hospital 39 25.5 
Public hospital 108 70.6 
Private doctor 5 
 
 
 
3.3 
 
 
As shown by table (4.21) 47,7% followed her pregnancies at high-risk department, while 
51.6 % of total cases did not follow at high-risk pregnancy department .( P-value-0 .000), 
when these results were discussed with concerned health providers, they agreed with it, as” 
there is no any reported case did not do us during follow up, despite overload, and high 
waiting time which is being a challenge in front of quality improvement at UNRWA health 
centers “ 
 
Finally, regarding the delivery place, 70.6 % of total cases delivered at public hospitals, 
25.5 % of total cases delivered at private hospitals, while 3.3 % of total cases delivered by 
a privatedoctor. 
 
4.16 Evaluation of Blood pressure and obesity indicators among the study population  
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Table (4.22) describe blood pressure measurements among both groups which there is 
differences between BP Measurement between them,76.4% of treated women had  BP 
below 130/86, while 90.9 % of untreated women  had  blood pressure below 130/86, 
20.5% of treated women and 17% of untreated women had BP  130-139/86-89, and 3.2 % 
of treated women  and 1.4% of untreated women  had BP more or and equal to 140/90 
(chi-square 25.42, with P-value-0.000), regarding to that treated women with  
thromboprophylaxis during pregnancy  had a risk of HTN more than untreated , which that 
is consistent with literature as confirmed  a strong relationship between thrombosis and 
HTN diseases. 
 
Table 4.22: Relationship between blood pressure measurement and thromboprop-
hylaxis use 
 
Variables 
Cases (220) Controls(220)  
Freq. % Freq. % Chi Sig 
1 
Blood Pressure 
indicators for 
women 
 
<130/86 168 76.4 200 90.9 
25.42 .000 
130-139/86-88 45 20.5 17 7.7 
or > and 
=140/90 
7 3.2 3 1.4 
 
Table (4.23) compare between groups in BMI measurements, the majority of treated 
women, 35.9 % of them had normal weight (BMI 18.5-24.9), 33.6 % of treated women  
had overweight (BMI 25-29.9 ), 13.6 % of treated women had first class obesity (BMI30-
34.9), 7.3 % of treated women had second class of obesity (BMI 35-39.9 ), 7.3 % of treated 
women  had underweight below 18.5 and 2.3 % of treated women had 3
rd
 class of obesity 
(BMI more than 40 ), on the other hand the majority of untreated women 50,5 % of them 
had overweight (BMI 25-29.9), 18.2% of non-treated women had first class obesity (BMI 
18.5-24.9), 7.7% of non-treated women  had second class obesity (BMI 35-39.9 ), 5.5 % of 
non-treated women had under normal weight(BMI below 18.5 ), and 1.4 % of non-treated 
women had third class obesity (BMI more than 40 ).(chi-square 25.13, P-value-0.000), that 
means obesity is not a risk among treated women with thromboprophylyxsis use in 
pregnancy, which that is not consistent with literature which confirmed BMI indicator is 
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one of the main risks to start thromboprophylaxis in pregnancy and to measure risk of 
thrombosis. (Sultan AA., et al 2013) 
 
Table 4.23:Relationship between BMI(body mass index) measurement  and 
thromboprophylaxis use 
 
Variables 
Cases (220) Controls(220)  
Freq. % Freq. % Chi Sig 
1 
Obesity 
indicators 
for pregnant 
women 
Underweightless 
than18.5 kg 
16 7.3 12 5.5 
25.13 .000 
Natural Weight 
18.5-24.9 
79 35.9 37 16.8 
Overweight 
25-29.9 
74 33.6 111 50.5 
First-class obesity 
30-34.9 
30 13.6 40 18.2 
second-class 
obesity 
35-39.9 
16 7.3 17 7.7 
Third -class 
obesity 
More than 40 
5 2.3 3 1.4 
 
 
4.17   Maternal Health Record Review and Genetic Molecular Study Review 
 
This part describesthe quantitative results as maternal health records review (MMHR) and 
molecular genetic study review,MMHRs review includes 100 MR. Files which are selected 
by random sampling from the whole study cases who received thromboprophylaxis in their 
pregnancies, they were also selected from all clinics included in the study, we review the 
most important management practices as high-risk pregnancy, and highlighting the main 
findings to improve the quality of work, also this part includes another quantitative part 
which is involving genetic molecular study to evaluate the relationship between 
thromboprophylaxis use and genetic molecular study.   
 
4.18 Review of maternal medical health records  
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This part of the quantitative type of the study, which involves medical maternal health 
records MMHR, we review nearly 100 files were selected randomly , and we review 
according to the following domains, distribution of obstetric  history, risk factors among 
cases group(treated women) 
Table 4.24: Distribution of risk factors among cases group(thromboprophylaxis use) 
(100 MRR)  
        
No. factor Frequency % Frequency % 
Yes No 
1 Age>=35 23 77 
2 Para>=6 9 91 
3 Habitual abortions >=3 23 77 
4 Perinatal deaths>=2 3 97 
5 Pervious pre-eclampsia 3 97 
6 Pervious GDM 3 97 
7 History of antepartum hemorrhage 0 100 
8 History of post hemorrhage 7 93 
9 Pregnancy-induced hypertension 7 92 
10 DM with pregnancy 1 99 
11 History of CS 38 62 
12 Anima below 9 4 96 
 
As shown by previous table (4.24) , the most prevalent risk factorsamong this group is CS, 
which accounted 38 % , which that supported thromboprophylaxis therapy and matched 
high prevalent rate of CS  among risk pregnancy, followed by 23 % of cases are more or 
equal to 35 years old, 23 % of total cases had history of   habitual abortions 3 and more 
which all of these supported thromboprophylaxis use and matched global studies about 
thrombophilia, and 9% of cases were  multipara (P6and more) which had followed by 
history of PPH and PIH which accounted 7%,7% respectively,while 4% of cases had  
anemia below 9.3% of cases had previous GDM and previous preeclampsia respectively, 
and 1% of cases developed DM with pregnancy, these results summarize the most common 
risk factors among studied cases(with thromboprophylaxis use), regarding to frequency of 
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occurrence arranged  (CS, Age 35 and more, habitual abortion, Multipara, history of PPH 
and PIH ). 
 
 
 
Figure 4.5: Distribution of risk factors among cases group (thromboprophylaxis use ). 
(100 MMRR) 
 
Table 4.25:Frequency of risk factors among cases  
 
  
Factor 
One risk factor two risk 
factor 
More than 2 risk 
factors 
No. % No. % No. % 
1 
 
Frequency of risk 
factors among cases 
34 34% 54 54% 12 12% 
 
 
The table (4.25) summarizes the number of associated risk factors of  these cases, the 
majority of cases had two risk factors (54%), then one risk factor (34%), and followed by 
more than two risk factors (12%)of total cases, that means these cases are high-risk 
pregnancy and they are needing more and special follow up and management.    
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Figure 4.6:Frequency of risk factors among cases 
 
Table 4.26:Review of managementpractices. 
 
No. Factor Frequency Frequency 
Yes No 
1 Number of ANC visits(4and more ) 86 14 
2 Specialist assessment and follow up 68 42 
3 Preconception  care done  40 60 
4 Family planning was done 87 13 
5 Routine investigations were done 95 5 
6 Thrombophilia related investigation 
documentation 
20 80 
7 Early registration             78  22 
 
This table (4.26)and figure (4.6|)describes management practices of  these risky group, 
these cases are classified as alert or high-risk pregnancy and reviewed to theeight main 
items, number of ANC  visits, specialistassessment and follow up, preconception care, 
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family planning care, routine investigation done or not, related thrombophilia investigation 
documented or not  and about early registration and these results were discussed with 
concerned health providers. 
 
Figure 4.7: Review of management practices. 
 
As shown by previous figure 4.7,regarding to the number of ANC visits, 86% of cases had 
at least 4 ANC visits, 78 % of cases had early registration in first trimester, 40% of total 
cases had been registered in PCC program, 87% had family planning attendance,95% of 
cases did routine investigations, regarding to investigation regarding thrombophilia 
documentation, only 20 % of cases had documented related investigation also as shown by 
table 40% of cases had specialist follow up and assessment, concerned health providers 
especially FFHO not agreed with some results regarding to early registration (78%vs.22%) 
“These results will be more when we consider GA below 16 weeks as defined by UNRWA 
guidelines”, regarding to the number of ANC visits “Our goal is to improve that more than 
90%,that is explained by women follow up by out clinic specialists “regarding to specialist 
follow up and assessment, FFHO said that “we train our medical officers to get enough 
experiences to work with these cases “other concerned health provider “The main cause to 
this weak point, is the lack of medical officers experience of referral at spot time of 
pregnancy “regarding to preconception care concerned health provides agreed with that 
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“this percentage is a great of us, to be nearly 40% of risky groups to be enrolled in PCC 
program  prior to pregnancy, which that is being a challenging in front of us “, regarding 
to related investigation documentation (20%vs.80%), “which that is explained by the 
electronic medical records, untrained staff members and medical officers, which is a really 
week pain and is needing for hard efforts to improve”(concerned health providers).we 
summarize that with few words, PCC, early registration, and ANC visits more than 4 visits 
are continuity cycle, and it should be improved to improve the quality of maternal health. 
 
4.19 Genetic Molecular study review  
 
Table 4.27: Genetic Molecular study among cases group who use thrombopr-
ophylaixs 
 
 
No. Factor Homogenous Heterogeneous Normal  
TOTAL 
No. % No. % No. % 
1 
Prothrombin 
G2010A 
48 45.8 30 35.4 18 18.8 96 
2 ACE 1/0 41 42.7 36 37.5 19 19.8 96 
3 PAI - 4G/5G 34 35.4 45 46.9 17 17.7 96 
4 Factor V  34 35.4 39 40.6 23 24.0 96 
5 MTHFR 38 39.6 42 43.8 16 16.7 96 
6 Factor XIII 35 36.5 46 47.9 15 15.6 96 
 
Table (4.27)describes the genetic molecular studies among cases who used 
thromboprophylaxis during pregnancy, each gene has 3 descriptions 
(homozygous,heterozygous, normal ), nearly 154 of cases did genetic profile,112 of them 
did genetic molecular study, 96 of them had available investigations,There are six main 
inherited thrombophilia,factor V Leiden gene mutation (VFL),Prothrombin gene mutation, 
hyperhomocysteinemia, protein C deficiency, protein S deficiency, and anti-
thrombindeficiency, as shown in figure(6.4),factor v, Prothrombin and 
hyperhomocysteinemia done in patients who had thromboprophylaxis .Regarding to  
Prothrombin factor 45.8% is homozygous, 35.4% is heterozygous,and 18.8% of  cases is 
normal, that is constant with literature review the risk of VTE is three folds with 
80 
 
Prothrombin factor abnormality(Rosendaal et al,1998), also with Robesreteron et al (2006) 
in his met analysis study, pregnancy complicated diseases are associated with Prothrombin 
abnormalities, but on the other hand literature said that the prevalence of Prothrombin 
mutation in general population is 2%, and in thromboembolic events patients 6%, 
regarding to factor v35.4% is homozygous,40.6% is heterozygous, which that is consistent 
with Carp et al (2003),also Hellegran (2003) confirmed that women who had abnormal 
factor V genetic study, had a risk of 24%to 26%of thrombosis events in pregnancy, also 
Gardone and colleagues (2007) reported a 31.2%prevelance of factor V mutation in 
women with second trimester loss compared to 4.2% in matched controls, concerned health 
providers confirmed that “the most common gene is indicated to start heparin thereby is 
factor v mutation“, in the other hand literature review showed that  5%of general 
population had factor v mutation and 25% of patients who had venous thromboembolic 
events(Carp et al.,2003). 
 
 
 
Figure 4.8: Genetic Molecular study review 
 
regarding to hyperhomocysteinemia MTHFR 39.6% had homozygous geneticvariation, 
43.8% had heterozygous genetic variation which that is relevant to literature as Carp et al 
(2003) said prevalence of MTHFR 3% among population,10% to 25% in patients with 
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thromboembolic events, some of the studies confirmed its role in risk of pregnancy 
thrombosis as Robesteron et al (2006) described in his meta-analysis study, while 
Jaakelainen et al (2006) confirmed that there’s no role in pregnancy complications. 
Regarding to factor V111, and ACE factor, high levels are increasing the risk of deep 
venous thrombosis, but no clear significant in pregnancy complication, as said by 
(Kraaijenhagen et al, 2001), when these discussed with concerned health providers, as 
FFHO”genetic study which was done is incomplete as we need 13 genetic factors to be 
done to say that cases with positive thrombophilia, most of thegenetic study was done at 
unaccreditable labs, as people usually look for the cheapest one, so this should be 
considered” other concerned health provider said “Genetic study alone is not enough to 
diagnose thrombophilia and to determine the need of thromboprophylaxis”, another 
concerned health provider “if you do genetic study among all population, you will find the 
same percentages among healthy population who did not take thromboprophylaxis “  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 :Conclusions and Recommendations 
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5.1Conclusions 
 
The results of the study are unique in providing detailed documented information on the 
status of thromboprophylaxis use among pregnant women, by discussed different 
associated determinants, different management practices, different pregnancy outcomes, 
and how will thromboprophylaxis improve pregnancy outcomes and pregnancy 
complications. The aim of the study is to identify associated risk factors of 
thromboprophylaxis use, consequences, management practices that contribute to 
thrombophilia and the need of thromboprophylaxis among refugee risky pregnant, in order 
to explore possibilities for reducing maternal and fetal complications. Study is a 
comparative study that compares between  two groups of women who delivered at last 6 
months of 2016, one of them  are treated with of thromboprophylaxisand others are non-
treated with thromboprophylaxis during their last pregnancy, large five UNRWA health 
centers were selected for data collection, different associated determinants were discussed 
through an interviewed questionnaire,  as we discuss sociodemographic factors, past 
medical history, past obstetric history,  different associated pregnancy complications 
history of thrombosis and pregnancy outcome, also we discuss different management 
practices, different thromboprophylaxis experiences in different pregnancies, and how  
much the cost and the availability of medications at governmental hospitals and UNRWA 
health centers at the interviewed questionnaire, also medical record review discuses 
different associate risk factors and different associated management practices, In-depth 
interview discuss different related points that support findings of interviewed 
questionnaire. From the study we conclude that Jabalia UNRWA health center has a high-
frequency rate than other clinics most of them are unemployed, had average family income 
less than 1000NIS, also the majority of them had first-degree relative continuity,  
accumulation of different risk factors strongly associated and enhancing the use of 
thromboprophylaxis in pregnancy. 
 
Maternal age was strongly associated with thromboprophylaxis use as most of thecases age 
is more than 25 years old(62.2%), with early marriage age less than 20 years old(59.1%), 
and most of them had positive consenguity first degree relative of marriage(25%).History 
of non-communicable diseases is strongly associated with the use of thromboprophylaxis 
use in pregnancy, odds ratio (6.27), mainly DM, HTN, Respiratory diseases and heart 
diseases respectively. 
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History of hematological diseases is strongly associated with the risk of 
thromboprophylaxis use in pregnancy,odds ratio (233.3),  as most of them had congenital 
thrombophilia, history of thromboembolism disorder, and acquired thrombophilia,  also  
history of vascular diseases is strongly associated with thromboprophylaxis use, odds ratio 
(29.3), mainly varicose veins, deep venous thrombosis and thrombophlebitis respectively,  
on the other hand,there is a strong relationship between history of surgical operations and 
thromboprophylaxis use, odds ratio (5.6),mainly CS, abdominal surgery, and orthopedic 
surgery, women who had positive family  history, she had strong indication to 
thromboprophylaxis (odds ratio4.99), mainly inflammatory bowel diseases, congenital 
thrombophilia, acquired thrombophilia, SLE and rhematological diseases, respectively.  
 
Regarding to past obstetric history, the risk of thromboprophylaxis use is increasing more 
in  Gravida two and more(89.5%of treated women ), Para two  and more (74.5%of treated 
women), also the risk of thromboprophylaxis use is strongly associated with history of 
dead children, 29.1%of treated women had one and more history of dead children, majority 
of them 21.8%dieafter 28 weeks gestational age to less than 28 days after delivery 
(perinatal mortality). 
 
The risk of thromboprophylaxis use is increasing more in cases of infertility history (odds 
ratio 13.3), with a high frequency of infertility years more than 3 years (71.6%). Treated 
women had a risk of ahistory of pregnancy induction (odds ratio 4.83), 9.1% of treated 
women had failed IVF more than twice trial.  
 
The risk of thromboprophylaxis use is increasing more in cases with history of low birth 
weight, less than 2500 gram(odds ratio 2.2),majority of them had fetal weight 1.5-2.5 kg  
Also thromboprophylaxis use  is increasing with history of preterm labor, odds ratio (2.3), 
majority of them between 28-32 weeks gestational age, also thromboprophylaxis use is 
increasing more with strong relationship, with positive history of miscarriages(odds ratio 
18.4),it is highly indicated with more than twice miscarriages(56.1%), most of them had 
consecutive miscarriages (63.7%),majority of miscarriages occurred from one week to 12 
weeks pregnancy (60.8%), also thromboprophylaxis use is increasing more, also 
thromboprophylaxis use is increasing more in cases who had positive family history, 
regarding to history of pregnancy complications, thromboprophylaxis use is increasing 
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more in cases with history of pregnancy complications (odds ratio 57.36), mainly PIH, 
APH, PPH, PET, and GDM, respectively, also thromboprophylaxis use is strongly 
associated with history of thrombosis in pregnancy (odds ratio 11.2),mainly  deep venous  
thrombosis, pulmonary embolism and arterial thrombosis respectively. 
 
Research clarifies the role of thromboprophylaxis in pregnancy, majority of cases who use 
thromboprophylaxis during pregnancy did not complain of pregnancy 
complications(73.9%vesus 35.3%),on the other hand it describes how pregnancy outcomes 
improved by thromboprophylaxis use during pregnancy,majority of them had alive baby 
(78.2%),10.9% had abortion, 4.1% had early fetal deaths,3.6%had premature delivery 
,1.8% had perinatal mortality and 1.4%had congenital anomalies, in comparison to other 
pregnancies where thromboprophylaxis is not used 58.6%of cases did not use 
thromboprophylaxis in all pregnancies, 41.9%had alive birth, 38%of them had abortion 
,12.4% had early fetal deaths, 2.3% of them had congenital malformation, 1.6 % of them 
had intrauterine fetal deaths and 0.8% had early neonatal deaths . 
 
Regarding to fetal weight improvement,most cases(68.4%) who use thromboprophylaxis 
during pregnancy had normal fetal weight expected fetal weight  2500gm-4500gm, while 
15.7% had low birth weight (less than 2500 gm.)and 4.1% of cases had fetal weigh more 
than 4500 gm. which that confirmed by concerned health providers. 
 
Regarding to different management practices which followed, majority of cases who use 
thromboprophylaxis used combination therapy between low dose  aspirin 100 mg and 
heparin therapy(69%), most of them started heparin therapy at first trimester of gestational 
age (86.2%),63% of cases stopped thromboprophylaxis after delivery which that is not 
consistent with international guidelines which described the use of thromboprophylaxis use 
in the following 6 weeks after delivery, most of medications prescribed by private 
physicians, 80.2 % access this medication from out pocket money with high cost which is 
nearly more than 1500 NIS during pregnancy(66.7%),on the other hand, majority of cases 
did investigation profile which is supportive to start with heparin therapy 91.5% of them 
did complete investigation profile , 73.2 % of them had molecular genetic study , 17.6 % 
did coagulation profile , 8.5% of them did antiphospholipid syndrome and 0.7% of them 
did anti DNA antibodies, regarding to genetic thrombophilia abnormalities, cases who use 
thromboprophylaxis in their pregnancies had abnormalities in the following genes( 
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Prothrombin G2010A homogenous 45.8% heterogeneous 35.4% ACE/0 homogenous 
42.7%heterogeneous 37.5%, PAI-4g/5g homogenous 35.4%heterogenous 46.9%, factor V 
35.4% homogenous 40.6% heterogenous,MTHFR homogenous 39.6%heterogenous 43.8% 
and factor X111 36.5 %homogenous and 47.9%hetrogenous which that support the use of 
thromboprophylaxis during pregnancy, genetic study alone will not be enough  to decide to 
star thromboprophylaxis but it needs both risk factors and supportive investigations.  
 
Most cases of thromboprophylaxis use had accumulated risk factors 54%of them had two 
risk factors, 34% of them had one risk factor and 12 %had more than two risk factors, 
these files are high risky ,96.7%had specialist follow up, 38.6% visit specialist room more 
than 4 visits,35.3%had fetal us more than 4 times during pregnancy,70.6% of them 
delivered at public hospitals,which that indicated good follow up by UNRWA health 
centers for risky pregnancy. 
 
Regarding blood pressure measurement and body mass indexes measurements, cases who 
use thromboprophylaxis during pregnancy had a risk HTN than women who were not 
treated by thromboprophylaxis as 20.5 % had pre HTN stage, 3.2% had HTN, in contrast, 
its association with BMI as women who not treated with thromboprophylaxis is more a risk 
to Overweight and obesity than non- treated women, which that is not consistent with 
literature review.  
 
Thromboprophylaxis use among pregnant women had two borders,the first one she 
presence of real risk, the other border is overuse because of lack harmonization between 
different health sectors.  
 
6.2 Recommendations    
A high-risk pregnancy is increasing so the risk of thromboprophylaxis demand is 
increasing and also the research clarifies the role of thromboprophylaxis in improving the 
pregnancy outcomes, so research recommends  
1- Enhancing the availability of clear simple technical guidelines dealing with 
thromboprophylaxis use in pregnancy in order to control heparin use. 
2- Ensuring the access of heparintherapy MO –UNRWA installations with defined 
instructions in order to control the use of heparin and decrease out of pocket 
dependence  
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3- Improve the referral system and feedback between primary and secondary 
healthcare 
4- Expansion of preconception coverage in order to enter pregnancy in optimal health 
before pregnancy  
5- Encouraging teamwork and cooperation between different health sectors in order to 
improve the quality of health. 
6- Encouraging standardization of diagnostic criteria for cases 
withthromboprophylaxis use in pregnancy. 
7- Ensuring the presenceof  effective management plan of bad pregnancy outcomes in 
order to early detection of thrombosis risk 
8- Ensuring the presence of accreditable labs to do reliable thrombophilia 
investigations to justifythromboprophylaxis use in pregnancy  
9- Improving the comprehensive package of maternal health  care services in order to 
identify the maternal risk factors and improve maternal  health  
10- Conducting more researchers in different aspects of thromboprophylaxisuse, by 
using hospital-based studies. 
6.3 Area of further research 
1- Further analysis to detect confounder and interactions between risk factors of 
thrombophoplyaxi use among pregnant women  
2- Further researchers to detect the significance of genetic factors among thrombophilia 
and thromboprophylaixs use  
3- Further researches on evidence of IVF cases who used thromboprophylaxis 
4- Further researches of hospital-based studies of cases who use thromboprophylaxis 
5- Other types of researchers to detect the prevalence of thrombophilia, risk factors, 
and management practices 
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Annexes 
Annex (1) Study activities time table 
 
 
 
Annex (2) Sample size calculation 
 
Assumptions:  
        Odds ratio                 2 
        Exposed controls        15% 
         Alpha risk              5% 
        Power                   80% 
        Controls / Case ratio   1 
     Total exposed           20.5435% 
Estimated sample size:  
     Number of cases         215 
     Number of controls              215 
     Total                           430 
 
 
 
 
Activity Duration 2 3 4 5 6 7 8 9 10 11 
Proposal writing 3month           
Proposal defense 
And approval 
1month           
Expert committee 
Check for validity 
of instruments 
1month           
Pilot St dy 3month     3 mo.      
Modifications 2weeks           
Data Collection 3months           
Data Entry 3months           
Data Analysis 2months           
Research writing 2months           
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Annex (3) Sampling Distribution  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B=big  , M=middle , S=small 
 
 
RandomlyselectedlargeClinics 
21 UNRWA Primary Health Centers 
Gaza 
440Individuals 
Matching 
Cases +Controls 
5 PHC Clinics 
North MidZone KhanYouis Rafah 
2
M 
1
B 
- 2
M 
1
B 
2
S 
4
M 
1
B 
- 1
M 
1
B 
1
S 
2
M 
1
B 
2
S 
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Annex (4) Sampling process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SamplingProcess 
440Individuals In-depth interview (3 Key 
health providers ) 
Qualitative Quantitative 
Matching 
220 Controls 220 Cases 
Interviewed Questionnaire  
100 
 
Annex(5 ) Estimated budget 
 
 
Item 
 
Unit 
 
Expected USD 
Study tools MP3 recorder $200 
Transportation Three months-all Gaza Governorates $1,000 
Data collectors 300*$5per questionnaire $1,500 
Training workshop For data collectors $200 
Data entry and analysis  $1000 
Photocopying of research 
papers 
 
 
- 
$1000 
 
 
 
 
 
Internet used  $300 
 Total $5,300 
 
 
Annex (6) List of arbitrators 
 
 Name 
1- Dr. Bassam Abu Hamad 
2- Dr. Yehia Abed 
3- Dr. Khitam Abu Hamad 
4- Dr. Zoheir El Khatib 
5- Dr. Reem Lulu 
6- Dr. Jadallaha Ukasha 
7- Dr. Waleed Abu Hatab 
8- Dr. Ashraf  YA  El-Jedi 
9- Dr. Yousef Aljeesh 
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Annex (7): The study quantitative instrument - English 
Study questionnaire 
Dear participant 
I am maha safi, collecting data for a research study aboutThromboprophylaxis use among 
Pregnant Women Gaza Governorates. You have been selected to participate in this study 
and your participation has no direct or indirect implications on your work. 
This questionnaire is part of a study conducted by me as a requirement for a master degree 
in Public Health at Al Quds University. The findings and conclusions of this study may 
help in improving our conception. Filling this questionnaire takes about 30 minutes of your 
valuable time. Confidentiality will be provided and maintained and you don’t need to tell 
your name. Even though I welcomed and appreciate your participation, your participation 
is optional. This study is self-funded and findings will be used only for the research 
purpose. 
Please answer all questions as much as possible and if there is any ambiguous meaning, 
don’t hesitate to ask for more clarification. 
 
Part # 1   Demographic Characters : 
 
A) Wife 
…………….. 1. Serial number  
 Rafah Khan 
Younis 
Mid 
zoom 
Gaza North 
Gaza   
2.  Residency 
Village camp city 3. Place of living  
………………… 
…………… 
4. Age 
5. Age at marriage 
 i. Primary school 6. Total Years of 
schooling    ii. Secondary school 
 iii. University or collage  
 i. No 7. Are you working? 
 ii. Yes. If  yes specify  
 iii. Housewife     
 iv. Governmental employee 
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 v. Non-Governmental employee 
 vi. Self-employed 
B) Husband 
……………………………………………………………… 1-Age:  
……………………………………………………………… 2- Age at marriage: 
 i. Primary school 3- Total Years of 
schooling    ii. Secondary school 
 iii. University or collage  
 i. No 4- Are you working? 
 ii. Yes. If  yes specify  
 iii. Governmental employee    
 iv. Unemployed 
 v. Non-Governmental employee 
 vi. Self- employed 
 a) No 5- Consanguineous  
Marriage 
If yes, specify 
 
 b) Yes 
 i. 1-first degree   
 ii. 2-second degree 
 iii. 3- far relative    
C) Economic Level  
 i. less than 1000 NIS. 1- Average family 
income  ii. 1500-2000 NIS. 
 iii. more than 2000 NIS.  
 i. Owned 2- House 
 ii. Rented 
 i. Concrete house 3-Type of house  
 ii. Asbestoses house 
 iii. Mud house 
 i. One room 4-Number of rooms 
 ii. Two rooms   
 iii. Three or more rooms 
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Part # 2   Past Medical History :  
 
1- Is there a past history of Noncommunicable diseases (Diabetes Mellitus, 
Hypertension  
a) Yes   b) No    c) If yes, specify: 
i. Diabetes Mellitus    ii. Renal diseases  
iii. Hypertension  iv. Rheumatic Diseases   
v. Heart Diseases  vi. Systemic Lupus Erythroblastosis  
vii. Respiratory Diseases  viii. Others: specify   
ix. Malignancy    
2- Is there a past history of Hematological Diseases? 
a) Yes  b) No        c) If yes, specify  
i.  Congenital thrombophilia  
ii. Acquired thrombophilia     
iii. Thromboembolism  disorder  
 If you choose i , ii  specify   
i. Lab-based  
ii. Not lab based  
3- Is there a past history of vascular diseases? 
a) Yes  b) N
o 
 c) If you choose, yes  
specify 
 
i. Varicose veins   ii. Thrombophlebitis  
iii. Deep Venous thrombosis    iv. Vaclalitus  
4- Is there a past history of surgical operations   
i. Yes    
ii. No   
 If yes, specify    
4.1 Number of surgical operations 
i. One  
ii. Two to five  
iii. More than five   
4.2 Type of surgical operations 
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i. Cesarean section  
ii. Uterine surgery  
iii. Pelvic surgery  
iv. Abdominal surgery  
v. Orthopedic surgery      
5 Are there associated family diseases? 
a) Yes      b) No    
5.1 If yes, specify 
i. Congenital thrombophilia  
ii. Acquired thrombophilia  
iii. SLE  
iv. Inflammatory bowel diseases  
v. Rheumatological diseases   
vi. Inflammatory poly-arthropathy  
 
Part # 3 Past Obstetric history of the study population 
 
1. Gravida (Number of previous pregnancy)     
I. Primigravida  
II. Gravida  two to gravida five  
III. Gravida 6 or more   
2. Parity (number of previous alive complete deliveries)  
I. Para One  
II. Para two to para five  
III. Para 6 or more  
3. Number of alive children   
I. Zero  
II. One to two   
III. Three or more   
4. A number of dead children ………………….      
I. Zero  
II. One to two   
105 
 
III. Three or more  
 if you choose the ii or iii, specify for each dead child  
4.1 Child age at Death     
I. 28 GA. weeks - less than one week  
II. One week-less than 28 days  
III. 29 days to one year  
IV. More than one year  
4.2 Causes of death   
I. Unknown  
II. Birth trauma  
III. Congenital anomalies  
IV. Accidents or injury  
V. others  
5.  History of infertility   
a) Yes                               b) No                         
if yes specify  
5.1  Years of   infertility  
a) One to two years   
b) Three to five years  
c) More than five years  
5.2 History of pregnancy induction 
a) Yes b) No   
5.2.1  If yes, specify 
i. IVF (  Invitro  fertilization )   
ii. IUI (Intra uterine insemination     
iii. Sponto ous induction  
5.2.2 If your answer 1 and 2 then answer the following  
i. Time of failure  
a) None  
b) 1-2  
c) More than two  
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6. Is there a history of low birth weight?(fetal weight <2500gm) ? 
a) Yes              b) No  c) If yes, answer the following  
6.1 weight of baby  
a) less than or equal to 1.5 kg b) 2-> 1.5 -2.5 kg  
6.2 How many times do you have it ? 
a) 1-once              b) 2-twice  c) More than twice  
6.3 Is there a history of pretemlabor? 
a) yes b) No If yes specify  
6.3.1 Gestational age at delivery 
i. < 28 weeks ii. 28-32 weeks iii. 34-37 weeks  
7. Is there a history of miscarriages? 
a) Yes  b) No    If yes, specify the frequency   
7.1 Number of miscarriages 
i. One  ii. Two  iii. More than Two   
7.1.1 If two or more, were they consecutive?  
i. Consecutive    ii. Nonconsecutive   
7.1.2 Pregnancy age at abortion "Gestational age of abortion  " 
One Week to 12-week 
Pregnancy 
From 13 weeks to 
20 weeks Pregnancy 
More than 20 
weeksPregnancy 
Diverse 
 
Part # 4   History of contraceptive use 
1-  Is there a history of  contraceptive pills use  
a) Yes              b) No  c) If yes, specify    
1.1 Type of contraceptive pills   
i. Minipills  
ii. Combined oral contraceptive pills  
iii. Injectable hormone(DMPA injection)  
1.2 Duration of use  
i. Less than 2 years  
ii. 2 years -5 years   
iii. More than 5 years   
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Part # 5   History of Pregnancy Complications 
1- Is there a history of pregnancy complicated diseases? 
a) Yes   b) No  c) If yes,  specify: 
1.1 Type of pregnancy complications 
i. Pregnancy induced hypertension  ii. Pre- eclampsia  
iii. Gestational diabetes  iv. PIH and GDM  
v. others: specify…    
 
Part# 6  Thrombo- embolism (TE) &Thromboprophylaix in previous pregnances : 
 
1- Is there a history of TE in pregnancy ? 
a) Yes          b) No       
1.2 If  yes, type of TE: 
i. Deep venous TE  ii. Pulmonary Embolism   
iii. Arterial thrombosis (Myocardial 
infarction, Cerebrovascular accident) 
 
 
iv. Both (1 and 3) 
 
 
 
2 Did you take any thrombopropylaxis in previous pregnancies? 
 
a) Yes    b) No       
c)  c)   If  yes, specify the following  
 
2.1 Was it used in all pregnancies?  
a) Yes b) No c) If No,Answer the following about pregnancy (you do not 
use heparin therapy) 
2.1.1 What was the outcome of that pregnancy?  
i. An abortion  ii. Alive birth  
iii. Early fetal death  iv. Congenitally malformed baby  
v. Intra uterine fetal death.  vi. IUGR  
vii. Early neonatal mortality  viii. Low birth weight baby  
2.1.2 Is there associated complications of that pregnancy? 
Yes No If yes, specify 
2.1.2.1 What was the associated pregnancy complications in the index pregnancy? 
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i. PIH      i. APH  
ii. GDM  ii. PPH  
iii. both (1,2)  iii. Nothing  
iv. DVT    
2.1.2.2 Was that pregnancy associated with preterm labor?  
a) Yes b) No 
 
Part # 7  Last Pregnancy and thrombopropylaxis 
 
1- What was the outcome of last pregnancy? 
i. Abortion  ii. Alive baby  
iii. Premature delivery  iv. Congenital anomalies    
v. Early fetal death    vi. Perinatal mortality                         
1.1 If your answer “ ii ” the weight of last a live baby  
a) <2500gm  
b) 2500 -3500 gm  
c) 3500 - 4500 gm  
d) >4500 gm  
2. Have you used thromboprophylaxis in the last pregnancy? 
a)Yes b) No  
2.1 What is the type of thromboprophylaxis used in that pregnancy? 
i. Low dose aspirin alone  ii. Un-Fractioned heparin    
iii. low molecular weight heparin 
(clexane, fraxiparin)     
 iv. Combination of low 
dose aspirin and heparin  
therapy   
 
If you answer (ii, iii, iv), answer the following   
2.1.1 The dose of heparin therapy   
i. 5000I.U/U.N heparin/OD/SC  
ii. 5000I.U/U.N heparin/BID/SC  
iii. 0.3 mg fraxiparin/OD/SC  
iv. Clexane (20,40,60,80) mg/ OD/SC  
2.1.2 The frequency of heparin therapy   
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i. Daily  
ii. Alternative days  
iii. Weekly  
iv. others  
2.1.3 Gestational age at starting heparin   
i. First trimester(0-13 weeks)  
ii. Second trimester(14- 26 weeks)  
iii. Third trimester (27- 40 weeks)  
2.1.4 Gestational age at stopping heparin   
i. First trimester(0-13 weeks)  
ii. Second trimester(14- 26 weeks)  
iii. Third trimester (27- 40 weeks)  
iv. Directly after delivery  
v. 1 week after delivery  
2.1.5 Who prescribed that medication for you  
i. Hospital physician  
ii. UNRWA physician  
iii. Private physician  
2.1.6 How did you access to medication (thromobrophylaxis ) 
I. UNRWA clinics  
II. Public Hospitals  
III. Governmental clinics  
IV. Private Pharmacies  
V. Non-Governmental clinics  
2.1.7 Did you completely comply with regular use of the prescribed medications?  
i. Yes 
ii. No 
2.1.8 Did you perform a complete investigation profile to support the use of 
heparin therapy during pregnancy? 
a) Yes     b) No  c) If yes  specify: 
2.1.8.1Types of used thrombophilia investigation profile 
i. Molecular Genetic thrombophilia study  
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ii. Coagulation profile  
iii. Antiphospholipid Antibodies   
iv. Anti DNA antibodies      
v. All of the above  
vi. None of the above  
2.1.8.2 What was the total cost of heparin therapy?  
i. 5000-1000 NIS  
ii. 1000-1500 NIS  
iii. More than 1500NIS  
2.1.8.3 Did you suffer any heparin therapy side effects in last pregnancy? 
i. Painful injecting site   
ii. bone ache  
iii. Itching/allergy   
iv. Associated thrombocytopenia  
v. Ecchymosis patches  
vi. Bleeding  
vii. Others, specify  
2.1.8.4 Did you have any health complications during last pregnancy? 
a) Yes b) No c) if yes, specify 
2.1.8.4.1What is Types of pregnancy complications 
I. PIH  II. DVT  
III. GDM  IV. APH  
V. BOTH (i and  ii)  VI. PPH  
VII. Anemia   
Management practice and follow up among cases with thromboprophylaxis use    
2.2 Did you follow by specialist? 
I. Yes II. No III. if yes, specify 
2.2.1 How many times during pregnancy did you visit specialist room  
a) 1 times b) 2-4 times c) More than 4 
2.2.2 How many times has fetal us done for you at the clinic? 
a)one  b) 2-4 times C) more than 4 
2.2.3 Did you follow at high-risk department at the hospital ? 
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a) yes b) no  
3 Where did you deliver? 
a) Private hospital b) Public hospital c) Private 
doctor 
 
 
Part # 8  Evaluation of Blood pressure and obesity indicators among study  
population 
1- Blood Pressure indicators for women 
I. <130/86 II. 130-139/86-88 III. or > and =140/90 
 
2- Obesity indicators for pregnant women 
Underweightless 
than18.5 kg 
Natural 
Weight 
18.5-24.9 
Overweight 
25-29.9 
First-class 
obesity 
30-34.9 
Second 
class obesity 
35-39.9 
Third class 
obesity 
More than 
40 
 
 
 
Any notes ……………………………………………………………………………….. 
 
With best regards 
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 ....... ػض٠ضصٟ 
                      صق١ز ؽ١ذز ٚدؼذ 
 
 ٚ٠ضؼّٓ "ثعضخذثِّٛثٔؼجٌضؾٍطٍٍٕغجءثٌقٛثٍِفٟ ِقجفظجصغضر " دؼٕٛثْ  فىجٌظقز ثٌؼجِز       ٠ؼذ ثٌذجفظ سعجٌز ِجؽغض١ش
 ٚ٠ضطٍخ رٌه لشثءر وً ثٌم١ُ دؼٕج٠ز ٚثخض١جس ثٌذذ٠ً ثٌزٜ ٠ضفك ِغ  صغغ ثؽضثء ِخضٍفز صضؼٍك دؼذد ػٛثًِ ِضغ١شرثٌّم١جط 
 صضفك ِغ سأ٠ه  ثٌضٟ ثٌخجٔز فٟ)  (ٚؽٙز ٔظشن ٚرٌه دٛػغ ػلاِز
ٚثٌذجفظ إر ٠شىش ٌىُ صؼجٚٔىُ ثٌظجدق لإٔؾجص ٘زث ثٌذقظ ٚ٠ؤوذ ٌىُ أْ ِج صذٌْٛ دٗ ِٓ د١جٔجس صخؼغ ٌغش٠ز صجِز ٌٚٓ 
.  ٌٚىُ ٚثفش ثٌضق١زثٌؼٍّٟ،صغضخذَ إلا لأغشثع ثٌذقظ 
 
 
 اى ي ج ىشش ٍة:اىجؼءالا ه 
 
 اىؼ جة: ا لا 
اىغقٌ اىحـيـيً .  .1 
الإق ٍة  .2 شّجي غضر غضر ثٌٛعطٝ خجٔ١ٛٔظ سفـ
ٍن ُ اىَؼٍشة  .3 ثٌّذ٠ٕز ثٌّخ١ُ ثٌمش٠ز
 اىؼَغ .4 
اىؼَغ ػْض اىؼ از  .5
ٍجَىع ؿْىات اىضعاؿة  .6 ثٌّذسعز ثلادضذثة١ز  .  
 ثٌّذسعز ثٌغجٔٛ٠ز . ب 
 ؽجِؼز أٚ وٍ١ز . ت 
 او جؼَو؟ .7 ٔؼُ -1 لا- 2  فذدٞ. ثرث وجْ ٔؼُ
 ٘قىِٛ١زِٛظف .  
 ِٛظفٗ غ١ش فىِٛ١ز  . ب 
 ػًّ خجص . ت 
اىؼ ز : ج ٍّ  
اىؼَغ  .1 
اىؼَغ ػْض اىؼ از  .2 
ٍجَىع ؿْىات اىضعاؿة  .3 ثلادضذثة١ز خش٠ؼ ثٌّشفٍز .  
  ثٌغجٔٛ٠زخش٠ؼ ثٌّشفٍز . ب 
 ؽجِؼز أٚ وٍ١زخش٠ؼ  . ت 
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 ػَو؟ياو  .4 ٔؼُ -1 لا- 2 فذدٞ. ثرث وجْ ٔؼُ 
 ِٛظفقىِٟٛ .  
 ِٛظفغ١شفىِٟٛ . ب 
 ػٍّخجص . ت 
ػ از الأق عب  .5 لا  .  ٔؼُ .  ح إرث وجٔش ثلإؽجدز دٕؼُ، فذد
  ثلأٌٖٚٝثٌذسػ )a  
 ر ثٌغجٔ١زػثٌذس )b 
 دؼ١ذرلشثدز  )c 
اىَـحىى الاقح صي : ذ ىر 
  صسو الاؿغةٍحىؿظ .1 . ش١ىً0001ألً ِٓ  .  
 . ش١ىً0002-0051 . ب 
 . ش١ىً0002أوغش ِٓ  . ت 
 ٍْؼه .2 ٍِه خجص .  
 ِؤؽش . ب 
ّىع اى ٍث  .3 د١ش ثعّٕش  .  
 د١ش ثعذغش  . ب 
 د١ضجٌط١ٓ . ت 
 ػضص اىغغف .4 غشفز ٚثفذر .  
  غشفض١ٓ . ب 
 علاط غشف أٚ أوغش.  . ت 
 
 
 اىح عٌش ىط ٍ ىـ بق: اىجؼءاىر ًّ 
 
 
 ؟(............ ٍغض اىـنغي، اعجي ع  غظ اىضً، ( اىَؼضٌة اىَؼٍْةٍِ  ٍغاض اىغٍغ  جؼ ّى او .1
 :ٞإرث وجٔش ثلإؽجدز دٕؼُ، فذد لا .b ٔؼ ُ.a
  ِشثع ثٌىٍٝث . ب  ِشع ثٌغىشٞ . 
  ثلأِشثع ثٌشِٚجص١ضِ١ز . خ   ػغؾ ثٌذَثسصفجع.  . ت
  )ثٌزةذز(سثء ثٌقُثٌغؼٍذز  . ح  أِشثع لٍذ١ٗ . ز
  ثٚسثَ  . ص  ثِشثع ثٌؾٙجص ثٌضٕفغٟ . ر
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  ثخشٜ . ط
 جؼ ّى ٍِ  ٍغاض فً اىضًاو  .2
 إرث وجٔش ثلإؽجدز دٕؼُ، فذد لا .b ٔؼُ .a
  ثٌضخغش ثٌٛسثعٟ . 
  ٌضخغش ثٌّىضغخث . ب
  ثٌؾٍطجس ثٌذِٛ٠ز . ت
   :إرث ثخضشس ثلأٚي ٚثٌغجٟٔ صقذ٠ذ 
  ِغذش دجٌضقجٌ١ً ثٌطذ١ز . 
  غ١ش ِغذش دجٌضقجٌ١ً ثٌطذ١ز . ب
 الأ ػٍة اىضٍىٌة؟عا َؼٍْة فً ًجؼ ًّ ٍِ ااو  .3
  ٞإرث وجٔش ثلإؽجدز دٕؼُ، فذد لا )b ٔؼ ُ)a
  ثٌضٙجح ثٌٛس٠ذ ثٌخغجسٞ.  . ب  )ثٌذٚثٌٟ(صٛعغ ثلأٚسدر . 
   ثٌضٙجح ثلأٚػ١ز ثٌذِٛ٠ز . خ  ؽٍطز ٚس٠ذ٠ز ػّ١مز . ت
  او اْ ك ج عٌز ؿ بق ىيؼَيٍ ت اىجغادٍة؟ .4
 :دٞإرث وجٔش ثلإؽجدز دٕؼُ، فذ لا )b ٔؼ ُ)a
 ػضص اىؼَيٍ ت اىجغادٍة 4.1
  ٚثفذ . 
  ِشص١ٓ إٌٝ خّظ . ب
  أوغش ِٓ خّغز . ت
 ّىع  اىؼَيٍة اىجغادٍة 4.2
  ثٌؼٍّ١ز ثٌم١ظش٠ز . 
  ؽشثفز ثٌشفُ . ب
  ؽشثفز ثٌقٛع . ت
  ػٍّ١ز ؽشثف١ز فٟ ثٌذطٓ . خ
  ؽشثفز ثٌؼظجَ . ز
 ؟ب لأؿغةاو اْ ك اٍغاض ٍغج طة  .5
 :ٞإرث وجٔش ثلإؽجدز دٕؼُ، فذد 1.5 لا )b ٔؼ ُ)a
  ثٌٛسثعٟ ثٌضخغش ثٌذَ  . 
  ثٌضخغش ثٌذَ ثٌّىضغخ . ب
  )ثٌزةذز ثٌقّجِ١ز ثٌؾٙجص٠ز(ِشع ثٌزةذز ثٌقّشثء  . ت
  أِشثع ثلأِؼجء ثلاٌضٙجد١ز . خ
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  ثٌشِٚجصضَثِشثع  . ز
  ثٌضٙجح ثٌّفجطً ثٌّضؼذدر . ح
 
 ج عٌش ىىلاصاج ىـ بق: اىجؼءاىر ىد 
 
  )اىذَىلات اىـ بقةػضص (د ٍو .  .8
  )دىش٠ز( فًّ ثٌٚٝ . 
  فّٛلاسفًّ ِٓ  ثعٕ١ٓ إٌٝ خّغز   . ب
   فّٛلاس ثٚ ثوغش6 . ت
  اىـ بقة ػضص اىىلاصات   .9
  ٚثفذ . 
  خّغزثعٕ١ٓ إٌٝ   . ب
  عضز ِشثس  أٚ أوغش . ت
  ػيى قٍض اىذٍ ةاىظٌِ ػضص الأطي ه  .01
  طفش . 
  ٚثفذ ثٌٝ ثعٕ١ٓ  . ب
  علاعز أٚ أوغش . ت
  ػضص الأطي ه اىظٌِ جىفىا   .11
  طفش . 
   ثٌٝ ثعٕ١ٓ ٚثفذ . ب
  علاعز أٚ أوغش . ت
   إطا اسحغت اىر ًّ    اىر ىد، جذضٌض ىنو طيو ٍٍث 
   اىطيو ػْض  اىَىتػَغ.  4.1
  ثلً ِٓ ثعذٛع – ثعذٛع  فًّ 82 . 
 ٠ِٛج 82 ألٍّٓ فضٝأعذٛػٛثفذ . ب
 
   ٠ِٛج إٌٝ عٕز ٚثفذر92 . . ت
  أوغش ِٓ عٕز . خ
   ؿ  ب اىىف ة 4.2
  غ١ش ِؼشٚف . 
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   طذِز ثٌٛلادر . ب
   ثٌضشٛ٘جس ثٌخٍم١ز . ت
  فٛثدط أٚ إطجدجس . خ
  ػٛثًِ ثخشٜ . ز
  او جؼ ّى ٍِ ػقٌ؟ .21
 : صقذ٠ذ.رث وجٔش ثلإؽجدز دٕؼُ لا .b ٔؼ ُ.a
   ؿْىات اىؼقٌػضص 5.1
  عٕز إٌٝ عٕض١ٓ . 
  علاعز إٌٝ خّظ عٕٛثس . ب
  أوغش ِٓ خّظ عٕٛثس . ت
 او د  ىث لا دضاخ دَو؟ 5.2
 : ثٌطش٠مزٞ ٚػـ.ثرث وجْ ٔؼُ  1.2.5 لا .b ٔؼ ُ.a
  )ثؽفجي ثلأجد١خ(ٌضٍم١ـ ثلاططٕجػٟ ث . 
  )ثٌضٍم١ـ دثخً ثٌشفُ( IUI . ب
  )ثعضخذثَ ثٌّٕشطجس ( ثٌقظ ثٌطذٟ.  . ت
  :ب اج ى ػيى ٍ  ٌيى     اإطا م ُ ىضٌل اىجىاب  2.2.5
  :ػضص ٍغات ّج ح  اىذَو 5.2.1 
  طفش . 
  2-1 . ب
  أوغش ِٓ ثعٕ١ٓ . ت
   ػضص  ٍغات فشو اىذَو- 1
  طفش . 
  2-1 . ب
  أوغش ِٓ ثعٕ١ٓ . ت
)  جغاً0052< ػّ ىجٍِْ (او ىضٌل ٍىاىٍض  ىضت اقو ٍِ اىىػُ اىط ٍؼً ؟ .6
 :إرثوجٔجٌؾٛثدٕؼُ،ثلإؽجدزػٍىّج٠ٍٟ لا . ب ٔؼ ُ. 
     ػُ اىطيو6.1
 وؾُ 5.2 -5.1 ثوذش ِٓ  . ب وؾُ 5.1 ألٍّٕأٚ٠غجٚٞ . 
    ػضصاىذ لات6.2
 ثوغش ِٓ ِشص١ٓ .  س . ت ِشص١ٓ  . ب ِشر  . 
   ايذ و  لاصةٍ نغة؟6.3
 إرثوجٔجٌؾٛثدٕؼُ،ثلإؽجدزػٍىّج٠ٍٟ لا .b ٔؼ ُ.a
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 د ىبَْؼ ىذَو: اىجؼءاىغابغ
 
 ؟ طىٌو ٍِ اؿحشضاً د ىب ٍْغ اىذَوىضٌنَ  ًاو  -2
 دٕؼُ فذدٞإرث وجٔش ثلإؽجدز  لا .b ٔؼ ُ.a
  اّىاع  د ىب ٍْغ اىذَو .a
  فذٛح أفجد٠ز ثٌٙشِْٛ . 
  فذٛح صٕجة١ٗ ثٌٙشِْٛ . ب
  )APMDفمٓ (٘شِْٛ ػٓ ؽش٠ك ثٌقمٓ  . ت
  ٍضة الاؿحشضاً 1.2
   عٕٛثس2ألً ِٓ  . 
   عٕٛثس5- عٕز 2 . ب
   عٕٛثس5أوغش ِٓ  . ت
 
 
 
 
  ٍض ػي ج ىذَو اىـ بقة: اىجؼء اىش ٍؾ
     ػَغ اىذَو ػْض اىىلاصة6.3.1 
 أعجد١غ63-43 . ت أعجد١غ 23-82 . ب أعذٛػج 82< . 
 ايؼ ٍّث ٍِ اجه  ت ؿ بقة؟ .7
 إرثوجٔجٌؾٛثدٕؼُ،ثلإؽجدزػٍىّج٠ٍٟ لا .b ٔؼ ُ.a
  ػضص ٍغات الاجه  ت اىـ بقة7.1
ثوغش ِٓ  . ت ِشص١ٓ . ب ِشر . 
 ِشص١ٓ
   او م ُ الاجه ض  ب   تاطا م ّث الاج بة  7.1.1
 غ١ش صٛثٌٝ . ب صٛثٌٝ . 
" ػّشثٌقٍٍّلإؽٙجع "  عٕجٌقٍّؼٕذثلإؽٙجع7.1.2
 02 أعذٛػجإٌٝ 31 ِٓ أعذٛػجٌقًّ 21 أعذٛػٛثفذإٌٝ
 أعذٛػجثٌقًّ
 ِضٕٛع أعذٛػجثٌقًّ 02 أوغشِٓ
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 ػ ٍِّث ٍِ ٍض ػي ت اذْ ء اىذَىلات اىـ بقة؟او  .1
 : ٔؼُ فذدٞ.ثرث وجٔش ثلاؽجدز لا .b ٔؼ ُ.a
 ؟  ّىع اىَض ػي ت اىحً د يث 1.1
  صغُّ ثٌقًّ  . ب  ثسصفجع ػغؾ ثٌذَ ثٌٕجؽُ ػٓ ثٌقًّ . 
  " عىش فًّ ٚػغؾ ثٌقًّ ِؼج . خ  عىشٞ ثٌقًّ . ت
ثٔفظجي ( ِج لذً ثٌٛلادر ثٌٕضف . ح  ٔض٠ف ِج دؼذ ثٌٛلادر . ز
 (ثٌّش١ّز
 
    )…ٞفذد(أخشٜ .  . ر
 
 
  جشرغاىضٍىٍىاّؼ ىحجيظ: اىجؼءاىـ صؽ 
 
 اىذَىلات اىـ بقة؟ جيط جضٍىٌة  فً ػ ٍّث ٍِ او  .1
 يإطا م ُ اىجىاب ّؼٌ، دضص لا .b ٔؼ ُ.a
   ّىع اىجيطة اىحً د يث1.1
ؽٍطز ٚس٠ذ٠ز  . 
 ػّ١مز
– ثفضشجء ػؼٍز ثٌمٍخ(صؾٍؾ ثٌذَ ثٌشش٠جٟٔ  . ب 
 )ثٌذِجغ١زثٌؾٍطز 
 
    ثلأغذثد ثٌشةٛٞ . ت
 اىذَىلات اىـ بقة؟ٍىاّغ اىحجيظ  فً  اؿحشضٍث او .2
 ٞإرث وجٔش ثلإؽجدز دٕؼُ، فذد لا .b ٔؼ ُ.a
  ّىع ٍ ّغ اىحجيظ .b
  ثلأعذش٠ٓ فمؾ . 
  ثٌٙذجس٠ٓ . ب
  ثٌٙ١ذجس٠ٓؽشػز ِٕخفؼز ثٌٛصْ ِٓ  . ت
  ثٌؾّغ د١ٓ ثلأعذش٠ٓ ٚثٌٙ١ذجس٠ٓ . خ
  .  ٍ  ٌيىيدضص .خ , ت ، ب اطا م ُ اىجىاب  
   ػَغ اىذَو ػْض بضاٌة ٍ ّغ اىحجيظ2.1.1
  ) أعجد١غ31-0( ثلأٚي ِٓ ثٌقًّ   ثٌؾضء . 
  ) أعذٛػج62- 41( ثٌغجٟٔ ِٓ ثٌقًّ ثٌؾضء . ب
  ) أعذٛػج04- 72(ثٌغجٌظ   ثٌؾضء  . ت
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  اىهٍ  عٌٍِِ اىظي   ف ىل ػلاز    2.1.2
  أؽذجء ثٌّغضشفٝ . 
  أؽذجء ثلأٚٔشٚث . ب
  ثٌؼ١جدثس ثٌخجطز ٌلأؽذجء . ت
   ٌىٍٍ اىهٍ  عٌِمٌ جنيية اىؼلاز    2.1.3
   ش١ىً02-01 . 
   ش١ىً03-12 . ب
   ش١ىً04-13 . ت
  ب ؿحشضاً ػلاز اىهٍ  عٌِ فً اىذَو او اىحؼٍث  2.1.4
 :........ثرث وجْ لا ثروشٞ ثٌغذخ . ت لا  . ب ٔؼ ُ. 
  ػيى ٍىاّغ اىحجيظد يثمٍف   2.1.5
  ثٌّغضشف١جس ثٌؼجِز.  . ب  ػ١جدثس ثلأٚٔشٚث . 
  ثٌظ١ذٌ١جس ثٌخجطز . خ  ثٌؼ١جدثس ثٌقىِٛ١ز . ت
  ثٌّغضشف١جس ثٌخجطز . ح  ثٌؼ١جدثس غ١ش ثٌقىِٛ١ز . ز
 ؟جٌ اؿحشضاً ٍىاّغ اىحجيظ فً جٍَغ اىذَىلات او  2.1.6
 ػٓ ثٌقًّ ثٌزٜ ٌُ صغضخذَ ف١ٗ ِجٔغ ثٌضؾٍؾ: ثرث وجْ لا ثؽذ١ٝ ػٍٝ ثٌٕمجؽ ثٌضجٌ١ز .c لا .b ٔؼ ُ.a
 ٍ  اً ّحٍجة اظا اىذَو؟  : 2.1.6.1
  ثٌىجٍِزثٌٛلادر  . ب  ثلإؽٙجع . 
  ؽفً ِشٖٛ خٍم١ج . خ  ) ثعذٛع 82ثلً ِٓ (ٚفجر ثٌؾٕ١ٓ فٟ ٚلش ِذىش . ت
  صأخش ثٌّٕٛ دثخً ثٌشفُ  . ح  )ثعذٛع ٚثوغش82(.ٚفجر ثٌؾٕ١ٓ دثخً ثٌشفُ . ز
  ) ؽُ0052(ؽفً ثلً ِٓ ثٌٛصْ ثٌطذ١ؼٟ  . ص  ؽٕ١ٓ ِضٛلٝ فٛي ثٌٛلادر . ر
   او دضت ٍض ػي ت فً اظا اىذَو؟ 2.1.6.2
 : ٔؼُ فذدٞ.ثرث وجٔش لا )b ٔؼ ُ)a
   ّىع اىَض ػي ت اىحً د يث 2.1.6.2.1 
  )ثٔفظجي ثٌّش١ّز(ثٌٕضف ِج لذً ثٌٛلادر . ب  ثسصفجع ػغؾ ثٌذَ ثٌٕجؽُ ػٓ ثٌقًّ . 
  ٔض٠ف ِج دؼذ ثٌٛلادر . خ  عىشٜ ثٌقًّ  . ت
  ؽٍطز ٚس٠ذ٠ز ػّ١مز.  . ح  )3،1(وً ِٓ  . ز
    شٟء لا  . ر
   او  دب اظا اىذَو  لاصة ٍ نغة؟2.1.6.2.2
  لا . ب  ٔؼ ُ. 
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  اىذَو اىَ  ً: اىـ بغ اىجؼء 
 
 
 ٍ طا م ّث ّحٍجة اىذَو اىَ  ً؟ -1
   ؽفً ػٍٝ ل١ذ ثٌق١جر . ب   ثلإؽٙجع . 
  ثٌضشٛ٘جس ثٌخٍم١ز . خ  ٚلادر ِذىشر . ت
 82ثلً ِٓ (ٚفجر ثٌؾٕ١ٓ فٟ ٚلش ِذىش . ز
 )ثعذٛع
ٚف١جس ِج فٛي  . ح 
 ثٌٛلادر
 
  ػُ اىطيو اىـ بق" ب"إطا م ُ ىضٌل اىجىاب  1.1
  ؽُ0052< . 
   ؽُ0053-0052 . ب
   ؽُ0054 -0053 . ت
   ؽُ0054>  . خ
  ٘لاعضخذِش ِٛثٔغ ثٌضخغشف١جٌقّلالأخ١ش؟ -2
  لا ٔؼُ
  اىَـحشضً فً طىل اىذَو؟ٍ ّغ اىحجيظٍ  اى ّىع  1.2
   nirapehثٌٙ١ذجس٠ٓ غ١ش ثٌّؾضأ . ب  ثلأعذش٠ٓ ٚفذٖ . 
  ِض٠ؼ ِٓ ثلأعذش٠ٓ ٚ ثٌٙ١ذجس٠ٓ . خ  ٌؾض٠تٟثِٕخفؼز ثٌٛصْ  . ت
 ، الإج بة ػيى ٍ  ٌيً)اىر ًّ، اىر ىد، اىغابغ(إطا  ج ث 
  جغػة ػلاز اىهٍ  عٌِ1.1.2
   ِشر ٚثفذر صقش ثٌؾٍذ٘١ذجس٠ٓ ٚفذر 0005 . 
   ِشص١ٓ صقش ثٌؾٍذ٘١ذجس٠ٓ ٚفذر 0005 . ب
  ِشر ٚثفذر صقش ثٌؾٍذ   ٍِؾُ ِٓ 3.0 . ت
  ٍِؾُ ِشر ٚثفذر صقش ثٌؾٍذ)08-06-04-02(وٍىغجْ . خ
  ٍِؾُ ِشص١ٓ صقش ثٌؾٍذ )08-06-04-02(وٍىغجْ . ز
   ٍؼضه اسض اىهٍ  عٌِ طىه فحغة اىذَو2.1.2
  ِٟٚٞ . 
  ث٠جِّضذجدٌز . ب
   أعذٛػٟ . ت
  ثخشٜ . خ
   ػَغ اىذَو ػْض بضء جْ  ه اىهٍ  عٌِ3.1.2  
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  ) أعجد١غ31-0( ثلأٚي ِٓ ثٌقًّ ثٌؾضء . 
  ) أعذٛػج62- 41( ثٌغجٟٔ ِٓ ثٌقًّ ثٌؾضء . ب
  ) أعذٛػج04- 72( ثٌغجٌظ ثٌؾضء . ت
   ػَغ اىذَو فً  قف جْ  ه اىهٍ  عٌِ4.1.2
  ) أعجد١غ31-0( ثلأٚي ِٓ ثٌقًّ ثٌؾضء . 
  ) أعذٛػج62- 41( ثٌغجٟٔ ِٓ ثٌقًّ ثٌؾضء . ب
  ) أعذٛػج04- 72 (ثٌؾضء ثٌغجٌظ ِٓ ثٌقًّ . ت
  ِذجششر دؼذ ثٌٛلادر . خ
   أعذٛع دؼذ ثٌٛلادر1 . ز
 ؟ٍِ   ف اىض اء ىل 5.1.2
  أؽذجء ثٌّغضشفٝ . 
   أؽذجء ثلأٚٔشٚث . ب
   ثٌؼ١جدثس ثٌخجطز ٌلأؽذجء . ت
  ث٢خش٠ٓ.  . خ
    مٍيحَنْحَْ اىذ ىلإى  ىض اء6.1.2
  ػ١جدثصجلأٚٔشٚث )a
  ٌّغضشف١جصجٌؼجِز )b
  ثٌؼ١جدثصجٌقىِٛ١ز )c
  ثٌظ١ذٌ١جصجٌخجطز )d
  ثٌؼ١جدثصغ١شثٌقىِٛ١ز )e
 ؟ جْ  ه الاص ٌة فً بحؼيٍَ ت اىط ٍب  اىحؼٍثاو  2.6
 لا . ب ٔؼ ُ. 
 ........................................؟  ٍِ  جهة ّظغكٍ  اى اىـ ب اىغئٍـً ىحْ  ه اىهٍ  عٌِ .a
 او قَث بئجغاء جذيٍلات ٍش غٌة ىضػٌ اؿحشضاً ػلاز اىهٍ  عٌِ  ذْ ء اىذَو؟ 2.8
 :    فقذدٞ.ثرث وجٔش ٔؼُ  لا .b ٔؼ ُ.a
    ّىع اىحذ ىٍو اىَش غٌة2.8.1
  )ثٌؾ١ٕجس ثٌٛسثع١ز (صقجٌ١ً ثٌضخغش ثٌٛسثع١ز . 
  صقٍ١ً ػٛثًِ ثٌضؾٍؾ. . ب
  ثٌضقجٌ١ً ثلأؽغجَ ثٌّؼجدر . ت
   ِؼجدر  ٌٍقّغ ثٌٕٛٚٞصقجٌ١ً ثلأؽغجَ . خ
   سلاه فحغة اىذَو؟ٍ  اً اىحنيية الإجَ ىٍة ىيؼلاز اىهٍ  عٌِ 2.9
   ش١ىً0001-0005 . 
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   ش١ىً0051-1001 . ب
  ش١ىً0051أوغش ِٓ  . ت
 او جؼ ًّ ٍِ  ي آذ ع ج ّ ٍة  اذْ ء جْ  ه ػلاز اىهٍ  عٌِ فً اىذَو الأسٍغ؟ 2.01
  )وذِجس(ثٌذمغ  فّشثء  . ب   ِٕطمز  ثٌقمٓفٟأٌ  ُ. 
  ٔض٠ف . خ  آلاَ ثٌؼظجَ . ت
  )ٞفذد(أخشٜ  . ح  ثٌقغجع١ز/ فىز . . ز
     ثٌذِٛ٠زف١جٌظفجةـٔمض  . ر
 او ىضٌل  ي ٍض ػي ت  ذٍة  ذْ ء اىذَو الأسٍغ؟ 2.11
 .ٞإرث وجٔش ثلإؽجدز دٕؼُ، فذد لا .b ٔؼ ُ.a
   ّىع اىَض ػي ت اىحً د يث 2.11.1
  ؽٍطز ٚسد٠ز ػّ١مز . ب  ثسصفجع ػغؾ ثٌذَ . 
ثٔفظجي (ٔض٠ف لذً ثٌٛلادر  . خ  صغُّ ثٌقًّ- عىش ثٌقًّ . ت
 )ثٌّش١ّز
 
  ٔض٠ف لذً ثٌٛلادر  . ح  ػغؾ ثٌقًّ  ٚعىش ثٌقًّ . ز
 الاس ئٍة فى اىؼٍ صة ؟/ مْث جح بؼً ٍغ الأس ئًاو  2.21
 ثرث وجٔش ثلاؽجدز ٔؼُ فذد لا .b ٔؼ ُ.a
 الاس ئٍة؟/ الأس ئًمٌ ٍغة سلاه فحغة اىذَو  قَث بؼٌ عة غغفة  2.21.1
 4أوغش ِٓ  . ت  ِشثس4-2 . ب ِشر ٚثفذر . 
  الأس ئً؟ بح ىٌغ اىجٍِْ  ػْض اىط ٍبقَثمٌ ٍغة   2.21.2
 4أوغش ِٓ  . ت  ِشثس4-2 . ب ٚثفذ . 
 ػث فً قـٌ اىذَو اىشطغ فً اىَـحشيى؟ او ج ب 2.21.3
 لا . ب ٔؼ ُ. 
  ٍن ُ اىىلاصة 2.21.4
 ثٌطذ١خ ثٌخجص . ت ِغضشفٝ ػجَ  . ب ِغضشفٝ خجص . 
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Part (1) Distribution of obstetric history among cases group (thromboprophylaxis use) 
(100 MRR)  
 
No. factor Variable 
Yes No 
1 Age>=35   
2 Para>=6   
3 Habitual abortions >=3   
4 Perinatal deaths>=2   
5 Pervious pre- eclampsia   
6 Pervious GDM   
7 History of antepartum hemorrhage   
8 History of post hemorrhage   
9 Pregnancy induced hypertension   
10 DM with pregnancy   
11 History of CS   
12 Anima below 9   
 
 
Part (2)   Distribution of risk factors among cases  
 
No. Factor One risk 
factor 
two risk 
factor 
two risk factor 
Number Number Number 
1 
 
Distribution of risk 
factors among cases  
   
 
 
 
 
 
Part (3) Review of management practices. 
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No. Factor Frequency 
Yes No 
1 Type of  treatment   
2 Number of ANC visits(4and more )   
3 Specialist assessment and follow up   
4 Preconception  care   
5 Family planning   
6 Routine investigations   
7 Related investigation coagulation profile    
8 Early registration   
 
Annex (10): Genetic Molecular study review  
Genetic Molecular study among cases group who use  thromboprophylaxis . 
 
No. Factor Homogenous Heterogeneous Normal  
TOTAL No. % No. % No. % 
1 
Prothrombin 
G2010A 
       
2 ACE 1/0        
3 PAI - 4G/5G        
4 Factor U        
5 MTHFR        
6 Factor XIII        
 
 
 
 
 
 
 
 
Annex (11) In-depth Interview Questions  
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1- How can you describe the current status of Thromboprophylaxis use among pregnant 
women in Gaza governorates in the last years? 
2- How can you describe the epidemiological statistically features of existing risk factors 
that enhancing the use of Thromboprophylaxis among pregnant women? Past medical 
history, past obstetric history, maternal age and family history? 
3- How much genetic factors and acquired Thromboprophilia syndrome is affecting the use 
of Thromboprophylaxis use among pregnant women? 
4- What do you think the main basic evidence for starting Thromboprophylaxis use among 
pregnant women?[ Clinical –Investigation – both] 
5- How much of Thromboprophylaxis use among risky pregnant women is preventing bad 
pregnancy outcomes and pregnancy complications? 
6- What are the different managerial practices followed by health care providers of 
thrombophylaxis use in risky pregnant women? 
7- How much the distributed different mangment practices is adherent with international 
guidelines of Thromboprophylaxis among pregnant women? (Is there overuse or misuse) 
 8- Heparin thereby is highly expensive most of clients buy it from out pocket, how can 
UNRWA and ministry of health provide this thereby to the clients? 
9- Medical records review for these risky pregnant women showed the following? 
I. 14 % of women had less than 4 A.N.C visits during pregnancy period  
II. 42% of women had no specialist assessment and follow up during pregnancy period 
III. 60% of women had not enrolled in preconception care program during pregnancy 
period 
IV. 22% of women did not register early in pregnancy follow up 
V. 80% of MHR ( maternal health records) lost documentation of related 
Thromboprophillia investigations 
VI. 5% of MHR did not do routine ANC investigation  
                                 How can you agree with these results? 
10- Describe your recommendations and advices for improving maternal health services in 
UNRWA clinics? 
 
 
 
 
Annex (12): An official letter of approval  
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 اىذىاٍو فٍَذ فظ جغؼةىيْـ ءاؿحشضاٍَىاّغ اىحجيظ
 031
 
 ٍه  ؿٍَخ  فى   : اػضاص
  ػ ض اىغػاق اىنغص:ا غاف اىضمحىع 
  :ٍيشص اىضعاؿة 
ثٌقٍّٛثٌٛلادر٘ٛفذعمجةّف١ق١جرثٌّشأرٚثٌق١جرثلأعش٠زٌٚؼٍّ١زثٌقٍّّطجٌذىذ١شرٚصقذ٠جصفغ١ٌٛٛؽ١ٗ،صقغجٌؼذ٠ذِٕجٌضغ١شثصجٌفغ١ٌٛٛ
ؽ١زإٌىٍٍضى١فّؼجٌضغ١١شثصجٌؾذ٠ذرف١جٌٕغجءثٌقٛثًِ،٘ز٘جٌفضشرِٕجٌق١جرصقّلاٌؼذ٠ذِٕجٌّخجؽشثٌظق١زثٌض١مذصؤعشػٍىق١جرثلأِٛثٌؾٕٟ
 .ْ
. صقذعجٌضغ١شثصجٌفغ١ٌٛٛؽ١زثٌّخضٍفزأعٕجءػٍّ١زثٌقًّ،ٚثٌض١ضؤعشػٍىؾّ١ؼجؽٙضرثٌّشأر 
. ٚٔقّٕٙضّٛٔف١ضٍىجٌضغ١١شثصجٌض١ضؤعشػٍىؼٛثِلاٌضخغش. صشّلاٌضؼذ٠لاصجلأ٠ؼ١زٚثٌضغ١شثصجٌٙشِٛٔ١ز
ٚ٠شؽؼزٌىئٌىجٌض٠جدرثٌغجٔٛ٠زف١ضشو١ضثصؼجٍِّجلذلاٌضخغش،ٚثٌقذِٕجٌذشٚص١ٕجصجٌّؼجدرٌٍضخغشثٌض١ضقذعذشىٍطذ١ؼ١ٛص٠جدرف١جٌف١ذش٠ٕٛؽٟ
 .ْ،ثٌض١ضّ١ضثٌقٍّّؼفشؽجٌضخغش
ثٌٕغجءثٌقٛثٍِف١خطشِضضث٠ذِٕىٍّٕجٌؾٍطجصجٌذِٛ٠زثٌٛس٠ذ٠زٚثٌشش٠جٔ١زأعٕجءثٌقًّ،دجٌّمجسٔزِؼجٌٕغجءغ١شثٌقٛثًِ،خطشثٌؾٍطج
 .أػؼجفٛخطشثٌؾٍطجصجٌذِٛ٠زثٌٛس٠ذ٠ز 4 إٌٝ 3 ٠ضضث٠ذ) ثٌغىضجصجٌذِجغ١زٚثٌٕٛدجصجٌمٍذ١ز (صجٌذِٛ٠زثٌشش٠جٔ١ز
ِٕجٌّشػىجٌز٠ٕ١ؼجّٔٛٔٓ ثٌضؾٍؾ خلاي ٪ 05 ثِشثع ثٌضخغش،إِجِىضغذزأٚٚسثع١ز،لذصقٛلاٌضٛثصٕٔقٛصؼض٠ضثٌضخغشِج٠ظلاٌٝ
ِٕجٌٕغجءثٌٍٛثص١١ؼجّٕٔٛٔفمذثٔجٌقّلاٌّضىشسر ٪ 05 ثِشثع ثٌضخغشثٌّٛسٚعزٚثٌّىضغذز٠ّىٕجٌؼغٛسػٍ١ٙجف١أوغشِٓ.فضشٖ ثٌقًّ 
ثِشثػجٌضخغش٘١أ٠ؼجِضىشسرف١جٌٕغجءِؼأِشثػجٌّش١ّزٚثلأٚػ١زثٌذِٛ٠ز،ِغٍضغّّجٌقًّ،ٚصأخشثٌّٕٛدثخلاٌشفُ،ٚثٔمطجػجي,
 .ِش١ّز،ٚفمذثٔجٌؾٕ١ٕف١ٛلضّضأخش
ٔؾجفجٌقٍّ١ؼضّذثػضّجدثوذ١شثػٍىٕشجؽ ثٌذٚسر ثٌذِٛ٠ز فٝ ثٌّش١ّز دشىً وجفٝ ف١ظ ٚؽٛد ثٜ ِشجوً فٝ ثلاٚػ١ز ثٌذِٛ٠ز 
فٝ ثٌّش١ّز ٠ؤدٜ ثٌٝ  صغذ٠ز غ١ش وجف١ز ٌٍقًّ ِّج ٠ؤدٜ ثٌٝ ٔضجةؼ فًّ ع١تز لذً ثلاؽٙجع  
ٚفجر ثٌؾٕ١ٓ دثخً ثٌشفُ , صجخش ّٔٛ ثٌؾٕ١ٓ دثخً ثٌشفُ  ,،ِٚٛصجٌؾٕ١ٕذثخً ثٌشفُ)إِجخلالاٌشدؼجلأٚلأٚثٌغجٔ١ّٕجٌقًّ(
دؼغ ثٌذسثعجس , لا٠ؼشف ِذىجٔضشجسثِشثع ثٌضخغشد١ٕجٌٕغجءثٌقٛثٍِف١ؾّ١ؼأٔقجء ثٌؼجٌُ.ثٔفظجي ثٌّش١ّز , ٚفٛي ثٌٛلادر 
فٝ ثٌؾٕظ ثلاد١غ ٚأظٙشصجٌؼذ٠ذِٕجٌذسثعجصأْ ِؼذي ػٛثًِ ثٌضؾٍؾ ثٌّخضٍفز صضضث٠ذ ِغ ٪ 51-٪ 8 ثعذش ثٔٙج صضشثٚؿ ِٓ 
ثٌقجلاس رٚثس ٔضجػ ثٌقًّ ثٌغب 
ثٌقّلاٌخطشآخزف١جلاصد٠جدف١جٌغٕٛثصجلأخ١شردغذذضشثوّؼٛثِلاٌخطشثٌّخضٍفزٚص٠جدرٔضجةؾجٌقّلاٌغ١تز ٚفٝ ٔفظ ثٌٛلش  .
ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ثخذ فىجلاصد٠جد،لاصٛؽذد١جٔجصّضجفزفٛلاٌّقذدثصجٌّخضٍفزِٕجعضخذثِّٛثٔغ ثٌضؾٍؾ ٚو١ف١ز ثعضخذثِٗ ٚ 
دٚسٖ فٝ صقغ١ٓ ٔضجػ ثٌقًّ ،فجٌذسثعز صٙذفجٌٝ صقذ٠ذفجٌزثعضخذثِّٛثٔغ ثٌضؾٍؾ 
 . ٚلذ صجدؼش فىجٌّشثوضثٌظق١زثٌضجدؼزٌلأٚٔشٚثف١ّقجفظجصغضر6102 د١ٕجٌٕغجءثٌقٛثِلاٌٍٛثص١ضّٛلادصٕٙف١جٌغٕزثلأخ١شرِٕؼجَ
 
 ٍشنيةبذد
ثٌقٍّٙٛفضشرفش٠ذرِٕٕٛػٙجف١ق١جرولاِشأر،دٍٙٛ٘ذفطذ١ؼ١ٍىلأعشرٌٍقظٌٛؼٍىطفٍُٙ،ٚ٠ضّ١ضدجٌضغ١١شثصجٌفغ١ٌٛٛؽ١زثٌّؼمذرثٌّخضً
فزوّجصخؼؼجٌّشأرٌٍؼذ٠ذِٕجٌضغ١شثصجٌفغ١ٌٛٛؽ١ز،ٌزٌه،ثٌقٍّ١طشفّطجٌذىذ١شرٚصقذ٠جصفغ١ٌٛٛؽ١جٌٍّشأر،ف١ذؼؼجٌٕغجء،ثٌضى١فّغ
ٚفمجٌزٌه،ٚثفذرِٕأّ٘ٙزٖ ثٌّٛػٛػٙٛخطشصؾٍطجٌذِٛثعضخذثِّٛثٔغ .٘ز٘جٌضغ١١شثصغ١شوجف١زٌزٌى١ّىٕأٔضقذعّؼجػفجصجٌقًّ
 .ثٌضؾٍؾ
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ثٌقّلاٌخط١شف١غضرِ٘ٛؼجٌؼذ٠ذِٕجٌمؼج٠جثٌظق١زثٌّؼمذر،ف١جٌغٕٛثصجلأخ١شرثٔضشجسثٌقٍّخطش،ٔضجةؾجٌقّلاٌغ١تزٚثٌّؼجػفجصضش
ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ظج٘شرفذ٠غزفىجٌقًّ ثٌخطشٚثٌطٍذؼٍىجعضخذثَ .صث٠ذدشىٍىذ١ش،دغذذجٌضذ٘ٛسثلاؽضّجػ١ٛثلالضظجدٞ
ِٛثٔغ ثٌضؾٍط١ضدثدف١جٌغٕٛثصجلأخ١شر،ٚ٘ز٘جٌذسثعز٘١جٌذسثعزثلأٌٚىف١فٍغط١ٕغضؾش٠قٛلاعضخذثَ ِٛثٔغ ثٌضؾٍؾ  
ف١جٌقٍّلأٔٙجعٛفضم١غقؾّجٌّشىٍزد١ٕجٌٕغجءثٌقٛثِلاٌّقفٛفزدجٌّخجؽش،ٚعٛفٕٕجلشّخضٍفجٌّقذدثصجٌّشصذطزدٙز٘جٌظج٘شر،وٕضجا
ؽجٌقّلاٌّخضٍفزٚو١ف١ز ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ٚ٘ىزثعٛفضغجػذٔجػٍىجلإؽجدزػٍىجٌغؤثلاٌشة١غٟ ػٓ ثعضخذثَ ِٛثٔغ 
 .ثٌضؾٍطٙٛٔض١ؾزثلاصد٠جدثٌقًّ ثٌخطش ثٚ شجةغ فٝ ثٌقًّ
  اضافَذضصة
 صم١١ّجٌٛػؼجٌقجٌ١لاعضخذثَ ِٛثٔغ ثٌضؾٍؾ د١ٕجٌٕغجءثٌقٛثِلاٌّؼشػجصٍٍخطشف١ّشثوضثلأشٚث ثٌظق١زف١ّقجفظجصغضر. 1
صم١١ّّخضٍفجٌّقذدثصجٌّشصذطزدجعضخذثَ ِٛثٔغ ثٌضؾٍؾ . 2
 .د١ٕجٌٕغجءثٌقٛثِلاٌّؼشػجصٍٍخطشف١جٌّشثوضثٌظق١زثٌضجدؼزٌلأٚٔشٚثف١ّقجفظجصغضر
 .ثٌضؼشفؼٍىّشجولاٌٛلادرٚثٌؾٕ١ٕزثصجٌظٍزثٌض١ضغجّ٘ف١جعضخذثِّٛثٔؼجٌضؾٍطذ١ٕجٌٕغجءثٌقٛثِلاٌّقفٛفزدجٌّخجؽش. 3
 صم١١ّضأع١شثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ،ٌىٍّٕجلأِٙجصٛٔضجةؾجٌٛلادر. 4
 صم١١ّّّجسعجس ثٌطذ١ٗ فٝ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ د١ٕجٌٕغجءثٌقٛثًِ. 5
 ثلضشثفجصٛصٛط١جص١ّىٕأٔضغجػذف١ضؼض٠ضخذِجصجٌشػج٠زثٌظق١زثٌّٕجعذزف١ّج٠ضؼٍمذجٌقٛثِلاٌّؼشػجصٍٍخطش - 6
 
 :ٍْهجٍةاى ذد
٘زٖ ثٌذسثعز ٘ٝ دسثعز ٚطف١ز ٚصقٍ١ٍز ٌذسثعز ِقذدثس ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ٌٍغ١ذثس ثٌقٛثًِ فٝ لطجع غضر ِٚج 
٘ٝ ثٌّّجسعجس ثٌطذ١ز لاعضخذثَ ٘زٖ ثٌّٛثٔغ فٝ ثٌقًّ ٚو١ف١ز صجع١ش ٘زٖ ثٌّٛثٔغ ػٍٝ ٔضجةؼ ثٌقًّ ٚلذ ثؽش٠ش ٘زٖ 
 غضر  –ؽذجٌ١ج (ف١ظ صُ ثخض١جس خّظ ػ١جدثس وذشٜ  ,  AWRNUثٌذسثعز فٝ ثٌّشثوض ثٌظق١ز ثٌضجدؼز ٌٍٛوجٌز ثٌغٛط 
ٚلذ ثؽش٠ش ٘زٖ ثٌذسثعز ػٍٝ ِؾّٛػض١ٓ فٝ ثٌغ١ذثس ثٌقٛثًِ ثٌضٝ . دشىً ػشٛثةٝ  )سفـ–خجْ ٠ٛٔظ –ثٌٕظ١شثس 
فجٌىّٝ ػذجسر ػٓ , ٔضمغُ ؽّ١غ ثٌذ١جٔجس ثٌٝ ؽضة١ٓ وّٝ ٚٔٛػٝ .  َ 6102ٌٚذس خلاي ثٌغضز ثلاشٙش ثلاخ١شر فٝ ػجَ 
ع١ذثس ِظٕفجس فًّ خطش ٚفمج ٌضظٕ١ف ثٌٕظجَ ثٌظقٝ فٝ 022,   فجٌّؾّٛػز ثلاٌٚٝ ,ثعضذ١جْ ٠شًّ ِؾّٛػض١ٓ 
 ع١ذثس  ِظٕفجس فًّ ؽذ١ؼٝ ٚفمج 022ٚثٌّؾّٛػز ثٌغجٔ١ز , ٚوجٔش ػٍٝ ِٛثٔغ ثٌضؾٍؾ خلاي فضشٖ ثٌقًّ , ثٌٛوجٌز 
ٌضظٕ١ف ثٌٕظجَ ثٌظقٝ فٝ ثٌٛوجٌز ٌُٚ صغضخذَ ِٛثٔغ ثٌضؾٍؾ خلاي فضشٖ ثٌقًّ ٚلذ صُ ِمجسٔز ؽّ١غ ثٌقّٛلاس 
 – ثٌضجس٠خ ثٌطذٝ ثٌغجدك –ثٌؼٛثًِ ثلاؽضّجػ١ز ٚثلالضظجد٠ز  (ٚثٌّؤعشثس ثٌضٝ لذ صؤعش فٝ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ 
ِٓ ,  ٍِف صجدغ ٌشػج٠ز ثلاِِٛز ٚثلاؽفجي 001وّج أٔٗ صُ ِشثؽؼز  )ثٌضجس٠خ ثٌٛلادر ثٌغجدك–ثٌضجس٠خ ثٌؾشثفٝ ثٌغجدك 
ثِج ثٌؾضء ثٌٕٛػٝ ٘ٛ ػذجسٖ ػٓ .  ٚفمج ٌؼٛثًِ ػذ٠ذر –صٍه ثٌغ١ذثس ثٌضٝ ثعضخذِش ِٛثٔغ ثٌضؾٍؾ خلاي فضشٖ ثٌقًّ 
ٌٚمذ صُ دػُ ِج فظٍٕج ػٍ١ٙج  ,  AWRNUِمجدلاس صُ ثؽشثء٘جِغ ثخظجة١ٓ ٔغجء ٚٚلادر صجدغ ػٍُّٙ ٌٍّشثوض ثٌظق١ز 
 فٝ ثٌؾضء ثٌٕٛػٝ ِغ ِج صُ فظٌٛٗ فٝ ثٌؾضء ثٌىّٝ ِّج ثدٜ ثٌٝ لٛر ثٌٕضجةؼ ٚدػّٙج ثلافظجةٝ 
 :الاؿحْح ج جىاىحى ٍ ت
ٔضجةؾجٌذسثعزفش٠ذرِٕٕٛػٙجف١ضمذ٠ّّؼٍِٛجصّفظٍزِٛعمزػٕقجٌزثعضخذثَ ِٛثٔغ ثٌضؾٍؾ 
د١ٕجٌٕغجءثٌقٛثًِ،ِٕخلإٌّجلشزِخضٍفجٌّقذدثصجٌّشصذطز،ٚثٌّّجسعجصجٌطذ١ز ثٌّخضٍفز،ٔضجةؾجٌقّلاٌّخضٍفز،ٚو١ف١ٙجعضخذثَ 
ِٛثٔغ ثٌضؾٍؾ ػٍٝ صقغ١ٕٕضجةؾجٌقٍِّٛؼجػفجصجٌقًّ 
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،ٚثٌٙذفجٌشة١غ١ّٕٙز٘جٌذسثعز٘ٛصقذ٠ذػٛثِلاٌخطشثٌشة١غ١زإِجػٛثِلالأِأٚثٌؾٕ١ٓ،ٚثٌؼٛثلخ،ٚثٌّّجسعجصجٌطذ١زثٌض١ضغجّ٘ف١ج
. عضخذثَ ِٛثٔغ ثٌضؾٍؾ ٌذٜ ثٌقٛثًِ ثٌّخفٛفز  دجٌّخجطش،ِٕأؽلاوشجفئِىجٔ١جصٍٍقذِّٕؼجػفجصجلأِٛثٌؾٕ١ٓ
 ثٌذسثعز٘١ذسثعزِمجسٔزصمجسٔذ١ّٕؾّٛػض١ّٕٕجٌٕغجءثٌٍٛثصٟ ٚلادصٙٓ فٝ ثلاشٙش ثٌغضزثلأخ١شرِٕؼجَ
،ٚصّجٌضؼجٍِّؼّؾّٛػز ثعضخذِش ِٛثٔغ ثٌضؾٍؾ ٚثخشٜ ٌُ ٠غضخذَ ِٛثٔغ ثٌضؾٍؾ ثعٕجء فٍّٙٓ ثلاخ١ش 6102
ٚصّجخض١جسخّغزِشثوضطق١زصجدؼزٌلأٚٔشٚثِٕأؽلاٌذ١جٔجصٛصّّٕجلشزِؾّٛػزِٕجٌّقذدثصجٌّشصذطزدٙجِٕخلالاعضذ١جْ،ف١غٕٕجلشٓ
ثثٌؼٛثِلالاؽضّجػ١زثٌذ٠ّٛغشثف١زٚثٌضجس٠خجٌطذ١جٌّجػ١ٛصجس٠خجٌٛلادرثٌغجدمِٛؼجػفجصجٌقّلاٌّشصذطزدٙجٚصجس٠خضخغشثٌذِٛؿ
ط١ٍزثٌقًّ،وّجٕٔجلشضجٌّّجسعجصجٌطذ١ٙجٌّخضٍفز،،ِٚمذثسصىٍفزٚصٛثفشثلأدٚ٠زف١جٌّغضشف١جصجٌقىِٛ١زٚثٌّشثوضثٌظق١زثٌضجدؼزي
ٚفٝ ِمجدٍز ِغ ثخظجة١ٓ  صُ ِٕجلشز ثٌؼٛثًِ ثٌضٝ صذػُ ٔضجةؼ , وّجصّّشثؽؼزثٌغؾلاصجٌطذ١زٌٙٛلاء ثٌغ١ذثس ,لأٚٔشٚث
ثعضخٍظٕج  ِٓ ثٌذسثعز ثْ ِشوضؽذجٌ١جثٌظق١جٌضجدؼٍلأٚٔشٚث٠ضّضؼذّؼذٌّشصفؼؼٕجٌؼ١جدثصجلأخشٜ ٚفٝ ػذد , ثلاعضذ١جْ 
 0001 دخلالأعشرألٍّٓ ثٌقجلاس ثٌضٝ صغضخذَ ِٛثٔغ ثٌضؾٍؾ ِٚؼظّّّٕٙجٌؼجؽٍ١ٕؼٕجٌؼًّ،ٚوجّٔضٛعؾ
 .ش١ىً،وّجأٔغجٌذ١ضّٙىجٔٛث٠ضّضؼٍٛٔذسؽز ثٌٚٝ ِٓ ثٌمشثدز دمٛرثٌّشصذطزٚصؼض٠ضثعضخذثِّٛثٔؼجٌضؾٍطف١جٌقًّ
 عٕز 52 وجْ ثٔؼّشثلأِ١شصذطجسصذجؽجٚع١مجدجعضخذثِّٛثٔؼجٌضؾٍطىّجأّٔؼظّجٌقجلاصجٌؼّش٠زأوغشِٓ
 .)٪52(،ٚوجْ ِؼظُ دسفز لشثدز ٌّؼظّّّٕٙ١جٌذسؽزثلأٌٚىذٕغذز )٪1.95 (عٕز 02 ،ِؼغٕجٌضٚثؽجٌّذىشألٍّٓ)٪2.26(
٠شصذطضجس٠خجلأِشثػغ١شثٌّؼذ٠زثسصذجؽجٚع١مج دجعضخذثِّٛثٔؼجٌضؾٍؾ ف١ظ ثْ ثٌغ١ذثس ثٌضٝ ثعضخذِش ثٌّٛثٔغ ٌذ٠ٙج صجس٠خ 
-  ثٌؼغؾ–ٚثُ٘ ٘زٖ ثلاِشثع ثٌغىش ,  ِشثس 6ِٓ ثلاِشثع ثٌغ١ش ِؼذ٠ز ٠فٛس ثٌغ١ذثس فٝ ثٌّؾّٛػٝ ثلاخشٜ 
 .ثِشثع ثٌؾٙجص ثٌضٕفغٝ ٚثِشثع ثٌمٍخ 
 ِشر ػٓ ثٌقجلاس 92وّج ثعذش ثٌذسثعز ٚؽٛد ػلالز لٛ٠ز د١ٓ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ٚثِشثع ثلاٚػ١ز ثٌذِٛ٠ز ٚدمذس 
ٚثٌضؼجح ثٌٛس٠ذ ثٌخغجسٜ ػٍٝ ثٌضٛثٌٝ , ثٌضخغش ثٌٛس٠ذٜ ثٌؼّ١ك , ثٌطذ١ؼ١ز ٚثٌضٝ صشًّ ثِشثع صٛعغ ثلاٚػ١ز ثٌذِٛ٠ز 
 5 وّجثعذضضجٌذسثعزٚؽٛدػلالزلٛ٠زد١ٕجعضخذثِّٛثٔؼجٌضؾٍطٛصجس٠خجٌؼٍّ١جصجٌؾشثف١زثٌغجدمزدمذس.
 .ِشثصٛثّ٘ٙجثٌم١ظش٠زٚػٍّ١جصجٌذطٕٛػٍّ١جصجٌؼظجَ
 5 – ِشثس 4 وّجثٚػقضجٌشعجٌزٚؽٛدػلالزلٛ٠زِجد١ٕٛؽٛددصجس٠خجعش٠ٛثعضخذثِّٛثٔؼجٌضؾٍطذمذس
ِشثصف١جٌقجلاصجٌّشػ١زػٕجٌقجلاصجٌؼجد٠زٚثّ٘ٙذ٘جلاِشثػجٌضٙجدجصجلاِؼجءثٌّضِٕزٚأِشثػجٌضخغشثٌٛسثع١زٚثِشثػجٌضخغشثٌّىش
 .عذزٚثٌغؼٍذزثٌقّشثءٚثِشثػجٌشِٚجصضِجٌشفّٛثلاؽفجلاٌّضٛف١١ٓ
 : ف١ّج٠ضؼٍمذضجس٠خجٌقّٛلاصجٌغجدمزفمذثٚػقضجٌذسثعزػذرٔضجةؾّٕٙج
ثعضخذثِّٛثٔؼجٌضؾٍط١ضد٘ذِؼجٌقجلاصجٌض١ٍذ٠ٙجثؽفجٌّضٛف١ٕخجطزفجلاصجلاؽفجلاٌّضٛف١ٕذثخلاٌشفّٛثلاؽفجلاٌّضٛف١١ٕقٛلاٌٛلادردٓ
 % 8.12 عذز
 31 وّجأعذضضجٌذسثعزثٔجعضخذثِّٛثٔؼجٌضؾٍط١ضدثدِؼجٌقجلاصجٌض١ؼجٔضّٕؼمّخجطزفضشرثٌؼمّجٌض١ضؾجٚصصجوغشِٕؼجِ١ٕٛدٌٍىذمذس
 .ِشثصؼٕجٌقجلاصجٌطذ١ؼ١ز 4ِشرِٚؼّقجٚلاصضسثػزؽفلالأجد١ذجٌفجشٍزدمذس
 , ِشرػٕجٌقجلاصجٌؼجد٠ز 2 ؽّذمذس 0052 وّجثٔجعضخذثِّٛثٔؼجٌضؾٍط١ضدثدِؼجٌقجلاصجٌض١ضؼجٔ١ّٕٛلادثصجؽفجلالٍّٓ
 .ِشرػٕجٌقجلاصجٌطذ١ؼ١ز 2 وّجثٔٙ١ضدثدثعضخذثِّٙؼقجلاصجٌٛلادرثٌّذىشردمذس
 ثعذضضجٌذسثعزثٔجعضخذثِّٛثٔؼجٌضؾٍطف١جٌقٍّ١ضدثدِؼٛؽٛدصجس٠خّغذمّٕجلاؽٙجػجصخجطزثلاؽٙجػجصجٌّضىشسرأوغشِّٕشص١ٕذٕغذز
 %.8.06 ِٕجٌقجلاصجٌّشػ١زٚخجطزثٌشدؼجلإٌّٚجٌقٍّذٕغذز% 7.36
 11 وّجثٔجٌذسثعزثعذضضجٔجعضخذثِّٛثٔؼجٌضؾٍطجعٕجءثٌقٍّ١ضدثدف١قجٌزٚؽٛدصجس٠خطذ١ّٕجٌضؾٍطٛدٌىذمذس
 .ِشرٚ٠فٛلجٌقجلاصجٌطذ١ؼ١ز
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% 9.37 وّجثٚػقضجٌذسثعزثٔجعضخذثِّٛثٔؼجٌضؾٍطفجٌقٍّمذفغّٕٕظقزثلأِٙجصف١جٌقٍّٛطقزٔضجؽجٌقًّ
% 4.86 ِٕجٌقجلاصجٔؾذضجؽفجلاثطقجءوجٍِ١ٕجٌّٕٛ% 2.87 ِٕجٌقجلاصٍّضؼجٔ١ّّٕشجوٍظق١زِضؼٍمزدجٌقًّ
 .0054-0052ِٕجلاؽفجٌذٚثٚصثٔطذ١ؼ١زِجد١ٓ
 68 ِٚؼظّجٌقجلاصضذذثثٌؼلاؽّٕذذث٠زثٌقًّ%96 وّجثٚػقضجٌذسثعزثّٔؼظّجٌقجلاصؼلاػلاؽجصّض٠ؾّٕٙجلاعذش٠ٕٛثٌٙذجس٠ٓ
. ٠ٕٙ١جٌؼلاؽّؼٕٙج٠زثٌقٍّٛ٘ذث٠ضٕجلؼّؼجٌمٛثٔذذٕجٌّقىّزلاعضخذثِّٛثٔؼجٌضؾٍؾ% 36 ٚثٌّؼظُ% 
وّجثٔجٌغجٌذ١زثٌؼظّجِٕجٌقجلاصضقظٍؼلاِٛثٔؼجٌضؾٍطّٕجٌظ١ذٌ١جصجٌخجطزدأعّجٔغجٌ١زٚ٠ٛطفّٕمذلاٌمطجػجٌخجطٌٛغذذفمذثٔجٌضٕغٟ
 وّجٔجٌذسثعزثٚػقضجٔجٌغ١ذثصجٌٍٛثص١جعضخذِّٕٛثٔؼجٌضؾٍطٍذ٠ٕٕٙغذّشصفؼزِٕؼٛثِلاٌضؾٍطجٌٛسثع١ز.لذ١ٕمطجػجصجٌظقزثٌّخضٍفز
 )111X rotcaf dna RFHTM-VrotcaF-ECA-nibmorhtorP(
 ف١غٛؽٛدرٌىذػّجعضخذثِّٛثٔؼجٌضؾٍؾ
دجٌشغّّٕجّٔؼظّجٌقلاصجٌض١١ضّضشخ١ظٙجِٕجٌمطجػجٌخجطجٔٙجصقظىذشػج٠زخجطزِٕمذلالاخظجة١١ٕذثخً .
 ِؼجلافضفجظذذؼؼجٌّؤششثصجٌظق١زثٌض١١غضٛؽذجٌؼٍّؼلاصقغ١ٕٙج ِغً ثلاٌضقجق فٝ دشٔجِؼ AWRNUثٌّشثوضثٌظق١ز
ٚدجٌضجٌٝ ,  ص٠جسثس خلاي ثٌقًّ 4ثٌضغؾ١ً ثٌّذىش فٝ ثٌقًّ ٚػذد ثٌض٠جسثس ثٌضٝ ٠ؾخ ثْ صفٛق , سػج٠ز ِج لذً ثٌقًّ 
٠فغش ٔض١ؾز ص٠جدر ٔغذز ثٌقًّ ثٌخطش ِغ ٚؽٛد ص٠جدر فٝ ثلاعضخذثَ , لذ ثٚػقش ثٌشعجٌز ثْ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ 
 .ٌؼذَ ٚؽٛد صٕغ١ك ٚثػـ د١ٓ لطجػجس ثٌظقز ثٌّخضٍفزٚدشٚصٛولاس ٚثػقز ٌقىُ ثٌظشف
 
 :اىحى ٍ ت 
 . صٛف١ذ ثٌذشٚصٛولاس ثٌضٝ صقىُ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ ِج د١ٓ لطجػجس ثٌظقز ثٌّخضٍفز .1
 . صقف١ض ٚؽٛد ِٕجغّز د١ٓ ثٌشػج٠ز ثلاٌٚ١ز ٚثٌشػج٠ز ثٌغجٔٛ٠ز ٌضقغ١ٓ خذِجس ثلاِِٛز ٚثٌطفً .2
 .صشؾ١غ دشثِؼ سػج٠ز ِج لذً ثٌقًّ ٌضقغ١ٓ ٔضجػ ثٌقًّ ٚثٌٛلادر  .3
 .ثٌّشثلذز ٚثٌضؼٍ١ُ ثٌّغضّش ٌضقغ١ٓ ثٌخذِجس ثٌظق١ز ثٌّمذِز ٌلاِٙجس ثٌّشثؽؼجس  .4
ٌٍقظٛي ػٍٝ ِؼٍِٛجس وجف١ز فٝ ثعضخذثَ ِٛثٔغ ثٌضؾٍؾ فٝ  hcraeser noitcaصقف١ض ثٌذقظ ثٌؼٍّٝ ٚخجطز  .5
 .ثٌقًّ 
 
